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Abstract 
This thesis reports the organic synthesis and labelling of the D2/D3 agonist PHNO, the 
5-HTI A agonist Flesinoxan and some model compounds with short-lived positron 
emitters. These agonists are potential probes for brain imaging with positron emission 
tomography (PET). 
(+)-4-Propyl-3,4,4a, 5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-oI (PHNO) has 
subnanomolar affinities for the D2 and the D3 receptors. The labelling of PHNO with 
carbon-11 started with the alkylation of (+)-4-acetyl-3,4,4a, 5,6,10b-hexahydro-9- 
triisopropylsilyloxy-2H-naphtho[1,2-b][1,4]oxazine with ["C]iodomethane (60-87 % 
radiochernical yield). This represents the first reported 11 C-methylation of an amide a- 
position. The labelled intermediate, (+)-4-([3-"C]propionyl)-3,4,4a, 5,6,10b-hexahydro- 
9-triisopropylsilyloxy-2H-naphtho[1,2-b][1,4]oxazine, was then treated with lithium 
aluminium. hydride to give (+)-4-([3-"C]propyl)-3,, 4,4a, 5,6,10b-hexahydro-2H- 
naphtho[l, 2-b][l, 4]oxazin-9-ol ([3-11C]-(+)-PfINO). The radiosynthesis was carried out 
in a one-pot protocol and the radiochemical yield was 55-60 %. The radioligand is 
currently produced on an automated module and is under biological evaluation. 
The optimisation of this 1 'C-methylation/reduction route was first carried out on N- 
acetyl- 1,2,3,4-tetrahydroisoquinoline, providing N-([3 C]propyl)- 1,2,3,4- 
tetrahydroisoquinoline in 82-96 % radiochernical yields. 
(R)-(+)-N- [2- [4- [2,3 -dihydro-2-(hydroxymethyl)- 1,4-benzodioxin-5 -yl] -I -piperazinyl] 
ethyl] -4-fluorobenzamide (Flesinoxan) is a potent and selective 5-HTIA agonist. The 
target compound and the precursors needed for the radiochemistry were prepared in a 
multi-step synthesis. The reaction conditions for the 18 F-fluorination of Flesinoxan were 
optimised using a model arylpiperazine (6 % radiochemical yield). However, when 
similar conditions were used to label Flesinoxan, the radiochemical yields obtained 
were not sufficient to allow in vivo PET studies. 
A novel route for the radiosynthesis of [carbonyl-"C]amides via [carbonyl- 
"C]carboxylic-phosphinic anhydrides was also developed. This one-pot procedure was 
fast, simple, high-yielding and amenable to automation. Three model 4- 
fluoro[carbonyl-"C]benzamides (57-90 % radiochemical yields) and [carbonyl- 
"C]Flesinoxan (30-35 % isolated radiochemical yield, decay- corrected) were obtained 
using this methodology. 
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precursor 4.29 provided [carbonyl-"C]Flesinoxan. Column: Phenomenex Luna 
C, 18(2) (250 mm x 4.6 mm x5 micron). Mobile phase: 55 % (NH4)2HP040.05 M- 
45 % acetonitrile. Wavelength = 245 nm. Flow rate =I mIlmin. 
4.31. Radio-HPLC chromatogram of [carbonyl-"C]Flesinoxan showing adequate 
separation ftom other radioactive and non-radioactive products. The sample was 
spiked with non-radioactive Flesinoxan. Column: Phenomenex Luna C18(2) (250 
12 
mm x 4.6 mm x5 micron). Mobile phase: 65 % (NH4)2HP04 0.05 M-35 % 
acetonitrile. Wavelength = 245 nm. Flow rate =I mIlmin. 
4.32. Radio-HPLC chromatogram of the isolated [carbonyl-]]C]Flesinoxan. The 
radiochemical purity of the product was 100 %. Column: Phenomenex Luna 
C18(2) (250 mm x 4.6 mm x5 micron). Mobile phase: 65 % (NH4)2HP04 0.05 M- 
35 % acetonitrile. Wavelength = 245 nm. Flow rate =I ml/min. 
4.33. Devised systemfor the automated radiosynthesis of [carbonyl-"C]Flesinoxan. 
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1.1. Introduction 
Positron Emission Tomography (PET) is a non-invasive medical imaging technique that 
allows the diagnosis and assessment of numerous pathologies. Moreover, PET has been 
increasingly applied in areas of drug development such as target validation, 
pharmacokinetics, pharmacodynamics, receptor occupancy, toxicology or 
pathophysiology evaluation. 1-6 
This chapter includes a brief overview of PET as well as a survey on the radiochemistry 
of the most important PET nuclides: carbon- II and fluorine- 18. 
1.2. The role of PET in medical imaging 
Various imaging modalities are available for the diagnosis and the evaluation of 
diseases. Magnetic resonance imaging (MRI), X-ray imaging and X-ray computed 
tomography (X-ray CT or CT) produce excellent anatomical images. MRI reflects the 
magnetic resonance characteristics of certain populations of nuclei in tissue, whereas 
CT reflects tissue density as determined by the attenuation of X-rays. On the other 
hand, nuclear medicine imaging provides information about biochemical and 
physiological processes in the body. Single photon emission computed tomography 
(SPECT) and PET are the two imaging techniques used in nuclear medicine. Both 
involve the administration of compounds (radiopharmaceuticals) labelled with a 
gamma-ray-emitting or positron-emitting radionuclide to patients. The radioactivity is 
detected by the gamma camera and after mathematical reconstruction of the data, three- 
dimensional images showing the distribution of the radiopharmaceutical in the body are 
obtained. SPECT and PET are the most sensitive forms of computed tomography and 
can detect compounds in the nanomolar or picomolar range (Figure 1.1). Functional 
data obtained from PET and SPECT are often complemented with anatomical images 
from MRI or CT to aid in the correlation of structure and function. 7 
SPECT makes use of radionuclides such as technetium-99m(tl/2 : -": 6.01 h) and iodine- 
123 (ti/2= 13.2 h) that decay by emitting one gamma-ray per nuclear disintegration. A 
primary limitation of this technique is the difficulty in determining the exact origin 
within the subject of the detected gamma-rays. On the other hand, PET uses compounds 
labelled with short-lived positron emitting radionuclides (Table 1.1). Their shorter half- 
life reduces the radiation dose received by the subject. As a consequence, multiple 
studies can be conducted in short time intervals within safety limits. 
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Table 1.1. Some of the positron-emitting radionuclides used in PET 
Radionuclide Hatf life Decay mode , 
b, c Decayproduct 
Carbon- 11 20.4 min 99.8 % P+, 0.2 % EC Boron- 11 
Nitrogen- 13 10.0 min 100 % P+ Carbon- 13 
Oxygen- 15 2.0 min 99.9 %+0.1 % EC Nitrogen- 15 
Fluorine- 18 109.8 min 97 %3% EC Oxygen- 18 
Iron-52 8.3 h 56 % 44 % EC Manganese-52 
Cobalt-55 17.5 h 77 % 23 % EC Iron-55 
Copper-62 9.7 min 97 %+3% EC Nickel-62 
17.9 %+ý 37.1 % 
Copper-64 12.7 h 
45 % EC 
Nickel-64, Zinc-64 
Gallium-68 68 min 90 % P+, 10 % EC Zinc-68 
Bromine-75 97.0 min 71 %+ )29%EC 
Selenium-75 
Bromine-76 16.2 h 54 %+ ý46%EC 
Selenium-76 
Technetium-94m 52 min 72 % P+, 28 % EC Molybdenum-94 
Iodine- 124 4.2 days 23 %+ 177 
% EC Tellurium-124 
a#' = Positron emission. 
b, g -= Negatron emission. 
cEC = Electron capture. 
Drug ±dis buýtiýn Sensitivity 
V 
!L 
and 
olism 
Specificity 
Metabolism 
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The most common positron emitters utilised in PET are carbon- II (t1/2 = 20.4 min), 
nitrogen- 13 (t1/2 = 10.0 min), oxygen-15 (t 1 /2= 2.0 min) and fluorine-18 (tl/2= 109.8 
min). Carbon-11, nitrogen-13 or oxygen-15 can substitute stable atoms of the same 
elements in compounds of biological interest. The resulting radiolabelled compounds 
have the same biochemical and pharmacological properties as the original molecule. 
Fluorine is not normally present in natural biomolecules, although it is occasionally 
encountered in compounds of clinical interest. In some cases, fluorine-18 analogues of 
biomolecules have superior imaging properties compared to the original substrates. 
Two important examples are 6- [18 F]fluoro-L-DOPA and 2-deoxy-2- [18 F]fluoro-D- 
glucose. 
Several metallic po sitron- emitters are also available , including iron-52 
(t1/2 = 8.3 h), 
cobalt-55 (t1/2 = 17.5 h), copper-62 (t 1/2= 9.7 min), copper-6441/2 =12.7 h), gallium-68 
(tl/2= 68.1 min) and technetium-94m(t 1/2= 53 min). These radionuclides are generally 
incorporated into biologically revelant molecules by chelation. 
1.3. Basic principles of PET 
Radioactive decay involves the conversion of an unstable nucleus (parent) into a more 
stable product nucleus (daughter). The emission of particles and/or photons is always 
entailed in this process. Radionuclides used in PET decay by positron emission (P+ 
decay). In this decay mode, a proton in the nucleus is transformed into a neutron and a 
positron and a neutrino are ejected from the nucleus (Figure 1.2). The positron is the 
antiparticle of the electron. It has the same mass as an electron, but with a positive 
charge. The initial kinetic energy of the positron is lost by interactions with the 
surrounding matter. In vivo, the ejected positron travels a short distance (a few 
millimetres) within the body tissue before it eventually combines with an electron to 
form a positronium. This intermediate is immediately annihilated and its mass is 
converted into two 511 keV photons emitted at ca. 180' to each other. These high- 
energy annihilation photons can be externally detected and their origin 
localised in 
space. This in turn approximates closely to the location at which the positron was 
emitted. 
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Figure 1.2. Illustration of a positron decay and subsequent positron annihilation to give 
two 511 keVphotons in opposite directions. 
A PET scanner consists of a ring of detectors composed of inorganic crystals, such as 
bismuth germanate (Bi4Ge3Ol2, BGO), coupled to photomultiplier tubes. After 
radiopharmaceutical administration, multiple coincidence events are recorded by the 
rings of detector elements that surround the subject (Figure 1.3). The acquired data 
require correction for a number of phenomena such as tissue attenuation, scattered 
radiation, detector dead time, random coincidences and spatial resolution effects. 
Images are finally reconstructed using mathematical algorithms, providing an accurate 
reflection of the location and concentration of the positron emitter inside the subject. 
PET is therefore able to Provide in vivo quantitative measurements of physiological and 
biochemical processes such as blood flow, glucose metabolism, fatty acid metabolism, 
receptor distribution or tissue pharmacokinetics. 
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troduction 
Figure 1.3. The emitted annihilation photons emerging from a subject are detected in 
coincidence by a ring of detector elements. 
1.4. Production of positron-emitting radionuclides 
Commonly used positron emitters (carbon- 11, nitrogen- 13, oxygen- 15 and fluorine- 18) 
are produced by particle accelerators called cyclotrons. A cyclotron consists of a 
vacuum chamber containing two hollow semicircular metal electrodes called "dees" 
which are separated by a narrow gap, an arc ion source and a powerful electromagnet 
that produces a magnetic field perpendicular to the plane of the dees (Figure 1.4). 
loll s 
j 
Stripping foil 
or 
Electrostatic deflector 
Figure 1.4. Schematic depiction of a cyclotron: side view qeft) and top view (right). 
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The ion source is normally situated near the centre of the dees and is used to generate 
charged particles. Ions are produced by passing a gas supply (hydrogen, deuterium or 
helium) through the electric field of the ion source. An alternating current (AQ voltage 
generated by an oscillator is applied across the dees and the charged particles are 
immediately accelerated toward the dee with opposite potential. The particles are no 
longer affected by electric forces once inside the dee. However, they follow a circular 
path around to the opposite side of the dee under the influence of the magnetic field. 
The AC voltage across the dees is changed just when the ions arrive at the gap. The 
ions are then accelerated across the gap, enter the opposite dee and continue on a 
circular path. The particles gain energy and velocity each time they cross the gap and 
follow a spiralling path of increasing radius. The particle beam is extracted and directed 
to the target chamber once it has reached the desired energy. This extraction is 
performed by a negatively charged deflector in positive-ion cyclotrons, but almost all 
modem cyclotrons use negative ion sources (e. g. H- and D- ions). In this case, the beam 
is extracted by passing the negative ions through a thin carbon foil that strips their 
electrons off the nucleus. Hence, the original particles are now positively charged and 
the beam bends in the opposite direction due to the applied magnetic field. Exit ports 
finally guide the beam to the target chamber. The beam extraction efficiency in negative 
ion cyclotrons is nearly 100 %. Beam energies can be easily selected by moving the 
extraction foil to different radii and multiple beams can be extracted simultaneously in 
negative-ion cyclotrons. 
The target chamber contains the material required for the subsequent nuclear reaction 
and is usually cooled with water and helium to prevent overheating. The high-energy 
beam of charged particles enters the chamber through the target window, which is 
usually a thin metal foil. The bombardment of the target material by the accelerated 
particle beam eventually generates the radionuclides. 
1.5. Specific activity 
Specific activity (SA) is defined as the ratio of radioisotope activity to the mass of the 
compound into which the radioisotope has been incorporated. 
The specific activity is 
normally expressed in Bq x mol-1 units and measures the extent of the radiotracer 
dilution with non-labelled compound or carrier. The maximum theoretical specific 
activity of a radioisotope is obtained when there is no dilution 
by other isotopes of the 
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same element. The maximum SA depends on the radionuclide half-life and can be 
calculated by the following equation 9: 
(Bq/mol) = 
In 2- NA 
tl/2 
where SA,, aý, is the maximum specific activity, NAis Avogadro's number (6.023 x 1023 
atom / mol) andt 1/2 is the radionuclide half-life expressed in seconds. 
The accepted terminology expressing the dilution extent of a radiolabelled compound 
with unlabelled material is as follows: ' 0 
e Carrier Free (CF) refers to a sample of radiolabelled compound that does not 
contain stable compound (carrier). 
41 Carrier added (CA) applies to samples of radiolabelled compound that have been 
deliberately diluted with carrier. 
9 No carrier added (NCA) refers to samples of radiolabelled compound that have not 
been intentionally diluted with carrier. 
The specific activity of PET radiopharmaceuticals is a key issue in brain receptor 
studies. Radioligands with high specific activities are required to avoid pharmacological 
effects and to prevent the loss of the PET signal due to occupation of receptor sites by 
the stable compound. The amount of carrier is also critical in PET investigations that 
employ toxic compounds. 
In practice, carrier free radiopharmaceuticals are seldom produced since it is extremely 
difficult to exclude all sources of isotopic dilution such as target material, tubing, 
reagents or atmosphere. For instance, the 
SArnax for carbon- II is 3.41 X 105 GBq /ýLmol, 
but specific activities of current 
11 C-radiotracers are up to 200 Gl3q/ýtmol (i. e. the 
12C to 
1 1C ratio is about 103_104 to 
1). 5,11 In spite of the isotopic dilution, these values are 
sufficient to provide effective radioligands for the study of neurotransmitter receptors. 
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1.6. Carbon-11 chemistry 
1.6.1. Production of carbon-11 
Carbon- 11 is currently generated by bombarding a nitrogen gas target with <20 MeV 
protons via the 14N(p, oc)"C nuclear reaction. 12 The produced radionuclide has high 
specific activity due to its production from non-carbon material. Furthermore, the low 
threshold of the reaction (3.1 MeV) allows the formation of carbon- 11 with moderate 
particle energies. 
Carbon-11 is recovered as ["C]carbon dioxide when the target gas is nitrogen 
containing oxygen traces (ca. 0.1 %). [ 11 C] Carbon monoxide is also generated in this 
process, but it can be oxidised to ["C]carbon dioxide using copper (11) oxide if 
necessary. ["C]Methane can be obtained in-target if nitrogen containing ca. 5% 
hydrogen is used as the target gas. 13 
Both ["C]carbon dioxide and ["C]methane are recovered after the proton 
bombardment by flushing the target through fine bore tubing using an overpressure of 
helium or nitrogen gas. [11C]Carbon dioxide is then collected with cryogenic traps or 
carbon molecular sieves. ' 4-17 [ 11 C] Methane is efficiently trapped using a polymer-based 
gas chromatography solid support (PorapakTM Q). 
1.6.2. Labelling reagents derived from ["C]carbon dioxide 
[ 11 C] Carbon dioxide has been directly used in the preparation of [II C] sugars 18 , although 
this primary species is normally transformed into more useful labelling synthons 
(Scheme 1.1). For instance, the reaction between Grignard reagents and ["C]carbon 
dioxide leads to the formation of [11C]carboxylate salts. [carboxy-"C]Carboxylic acids 
are then obtained by hydrolysis of these labelled salts. Some [carboxy-"C]carboxylic 
acids such as [1-1 1 C]acetate or [1-11C]palmitate have been used for the study of 
myocardial fatty acid metabolism. 19,20 [11C]Acid chlorides can be produced from 
["CIcarboxylate salts or from ["CIcarboxylic acids. These valuable intermediates will 
be discussed in depth in Chapter 4 of this thesis. 
["C]Alcohols have been prepared by reduction of [11C]carboxylate salts with lithium 
alurninium. hydride and used in blood-brain permeability studies 
21 
and cerebral blood 
22 11 
flow measurements. [I C]Ethylene can be produced by dehydration of [I 
"C]ethanol over heated quartz glass. 23 Moreover, the treatment of ["C]alcohols with 
29 
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hydriodic acid generates ["C]alkyl iodides. ["C]Iodoethane 
'24 [1 - 
11 C] iodopropane 25,26 
and [1-11C]iodobutane 27 have been synthesised from ["C]alcohols and employed in 
alkylation reactions. 
0 
R-N= 11 C=O lill I RHN- C-NHR 
0 
III H2N-1 C-NH2 
H2N- 11 CN 
0 
lill H3C- C-CH3 
11 Co 
- R- CH20H 
RCH= 11 CH2 
R- CH21 
C- 0 2] R- 
11 C02M9X R- C02H olm R- COO 
I 
CH30H CH31 
CH20 
Scheme 1.1. Some labelling blocks derivedftomPICIC02. 
["C]Acetone is obtained when ["C]carbon dioxide is reacted with methyl lithium. 
28,29 
In this reaction, the molar ratio of methyl lithium needs to be carefully controlled to 
avoid the formation of [2-"C]tert-butanol. ["C]Acetone has been used in the 
radiosynthesis of [11C]sarin 30 and compounds containing isopropY131-34 or acetonide 31 
functions. 
["C]Formaldehyde has been typically obtained in a two-step procedure involving the 
reduction of ["C]carbon dioxide to ["C]methanol with lithium aluminium hydride, 
followed by oxidation of the labelled alcohol with silver catalysts 36,37 or ferric 
molybdenum oxide. 38,39 ["C]Formaldehyde can also be directly produced from 
30 
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[I 'C]carbon dioxide by metal hydride reduction at low temperature. 
4042 The main 
synthetic applications of ["C]formaldehyde have been the reductive formylation of 
amineS36,43,44 and ring-closure reactions . 
40,41,45-47 
["C]Cyanamide is a versatile synthon that has been produced from ["C]carbon 
dioxide. 48A BaO/AI203 column was first used to trap the ["C]carbon dioxide and the 
resulting barium ["C]carbonate was then converted into barium ["C]cyanamide with 
ammonia. Hydrolysis of this barium intermediate provided ["C]cyanamide in 55-65 % 
radiochemical yield. [1 'C]Benzylguanidine, [1 'C]4-methyloxazol-2-amine and [1 'C]urea 
have been obtained from [ 11 C] cyanamide. 48 
["C]Urea can be prepared by reaction of ["C]carbon dioxide with supercritical 
ammonia 49 or via the hydrolysis of a [11 Clbis(trimethylsilyl)carbodiimide adduct . 
50 The 
one-pot synthesis of unsymmetrical ["C]ureas using triphenylphosphinimines has been 
recently described. 51 In this method, [''C]carbon dioxide was reacted with a 
triphenylphosphinimine to provide [ 11 C] isocyanates. The reaction of these intermediates 
with arnines provided the desired unsymmetrical [ 11 C] ureas - 
1.6.3. Labelling reagents derived from ["CImethane 
["C]Diazomethane has been prepared from [''C]methane via ["C]chloroform 
52 and 
used in the "C-methylation of carboxylic acids (Scheme 1.2). 
53 Aldehydes can also be 
"C-methylated by ["C]diazomethane, as shown in the preparation of the anticancer 
drug ["C]daunorubicin. 54 
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11 CH4 
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ON 
330 OC 
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\ 
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ý2H 
1 11 CICH2N2 
N 
H 
/0 
CH3 
1 11 Cjlsrodipine 
H0 
y 
OH 
OCH3 0 OH 1 
0 
OH NHCOF3 
1 11 CICH2N2 
ii) NaOH 
0 OH 0 
""'OH 
OCH3 0 OH 0 
0 
OH NH2 
IIIC]Daunorubicin 
CH3 ""'OH 
0C113 0 OH 0 
0 --7 
,i OH NH2 
Scheme 1.2. Preparation of P'C]diazomethane and application to the synthesis of 
[ 11 C]Daunorubicin and P 'C]Isrodipine. 
["C]Phosgene can be generated from ["C]methane in a two-step procedure (Scheme 
1.3). 55 The first step involves the formation of [ 11 C] carbon tetrachloride by chlorination 
at high temperature. ["C]Phosgene is finally obtained by catalytic oxidation of 
["C]carbon tetrachloride over heated iron filings. This labelling reagent has been 
employed in ring-closure reactions, such as the synthesis of the P-adrenergic receptor 
56 
radioligand S-["C]CGP 12177. ["C]Phosgene has been also the starting material in 
the preparation of [ 11 C] alkyl chloroformate, [ 11 C] urea and [ 11 C] dialkyl carbonates. 57 
11 CH2N2 
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11 CH4 
C12 I CUC12 
IN- 
Pumice stone / 380 OC 
11 Fe / 02 (2 %) 11 CC14 
3000C 
--»- C0C12 
>ýN 
NH2 
H 
OH NH2 
1 11 
CICOC12 
N NH 
H 
OH HC 
0 
S-["CICGP 12177 
Scheme 1.3. Production of P'C]phosgene ftom P'C]methane and application to the 
radiosynthesis of S-P'C]CGP 12177. 
Hydrogen [11C]cyanide is prepared by passage of [11C]methane in a low concentration 
of ammonia over heated platinum. 13 Hydrogen [11C]cyanide has been directly used in 
the preparation of [11C]glucose '58 
2-deoxy-D-[1-11C]glucose 59,60 and [11C]amines. 61,62 
Moreover, several [carboxy- 11 C] amino acids have been synthesised via the Bucherer- 
Strecker reaction (Scheme 1.4). 63-65 In this reaction, aldehydes or ketones were treated 
with an ammonium salt and potassium [11C]cyanide to yield a hydantoin. Alkaline 
hydrolysis of this intermediate provided the labelled racemic amino acid. 
0 RI 
II // R, 111CICN- R2 --)--ýýc \ 
NH 
OH- 
R, 11 C02H 
ý=O 0- R2-'ýý 
R2 (NH4)2CO3 HN---ý NH2 
0 ["CID, L-amino acid 
Scheme 1.4. Bucherer-Strecker synthesis of []-"C]amino acids. 
Hydrogen ["C]cyanide is also the starting point for the radiosynthesis of other labelling 
agents such as [1 
'C]methylamine, 66 [1 'C]haloalkanonitriles, 67 
[1 'C]cyanoalkyltriphenylphosphoranes, 68 ["C]urea, 69 ["C]oxalic acid 70 or 
["C]cyanomethyl pivalate 71 (Scheme 1.5). There are also many examples of aryl ring 
11 C-cyanations through transition-metal mediated reactions. 
72-74 
["C]Cyanogen bromide deserves especial attention since the carbon atom has reversed 
polarity and acts as an electrophilic source of [11 C]cyanide. This intermediate 
has been 
prepared by bromination of hydrogen ["C]cyanide with bromine or pyridinium 
tribromide. 
75,76 
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it 
C]Guanidines 
577,78 ["C]cyanamides '48 ["C]cyanates and ["C]thiocyanateS79 were 
obtained when ["Clcyanogen bromide was reacted with nucleophiles (Scheme 1-5). 
["C]Cyanogen bromide has also been applied to the labelling of proteins 80 and 
polysaccharides. 81 
Jim CH2N2 
IN- COC12 
101. CH31 
NH3 
]o- H 11 CN 
pt / looo Oc 
(E) E) 
C5H6NBr3 
or 
Br2 / triglyme 
11 CNBr 
Scheme 1.5. Labelling synthons obtainedftom P 'C]methane. 
1.6.4. ["ClIodomethane 
11 CH3NH2 
X-(CH2)n- 11 CN 
E) (D X Ph3P-(CH2), - CN 
11 CO(NH2)2 
H02C- 11 C02H 
(CH3)3CC02CH2- 11 CN 
NH 
1111 1 R-NH CNHR 
R-NH 11 CN 
R-0 11 CN 
R-S 11 CN 
["C]Iodomethane is arguably the most important carbon-11 labelling reagent. It has 
been classically prepared from ["C]carbon dioxide by reduction with lithium 
aluminiurn hydride followed by treatment with hydriodic acid. 36 Other reagents such as 
triphenylphosphine diiodide, 82 diphosphorus tetraiodide 83 and triphenylphosphite ethyl 
iodide 84 have been used in the iodination step instead of the corrosive hydriodic acid. 
Lithium aluminium hydride readily absorbs carbon dioxide from the air. Therefore, the 
specific radioactivity of [1 
'C]iodomethane prepared by the reduction- iodination route is 
moderate (74-222 GBq/pmol). 
82,85 
["C]Iodomethane has been produced from ["CImethane employing different 
routes. 86,87 However, the preferred method for [I 
'Cliodomethane production is the gas- 
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phase reaction between [1 'C]methane and molecular iodine (Scheme 1.6) . 
88,89 This 
reaction is carried out in a circulatory system in which gaseous ["C]methane and iodine 
are repeatedly passed through a furnace. The generated ["C]iodomethane is trapped 
using PorapakTMQ and the radiochemical yield is ca. 80 %. The specific activity of 
87 [11 C]iodomethane produced from C]methane is 3 70-412 GBq/ýtmol . 
11 
CH4 + 12 0 
11 CH31 + HI 
Scheme 1.6 Synthesis of P1 C]iodomethane from P 'C]methane and iodine. 
["C]Iodomethane has been utilised in the "C-methylation of numerous compounds 
containing nucleophilic groups such as amines, 90 amides, 91 alcohols, 92,93 thiolS94 and 
carboxylic acids 95 (Figure 1.5). The "C-methylation of amines normally occurs using 
the free base desmethyl precursor or by generating the free base in situ from a 
hydrochloride salt. The 11 C-methylation of amides and hydroxyl groups requires strong 
bases such as sodium hydroxide. 
S-11C-Methylations can be carried out using ["C]iodomethane and a thiol. However, 
thiols can be unstable and difficult to handle. This problem has been overcome by 
preparing fresh thiols for each radiotracer synthesis or by the in situ generation of thiols 
from thioester precursors (Scheme 1.7). 96 
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N-11CH3 N 
C02Et 
N 
C]Flumazenil 
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H311CO 
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H 
N, 
*, ý\ N 
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H3 11 c 
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(Opiate receptor radioligand) 
Fý, ýý N 
C02 CH3 
11 Clß-CIT-FE 
(Serotonin transporter radioligand) (Dopamine transporter radioligand) 
Figure 1.5. Examples of P1 Qradioligands prepared by reaction 
'C]iodomethane and desmethyl precursors. 
between 
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HO CH3 ýH3 
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0 
SR 
a ( (D (D (Bu)4N OH -)o- 
CH30H 
SH 
QHý 
1 11 CICH31 
»- 
DMF, 50 OC 
s 11 CH3 
HC 
R= CH3, C3H7, C6H5 
Thiol intermediate 111CIMcN5652 
(Scrotonin transporter radioligand) 
Scheme 1.7. Synthesis of PIC]McN5652 by reaction between P'C]iodomethane and an 
in situ generated thiol. 
1.6.5. Labelling reagents derived from [IIC]iodomethane 
S-11C-Methylations can also be performed through the reaction between 
["C]methanethiol and aryl halides (Scheme 1.8). ["C]Methanethiol is effectively 
prepared by distilling ["C]iodomethane into a solution of sodium hydrogen sulphide in 
DMF at room temperature. 97 
CH31 
NaSH 
CH3SH + Nal 
DMF 
Hal s 11 CH3 
1 
l"C]Methanethiol 1 
ö 
(i 
Scheme 1.8. Preparation of P1 Qmethanethiol and reaction with aryl halides. 
["C]Methyl triflate is a highly reactive "C-methylating agent that is prepared by 
passage of ["C]iodomethane 
98 or ["C]bromomethane99,100 over graphitised carbon 
impregnated with silver triflate (Scheme 1.9). The reactivities of [1, C]methyl triflate 
and ["Cliodomethane have been compared in the synthesis of some common 
PET 
radioligands. 
101,102 ["C]Methyl triflate usually gave higher yields and required smaller 
amounts of precursor than [ 
11 C] iodomethane. 103,104 
0 
C 
AgOS02CF3 
CH 
11 
113-1 3-0- ý111-"'3 
0 
Scheme 1.9. Radiosynthesis of P1 Clmethyl triflate ftom P1 C]iodomethane. 
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[11 C]Methyl lithium has been prepared in almost quantitative yield by halogen-metal 
exchange reaction between butyl lithium and ["C]iodomethane (Scheme 1.10). 105 
["C]Methyl lithium has been used in steroid labelling, 105 in the synthesis of 
["Clacetatel 06 and in the preparation of [1 'C]methanesulphonyl chloride. 107 
CH31 n-BuLi CH3Li + n-Bul 
-80 OC 
Scheme 1.10. Radiosynthesis of P1 Qmethyl lithium from P 'C]iodomethane. 
Lithium ["C]methyl(2-thienyl)cuprates are highly reactive copper complexes that are 
prepared by reacting [11C]methyl lithium with lithium (2-thienyl)cyanocuprate or 
lithium (2-thienyl)iodocuprate. Lithium ["C]methyl(2-thienyl)cuprates have been used 
in two reactions: cross-coupling with acid chlorides 108 and 1,4-addition to a, p- 
unsaturated ketones' 09 (Scheme 1.11). 
0 
cl 
i) Li"CH3(2-thienyl)Cu(LiCN) 
CI-Si(CH3)3 / THF 
121-11CIProgesterone 
OAc 
i) Li'ICH3(2-thienyl)Cu(LiCN) 
ii) HCI 
H 
H 
I CIMesterolone 
H 
Scheme 1.11. Application of lithium P'C]methyl(2-thienyl)cyanocuprate to the 
synthesis of [21 -11 Cjprogesterone and P1 Qmesterolone. 
["C]Nitromethane has been obtained by passage of ["C]iodomethane over 
hot silver 
nitrite or sodium nitrite. 
110,111 [ 11 C]Nitromethane has been used in the radiosynthesis of 
"C-ring-labelled benzenoid compounds, 110,112,113 but it also underwent addition or 
condensation when reacted with aldehydes 
(Scheme 1.12). 1 14-116 
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Scheme 1.12. Reactions of [11 Qnitromethane with aldehydes and pentamethinium salts. 
1.6.6. "C-Carbonylations using ["Clcarbon monoxide 
[1 1C]Carbon monoxide is prepared by thermal reduction of target-produced [I 1C]carbon 
dioxide with charcoal or transition metals (zinc, molybdenum). ' 17,1 18 Despite the low 
reactivity and solubility problems of [ 11 C] CO, palladium-mediated carbonylations using 
that precursor have become one of the most frequently used methods for the 
introduction of carbon- II into organic compounds (Scheme 1.13). 5 Some methods for 
the efficient [11C]CO trapping have been described in the literature, such as the re- 
circulation of [11C]CO through the reaction media, the concentration and enclosure of 
[11C]CO in a microautoclave, the use of a high pressure reactor or the use of a modified 
microautoclave for photoinitiated carbonylations. 11 
7,119-123 
[carbonyl- 11 C] Ketones were obtained by reaction of aryl halides, 
124,125 
aryl 
triflates 
119,126 
or diaryliodonium salts 
127,128 
with [1 'C]carbon monoxide and tin reagents 
in the presence of palladium catalysts (Stille couplings). [carbonyl- 11 C] Ketones could 
also be attained when boronic acids were used instead of tin reagents (Suzuki 
couplings) . 
11 7,129,130 [11C]Amines were obtained by reductive amination of [carbonyl- 
'C]ketones prepared by palladium-mediated 11 C-carbonylations. 131 
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Scheme 1.13. Production of Qcarbon monoxide and synthetic applications of this 
labelling synthon. 
Aromatic and benzylic [carboxy-"C]carboxylic acids were prepared by palladium- 
mediated "C-carbonylation of aryl and benzyl halides. 132 In contrast, aliphatic 
[carboxy-IIC]carboxylic acids were obtained from photoinitiated radical 1IC- 
carbonylation of alkyl iodides. ' 33,134 The palladium-mediated synthesis of [carbonyl- 
1 1C]esters from halides, [1 1C]carbon monoxide and alcohols has had limited success. 135 
However, aliphatic [carbonyl- 11 C] esters were efficiently synthesised from [11C]carbon 
monoxide and alkyl iodides by a photoinduced radical -mediated reaction. 
136,137 Diethyl 
[carbonyl- 11 C] malonate ester has been recently prepared by the rhodium-promoted 11 C- 
carbonylation of a diazo compound. 138 
[carbonyl-"C]Benzamides and aliphatic [carbonyl-"C]amides have been generated by 
palladium-promoted 1 
'C-carbonylations and photoinitiated 11 C-carbonylations 
respectively. The radiosynthesis of [carbonyl-"C]amides will be discussed in detail in 
Chapter 4 of this thesis. [carbonyl-"C]Imides and hydrazides were both synthesised 
from [11 C]carbon monoxide in palladium -mediated 
11 C-carbonylations. 139,140 
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Amines, amino alcohols and alcohols reacted with ["C]carbon monoxide to yield 
labelled ureas, carbarnates and carbonates. 141 This "C-carbonylation reaction was 
catalysed by a tetrabutyl ammonium fluoride- selenium complex. The formation of 11C- 
labelled ureas, carbamates and hydroxyureas from ["C]carbon monoxide was also 
promoted by a rhodium (1) complex. 
142,143 
1.7. Fluorine-18 chemistry 
The incorporation of fluorine can profoundly affect the physical and biological 
properties of compounds (lipophilicity, acidity, reactivity, in vivo biodistribution, 
metabolism). 144 This important fact has been applied in the pharmaceutical industry to 
develop various drugs containing fluorine in their structures. 145 
Fluorine-18 (tI/2 ý-- 109.8 min) decays by positron emission in 97 % and by electron 
capture in 3 %. The longer half-life of fluorine-18 compared to carbon-11 presents 
some advantages. 18F-Radiotracers can be prepared by lengthy protocols in high 
specific activities and transported to medical centres with PET cameras but without a 
cyclotron. Furthermore, biological processes occurring within minutes or hours can 
potentially be imaged with 18 F-labelled compounds. C_18 F bonds are strong and their 
enzymatic cleavage gives [18 F]fluoride as metabolite. Besides that, positrons emitted by 
fluorine-18 have lower energy than those emitted by carbon-11 (0.635 MeV and 0.96 
MeV respectively). Therefore, final images obtained from 
18F-tracers have higher 
resolution. 
Fluorine-18 appears in 2-deoxy-2-[ 18 F]fluoro-D-glucose ([18 F]FDG), which is the most 
widely used PET radiopharmaceutical. This compound has found numerous 
applications in medicine, especially in oncology. Moreover, several other 
18 F- 
radiopharmaceuticals such as 6- [18 F]fluoro-3,4-dihydroxy-L-phenylalanine 
(6- 
[18 F]fluoro-L-DOPA), [18 F]altanserin or 3'-deoxy-3 i_[18 F]fluorothymidine ([18 F]FLT) 
are routinely prepared worldwide. 
1.7.1. Production of fluorine-18 
Fluorine- 18 can be generated by cyclotrons in two different chemical fonns: 
nucleophilic 
[18 F]fluoride or electrophilic molecular [18 F]fluorine (1 
8 F- 19 F, [18 F]F2). 
1 18 F]Fluoride is normally prepared from the 180(p, n) 
18 F nuclear reaction on 
18 0- 
41 
Chanter I General Introduction 
enriched water. 
146 This is the preferred production method due to the high yields and 
the high specific activity of the produced [18 F]fluoride. 147 The expensive and scarce 
18 O-enriched water can be recovered with an ion exchange resin after the irradiation 
process. 1 
48,149 Other strategies for the production of [18 F]fluoride that avoid the use of 
18 O-enriched water have been explored. 
150,151 
[18 F]F2 is preferentially produced by the irradiation of neon gas with deuterons [ 2Ne(d, 
(X) 
18 F]. 152,153 The addition of stable fluorine (0.1 % v/v) is required to promote efficient 
exchange and to recover the labelled fluorine from the target walls. [1 
8 F]F2 can also be 
produced from [18 F]fluoride by the 18 0(p, n) 
18 F nuclear reaction (Scheme 1.14). 
154,155 In 
this case, no-carrier-added [18 F]fluoride is reacted with iodomethane to yield 
[18 F]fluoromethane. This labelled intermediate is then mixed with carrier F2 and 
electrical discharges promote isotopic exchange to provide [18 F]F2 in specific activities 
up to 55 GBq/ýtmol. 
1 18 OIH20 
i) Proton irradiation 
op K [18 FIF/K2.22. 
CH31 
-4- CH3 
18 F 
F2 / Ne 18 F]F2 
ii) K2CO3 / K2.2.2. Electrical discharge 
Scheme]. 14. Production o molecular [18 F]fluorineftom [ 
18 Fffluoride. ýf 
All the methods for the production of electrophilic [18 F]fluorine require the addition of 
the stable isotope. Thus, the specific radioactivity of [18 ]F2 is always low. In contrast, 
[18 F]fluoride is generated by no-carrier- added procedures in high specific radioactivities 
(50-500 GBq/Vtmol). The main sources of isotopic dilution for fluorine- 18 are the target 
walls, solvents and chemicals used in the radiosyntheses. 156 
1.7.2. Electrophilic radiofluorinations 
1.7.2.1. Molecular [1 8 FIfluorine 
Molecular [18F]fluorine was one of the first fluorinating agents used in PET 
radiochemistry. This labelled synthon reacts with electron-rich alkenes and aromatic 
compounds via hydrogen substitutions or electrophilic additions. [18 F]F2 is a highly 
reactive agent and reacts indiscriminately with the substrates. Therefore, complex 
mixtures of radioactive products are usually obtained. Some other fluorine-18 
electrophilic reagents with superior properties will be described below. These 
electrophilic 
18 F-fluorination reagents are always prepared from carrier-added 
molecular [18 FIfluorine. Therefore, the final radiotracers have low specific activities. 
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Furthermore, the maximum theoretical radiochemical yield in electrophilic 18 F- 
fluorinations is 50 %, since only one of the fluorine atoms in [18 F]F2 is incorporated 
into the final electrophilic reagent. 
The reactivity of elemental fluorine can be moderated by dilution with an inert gas 
152,157 
or in strongly acidic media. 
158-160 For example, [18 F]F2 diluted with neon was used in 
the first preparation of [18 F]FDG from 2,4,6-tri-O-acetyl-D-glucal (Scheme 1.15). 161-163 
The addition of the fluorinating agent to the precursor double bond followed by acidic 
removal of the protecting groups gave a mixture of [18 F]FDG and 2-deoxy-2- 
[18 F]fluoromannose ([18 F]FDM). The isomers were finally separated by preparative gas 
chromatography and [18 F]FDG was obtained in 8% radiochernical yield. 
OAc 
AcO __--O 
A Co 
j) 1 18 FIF2/Neon/CFC13 
ii) HCI 
OH 
-ýýO HO Hoý OH 
OH 
18 V- 0 
HO" 
ýý 
Hoýýý OH 
1 18 FjFDG 
of 
P8 P8F F. Scheme 1.15. Original radiosynthesis F]FDG via ]2 
1 18 F]FDM 
1.7.2.2. [18 FjAcetyl hypofluorite 
[18 F]Acetyl hypofluorite ([18 F]CH3CO2F) is prepared by reacting [ 18 F]F2 gas with alkali 
metal acetate/acetic acid mixtures (Scheme 1.16). 1 
64-166 Reactions involving [18 F]F2 
only occur in a few solvents such as fluorotrichloromethane. In contrast, [18 flacetyl 
hypofluorite is soluble in several organic solvents such as hexane or methanol. 
1 18 F]F2 
CH3CO2H / CH3CO2Na 
-imp- 1 
18 F]CH3CO2F 
Scheme 1.16. Preparation of [ 18 F]acetyl hypofluoriteftom P8 F]F2 
[18F]CH3CO2F reacts with alkenes to give vicinal fluoro acetoxy intermediates. This is a 
syn electrophilic addition and the fluorine atom generally attacks the more nucleophilic 
carbon of the double bond. 
167 The vicinal [18 F]fluoro acetoxy substrates undergo 
elimination in the presence of base or heat to give 
[18 F]alkenyl fluorides. For instance,, 
5- [18 F]fluorouracil has been prepared from uracil using this synthetic protocol (Scheme 
168 
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Scheme 1.17. Synthesis of 5-p8F]fluorouracil by electrophilic addition of 
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1.7.2.3.18 F-Fluorination of aromatic compounds via [18 FIF2 and [18 F] acetyl 
hypofluorite 
Arenes, containing electron-donating groups react with [18F]acetyl hypofluorite and 
[18 F]F2 to give mainly ortho fluorination products. The radiosynthesis of 6j, 8 F]fluoro- 
L-DOPA, 169 a fluorinated analogue of the anti-Parkinson drug L-DOPA, is an example 
of such a reaction (Scheme 1.18). 170,171 Both 2-[18F] and 6-[ 18 F]fluoro-L-DOPA are 
obtained after reaction with [18F]acetyl hypofluorite, but the isomers can be adequately 
separated with HPLC. 
13 
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113 
j) 118 FICH3CO2F 
ii) HI 
C02H 
NH2 
is F 
OH 
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2-1 18 F]Fluoro-L-DOPA 
+ 
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6- 118 F]Fluoro-L-DOPA 
Scheme 1.18. Synthesis of 6-P8 F]fluoro-L-DOPA using P8 F]aceryl hypofluorite. 170 
The regioselective introduction of fluorine- 18 on aromatic rings can be achieved by 18 F- 
fluorodemetallations. In this reaction, a metallic substituent (normally a tin or mercuric 
derivative) is displaced by an electrophilic fluorine-18 atom from [18 F]F2 Or 
[18 F]CH3CO2F. 172-175 Mercuric precursors have been used in the preparation of 6- 
[18 F]fluoro-L-DOPA, 
176,177 
although 
18 F-fluorodestannylation is currently the preferred 
method for the synthesis of this radiopharmaceutical (Scheme 
1.19). 178-180 
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Scheme 1.19. Synthesis of 6-P8 F]fluoro-L-DOPAftom organometallic precursors. 
The 18 F-fluorodernetallation of metalloarenes is a fast and regioselective reaction. 
However, the required organometallic precursors can be difficult to synthesise and the 
formulated radiotracers must be completely devoid of toxic metal traces. 
1.7.2.4. [18 FIXenon difluoride 
[18 F]Xenon difluoride ([18 F]XeF2) is a valuable fluorinating synthon that has been used 
in the labelling of [18 F]FDG and 6- [18 F]fluoro-L-DOPA. 
181,182 [18 F]XeF2 has been 
prepared from the reaction between [18 F]F2 and xenon at high pressure 
183 
and by 
isotopic exchange between Bronsted or Lewis acids ([18 F]HF, [18 F]SiF4 or [18 F]AsF5) 
and a sulfuryl chloride solution containing XeF2- 
184 Constantinou et al. have also 
reported a straightforward preparation of [18 F]XeF2 
from [18 F]fluoride and XeF2- 185This 
18 F for 19F exchange was carried out in dichloromethane or acetonitrile and was 
catalysed by the Cs+-Kryptofix 2.2.2 complex. 2- [18 F]Fluorocyclohexanone was then 
synthesised by reacting [18 F]XeF2 and 1-[(trimethylsilyl)oxy]cyclohexene (Scheme 
1.20). 
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18/19 F-Si(cH3)3 
Scheme 1.20. Radiosynthesis of 2_P8 F]fluorocyclohexanone using 
P8 F]XeF2. 
1.7.2.5. N- [18 FIfluoro compounds 
N- [18 F]Fluoro compounds are excellent electrophilic fluorinating reagents. 
186 
[18 F]Fluoro-2-pyridone, 187,188 N-[18F]fluoropyridinium triflate 189 and N- [18 F]fluoro-N- 
alkylsulfonamides'90 have been prepared using [18 F]F2 and have been applied to the 
[18 F]fluorination of carbanions (Scheme 1.21). 
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[ 18 F]Fluorination of organometallic reagents via N-[ 18 F]fluoro 
1.7.3. Nucleophilic radiofluorinations 
No-carrier-added [18 F]fluoride is normally obtained by proton irradiation of a target 
filled with 180-enriched water. Aqueous [18 F]fluoride is the product recovered from the 
target. This highly solvated aqueous [18 Ffluoride is rather unreactive. Anhydrous 
acetonitrile is therefore added to the vessel containing the hydrated [18 Ffluoride 
for 
46 
troduction 
azeotropical removal of water. Three acetonitrile addition-evaporation cycles normally 
provide the [18 F]fluoride ion in a reasonably anhydrous form. However, [ 18 F]fluoride 
also needs to be combined with the aminopolyether Kryptofix 2.2.2 (K2.2.2. ), a crown 
ether or large cations such as cesium, rubidium or tetraalkylammonium (Scheme 1.22). 
These additives increase the solubility and the reactivity of the inorganic [18 F]fluoride 
in the organic reaction media. The counterion of these added cations is usually the non- 
nucleophilic carbonate, which does not compete with [18 F]fluoride in nucleophilic 
displacement reactions. The less basic potassium oxalate has been also utilised in cases 
where the basicity of the carbonate anion can affect the reaction substrates. 
191,192 
18 F-(1120)n + K2CO3 + 
ý-0, 'ý-ýOJ 
Kryptofix 2.2.2 
00 
Heat K+ 18 N O\ N+ F- 
CH3CN /0 (d ry) ý-o 
0i 
+ C03 2- 
Scheme 1.22. Activation of [ 18 F]fluoride using the K'lKryptofix 2.2.2 system. 
The activated [18 F]fluoride anion is a strong base as well as a strong nucleophile. 
Therefore, reactions fail if performed in polar protic solvents such as methanol. Thus, 
nucleophilic radiofluorinations using [18 F]fluoride are generally carried out in dipolar 
aprotic solvents. 
1.7.3.1. Nucleophilic aliphatic substitutions 
1.7.3.1.1. Direct 18 F-fluorinations on complex structures 
A leaving group is displaced by [18 F]fluoride in aliphatic nucleophilic 
radiofluorinations. Since this exchange is a bimolecular nucleophilic substitution (SN2), 
inversion of stereochemistry takes place during the reaction. The leaving group is 
typically a halide (bromide, iodide) or a sulphonate (mesylate, tosylate, triflate or 
nosylate). There are certain functional groups such as hydroxy, carboxy or amino that 
must be protected during the 
18 F-fluorination step. 
Some of the most important PET radiopharmaceuticals are prepared by [18F]fluoride 
attack on protected substrates. For instance, the current radiosynthesis of [18 F]FDG 
involves the reaction between [18 F]fluoride and 1,3,4,6-tetraacetyl-p-D- 
mannopyranose-2-triflate (Scheme 1.23). 
193- 195 The final product is obtained by 
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cleavage of the acetyl protecting groups. The total radiosynthesis time is around 45 min 
and the radiochernical yields are 40-55 %. 
OAc OAe OH 
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AcO 
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ý, 
OAc CH3CN AeO OAc HO OR 
18 F 18 F 
1 18 FjFDG 
Scheme 1.23. Radiosynthesis of [18F]FDG using no-carrier-added [ 18 Fjfluoride. 
A similar procedure was also used in the radiosynthesis of [18 F]FLT, a cell proliferation 
marker. 1 
96-198 The nosylate (4-nitrobenzenesulphonate) leaving group in the protected 
precursor was displaced by [18 F]fluoride and [18 F]FLT was obtained in 20 % 
radiochemical yield after removal of the protecting groups (Scheme 1.24). 199 Some 
other precursors have also been suggested for the synthesis of [ 
18 F]FLT . 
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Scheme 1.24. Radiosynthesis of 3'-deoxy-3 _P8 F]fluorothymidine (p 
8Fj FL T). 
1.7.3.1.2.18 F-Fluorinations via aliphatic prosthetic groups 
The direct incorporation of fluorine- 18 into certain substrates is not possible or gives 
low radiochemical yields. The 
18 F-fluorination of these compounds must be achieved 
through 18 F-synthons. The precursors for these 
18 F-building blocks are bifunctional and 
mostly react with suitable substrates by alkylation or acylation. 
For example, numerous 
[18 F]fluorohaloalkanes and [18 F]sulphonatefluoroalkanes have been used for 
18 F- 
fluoroalkylation reactions on phenols, amines, amides, thiols or carboxylic acids 
(Scheme 1.25 ). 201-210 
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Scheme 1.25. Radiosynthesis of[ 18 F]fluoroalkyl precursors and possible reactions with 
nucleophiles. 
Aliphatic 18 F-fluoroacylating reagents have been described as useful prosthetic groups 
211-213 for the introduction of fluorine- 18 into peptides and proteins. In these reagents, 
the [18 F]fluoroacyl moiety was activated by p-nitrophenoxy, N-oxysuccinimide or 
imidazoyl substituents and [18F]amides were obtained by reaction of the 
18 F- 
fluoroacylating compounds with primary amines. One example of this approach was the 
radiosynthesis of (2-[18F]fluoropropionyl-D-Phel)-octreotide by reaction of 4- 
nitrophenyl 2- [18 Ffluoropropionate ([18 F]NPFP) with the D-Phe-octreotide amino 
group (Scheme 1.26). 214 
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Scheme 1.26 Radiosynthesis of 2-P8F]fluoropropionyl-D-Phe-octreotide using 
ý8F]NpFp. 
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The copper-catalysed Huisgen 1,3-dipolar cycloaddition (click reaction) has also been 
recently used to incorporate 18 F-prosthetic groups into small molecules and peptides. In 
this reaction, 1,4-disubstituted 1,2,3-triazoles were obtained from terminal alkynes and 
azides. [18 F]FluoroalkyneS215 and 2-[ 18 F]fluoroethylazide 216 have been utilised in the 
click reaction (Scheme 1.27). These transformations were highly efficient and were 
carried out in aqueous media under mild conditions. 
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Scheme 1.27.18F-Labelling ofpeptides and small molecules using click chemistry. 
1.7.3.2. Aromatic nucleophilic substitutions 
1.7.3.2.1. Direct 18 F-fluorinations on electron-deficient aromatic rings 
The incorporation of [18 F]fluoride into aromatic rings via aromatic nucleophilic 
substitutions (SNAr) requires two conditions: arenes must be activated by the presence 
of electron-withdrawing groups (e. g. nitro, cyano or acyl moieties) and a good leaving 
group must be present (e. g. nitro, trimethylammonium, fluoro, chloro) in either ortho or 
para position to the activating functionalities. 
217,218 This methodology has allowed the 
18 219-226 
one-step F-fluorination of several complex structures (Scheme 1.28) . 
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Scheme 1.28. Synthesis of 18F-radioligands by one-step SNAr on complex 
structures. 
192,220,225 
1.7.3.2.2.18 F-Fluorinations of arenes without electron-withdrawing substituents 
The introduction of [18 F]fluoride into aromatic rings without electron-withdrawing 
substituents has been achieved by the Balz-Schiemann reaction (Scheme 1.29). 227-231 
This process involved the synthesis of [ 18 F]aryldiazonium salts by fluoride isotopic 
exchange. The pyrolysis of the labelled intermediates provided the desired 
[18 F]fluoroarenes. Although the Balz-Schiemann reaction was regiospecific and 
compatible with most functional groups, the specific radioactivity of the 
18 F-products 
was low and the maximum theoretical yield was only 25 %. The isotopic dilution 
drawback has been overcome by the use of tetrachloroborate salts instead of the initial 
tetrafluoroborates. 
228 
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Scheme 1.29. Radiosynthesis of P8 F]fluoroarenes via the Balz-Schiemann reaction 
[18 FIFluoroarenes have also been prepared from [18 F]fluoride by the Wallach reaction 
(Scheme 1.3 0). 232-235 This method was regiospecific and involved the acid 
decomposition of aryl piperidinyl triazenes. However, the Wallach reaction has not 
been widely used in 18 F-fluorinations due to the formation of complex product mixtures 
and the low radiochernical yields. 
N-N 18 F]Fluoride 
% // -N 
Scheme 1.30. Radiosynthesis of P8 F]fluoroarenes via the Wallach reaction. 
The reaction between [18 F]fluoride and diaryliodonium salts has been proposed as a 
promising approach for the radiosynthesis of [18 F]fluoroarenes (Scheme 1.3 1 ). 
23 6-241 
18 F-Labelled products can be obtained in high yields and the reaction selectivity is 
controlled by the electronic and steric properties of the aromatic rings present in the 
iodonium salt. 
242 
01 18 FIFluoride 18 18 
R--O-I) Aw- R- F+ F-0 
GD A 
R= CH3, OCH31 Cl 
A= Br, OTf 
Scheme 1.31. Radiosynthesis of P8 F]fluoroarenes via diaryliodonium salts. 
1.7.3.2.3.18 F-Fluorinations using aromatic prosthetic groups 
2-[ 18 F], 3 _[18 F] and 4- [18 F]fluoronitrobenzene have been synthesised from dinitro and 
trimethylammonium-nitro precursors in very high radiochemical yields. 
217,243-249These 
simple 
18 F-synthons have been further reacted to provide useful 
18 F-labelling reagents. 
For example, 4-[ 
18 F]fluoroaniline 250 was easily prepared by reduction of the nitro group 
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in 4- [18 FIfluoronitrobenzene and was converted into a diazonium salt or was directly 
employed in alkylations and nucleophilic additions (Scheme 1.32). 246,247,251,252 
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Scheme 1.32. Radiosynthesis and reactions of 4-P8F]fluoroaniline. 
246,247,251 
2- [18 F] and 4- [18 F]fluorobenzaldehydes are obtained in high radiochemical yields from 
nitro and trimethylammoniumbenzaldehydes . 
217,243,253,254 [18 F]Fluorobenzaldehydes can 
participate in reductive aminations, 
255 
nucleophilic additions 
256,257 
and oxime 
formation 258,259 (Scheme 1.33). 
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Scheme 1.33. Some reactions of P' 'F]fluorobenzaldehydeS. 
255,257,258 
[18F]Fluoroarenes have been obtained from [18 F]fluorobenzaldehydes by 
decarbonylation with Pd/C260 or tris(triphenylphosphine)rhodium (1) chloride 
(Wilkinson catalyst) . 
26 1 For instance, 4- [18 F]fluorobromobenzene has been synthesised 
via this route and has been used in cross-coupling reactions with organostannanes 
(Scheme 1.34). 262,263 
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Scheme 1.34. Synthesis of 4-P8 FIfluorobromobenzene by P8 F]fluorobenzaldehyde 
decarbonylation. 4-P8 F]Fluorobiphenyl was then obtained using a palladium-mediated 
cross-coupling reaction. 
[18 F]Fluorobenzyl halides are arguably the most versatile 18 F-labelling blocks that can 
be derived from [18F]fluorobenzaldehydes. 4-[18F]Fluorobenzyl iodide can be directly 
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obtained from 4-[ 18 F]fluorobenzaldehyde by reductive iodination using 
diiodosilane, 264,265 although the synthesis of 
18 F]fluorobenzyl halides from 
[ 18 F]fluorobenzaldehydes usually involves the reduction to [18 F]fluorobenzyl alcohols 
followed by halogenation (Scheme 1.35). 266-270 
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Scheme 1.35. Preparation of 4_P8 F]fluorobenzyl halides ftom 4- 
P8 F]fluorobenzaldehyde. 
[18 F]Fluorobenzyl halides have been used in alkylation reactions to provide receptor- 
binding radioligands 
265,271,272 
as well as labelled amino acids 
273-275 (Scheme 1.36). 
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Scheme 1.36 Application of P8 Fjfluorobenzyl bromides to the radiosynthesis of the 
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[18 F]Fluoroarylketones have been efficiently obtained viaSNAr reaction on nitro 
276 
or 
trimethylammonium precursors . 
277 4- [18 F]Fluoroarylketones have been further 
transformed into 4- [18 F]fluorophenol by the Baeyer-Villiger reaction (Scheme 
1.37) . 
278,279 Both m-chloroperbenzoic acid and hydrogen peroxide have been used in 
this oxidation, although the latter reagent provided 4- [18 F]fluorophenol in higher 
radiochemical yields. 
280 
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Scheme 1.37. Synthesis of 4, -p8F]fluorophenolftom 4_P8 F]fluoroarylketones. 
4- [18 F]Fluorophenacyl bromide ([18F]FPB)276 has been obtained by polymer-supported 
bromination of 4-[18F]fluoroacetophenone and has been applied to the radiolabelling of 
peptides and proteins (Scheme 1.3 8). 
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Scheme 1.38. Synthesis and reactivity Qf 4_[18 F]fluorophenacyl bromide (p 8F]FpB). 
4- [18 F]Fluorobenzonitrile has been obtained in 80-85 % radiochernical yield from 4- 
cyano-N, N, N-trimethylanilinium trifluoromethanesulphonate. 
245,282 N-(4- 
[18 F]fluorobenzyl)-2-bromoacetamide is a synthon that has found use in the 
radiolabelling of oligonucleotides (Scheme 1.39). 
282,283 This compound was prepared by 
reduction of the 4- [18 F]fluorobenzonitrile cyano group followed by acylation of the 
resulting amine with bromoacetyl bromide. 
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1.8. Criteria for the selection of candidate radioligands 
Potential radioligands for the in vivo visualisation of neurotransmitters or brain receptor 
systems must fulfil several criteria. 
4,284-286 Besides that, an additional obstacle in the 
development of radioligands is the impossibility to predict the in vivo behaviour of 
candidates from in vitro data. Nevertheless, the following criteria are crucial for 
designing successful radioligands: 
-Target selection and affinity. 
Potential biological targets (usually receptors or enzymes) in the central nervous system 
must exist in sufficient density in order to be imaged or measured with PET. 
Furthermore, candidate radioligands should have high affinity for the target region. 
Typical brain radioligands have receptor affinities in the nanomolar or subnanomolar 
range. 4 The affinity required to obtain sufficient image contrast depends on the target 
density. Ligands with higher affinities are needed to image receptors with lower 
concentrations. This fact can be illustrated by [11C]FLB 457, a D2/D3 receptor 
antagonist. 286 This radioligand has extremely high affinity for the D2 receptors (KD = 20 
PM) and allows the visualisation of extrastriatal regions with low D2 receptor densities. 
However, increases in target affinity do not improve signal-to-noise ratios if the non- 
specific binding is also increased. Besides that, radioligands with very high affinities 
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must be prepared in higher specific radioactivity to avoid possible pharmacological 
effects. 
-Selectivity for the target. 
Radioligands should ideally bind with high affinity to only one target type. 
Nevertheless, a lack of selectivity is acceptable if the target sites are anatomically 
separated. For instance, derivatives of spiperone labelled with carbon- II or fluorine- 18 
display high affinity for D2 and 5-HT2A receptors. The differential localisation of D2 
receptors (largely in the basal ganglia) and 5-HT2A receptors (mainly in frontal cortex) 
in human brain simplifies the modelling and interpretation of the binding data. 285 
-Lipophilicity. 
287 
, 
288 
Lipophilicity can be defined as the affinity of a molecule or moiety for a lipophilic 
environment. The distribution of solutes between octanol and an aqueous buffer, as 
expressed by the partition coefficient (log P) is often used as an index of lipophilicity. 
This index can be determined experimentally or using computer software. 
The radiotracer lipophilicity plays an important role in brain uptake and non-specific 
binding, with a moderate liPophilicity being required to cross the blood-brain barrier. In 
general, the maximum log P for successful radioligands is around 3.5. Higher 
lipophilicities increase non-specific binding to plasma proteins and other peripheral 
binding sites. A consequence of high non-specific binding is the reduction in brain 
uptake and in radioligand plasma free fraction. Furthermore, highly lipophilic substrates 
often undergo increased metabolic rates as well as high liver and lung uptake. 
The molecular weight and the number of hydrogen donors and acceptors in a molecule 
are important factors that affect lipophilicity. Therefore, modulation of this parameter is 
possible by appropriate functionalisation of the radioligand. 
-Stereo selectivity. 
289 
Radioligands that display high affinity are often stereoselective in their binding to the 
receptor site. In vivo PET studies should be carried out using single enantiomers (not 
racernates), especially if quantitative information is to be obtained. Confusing effects 
can be caused by differential distribution, metabolism, protein binding or 
pharmacokinetics in the enantiomers of a racemic radioligand. Moreover, higher signal 
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to noise ratios can be obtained by avoiding the contributions to non-specific binding by 
the less potent enantiorner. 
-Metabolism. 
The majority of drugs suffer metabolic degradation in vivo. Hence, it is desirable to 
understand the radioligand metabolism before any prospective clinical application is 
addressed. Ideally, radiolabelled metabolites should not bind to the receptors of interest 
or even cross the blood-brain barrier. Furthermore, radioligands that undergo very fast 
metabolism are very difficult to quantify. 
Metabolism after the radiopharmaceutical administration is normally measured from 
serial plasma samples with HPLC. Brain radioligands should preferably have a small 
number of metabolites that are more polar than the parent compound. Tracer metabolic 
issues have been solved by different approaches, such as labelling in different 
positions 290 or using deuterated analogues. 291 
-Toxicity. 
3,6 
Prospective radioligands should be non-toxic and should not show adverse 
pharmacological effects at the administered dose. Radioligands based on therapeutic 
agents satisfy the non-toxicity requirement. Analogues of therapeutic agents or novel 
entities require toxicological screening prior to human use, despite the low amount of 
radiolabelled tracer injected in PET studies (less than a microgram). 
-Radiolabelling strategy. 
The radiolabelling step is usually one of the most challenging aspects in 
radiopharmaceutical development. Any potential radioligand should be amenable to 
labelling with a positron emitter using an automated or a remotely-controlled system in 
order to protect personnel from radioactivity. The complexity and duration of 
radiosyntheses are limited by the short half-life of the radionuclides employed. Besides 
that, radioligands for the central nervous system need to be produced in high specific 
radioactivity and sufficient radiochemical yield and purity for human administration. 
Finally, the routine production of radioligands for clinical PET studies must be reliable 
and reproducible. 
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1.9. Aims of the thesis 
Chemical synaptic transmission is exerted by the binding of neurotransmitters to 
specific membrane proteins (receptors). Neurotransmitter receptors can be divided into 
two major classes: ionotropic receptors and G-protein-coupled receptors (GPCR). 
When neurotransmitters bind to a receptor, the resulting complex triggers changes in 
postsynaptic potential (ionotropic receptors) or the release of second messengers 
(GPCR) that ultimately lead to a physiological response. 
Molecules that mimic the action of the neurotransmitter at the receptor are termed 
agonists. Ligands that bind to the receptor without producing a response are called 
antagonists. 
Most of the PET tracers used to study neurotransmitter receptors in vivo are antagonists. 
Nevertheless, PET agonists are also available for a number of systems such as the 
serotonin- I A5 
292,293 dopamine-2 '294 nicotinic-(x4p2 '295,296 muscarinic-2,297 ýt-opioid 
298,299 
and r, -opioid receptors. 
300,301 
Antagonist radioligands used to visualise G-protein-coupled receptors with PET do not 
distinguish between the high- and low-affinity states of the receptors. In contrast, 
agonists bind preferentially to the high-affinity state of the receptors. Therefore, the use 
of agonist radioligands to image the high-affinity state of the receptors has some 
potential applications such as the measurement of the high-affinity state/low-affinity 
state ratio in vivo, studies of pathological conditions in which the proportion of high and 
low-affinity states may be altered, the measurement of endogenous neurotransmitter 
release or the study of therapeutic drugs and anaesthetics that shift receptors from the 
high-affinity state to the low-affinity state. The use of an agonist PET radioligand could 
also measure more accurately receptor occupancies by agonist drugs. 
The following chapters of this thesis describe the chemical and radiochemical routes 
employed for the labelling of a dopamine-2 agonist [(+)-PHNO] and a serotonin-lA 
agonist (Flesinoxan). 
(+)-pHNO is a full agonist that shows subnanomolar affinity and high selectivity for 
D2/D3 receptors in vitro. More importantly, this radioligand has been labelled with 
carbon- II and has allowed the PET imaging of the high-affinity state of the D2/D3 
receptors in human volunteers. However, one limitation for the widespread use of 
[I I Cl- 
(+)-pHNo is its radiosynthesis. The published labelling procedure involves the 
introduction of carbon- II in the position I of its N-propyl moiety via 
11 C-amidation 
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with [carbonyl-"C]propionyl chloride. This is followed by reduction of the carbonyl 
group. 
Records at Hammersmith Imanet and other PET centres show that the radiosynthesis of 
[carbonyl- 11 C] acid chlorides is low yielding, unreliable and difficult to adapt to 
commercial synthesis modules. Therefore, the main objective for this project was the 
development of an alternative "C-methylation/reduction/deprotection labelling route 
that was simpler, more robust and easier to automate than the described protocol. This 
radiosynthesis should be carried out in a one-pot protocol in order to be implemented 
on a commercial 11 C-methylation module. 
Despite numerous efforts, no PET agonist for the 5-HTIAreceptors has been validated 
in man yet. Nonetheless, Flesinoxan shows several favourable properties as a candidate 
radioligand. This compound displays subnanomolar affinity and selectivity for the 5- 
HTIAreceptors. Moreover, it is a potent agonist at the 5-HTIAreceptors and crosses the 
blood-brain barrier in rats and man. 
The aim of this project was the radiolabelling of Flesinoxan with a positron-emitting 
radionuclide for subsequent biological evaluation in vivo, as well as the preparation of 
non-radioactive Flesinoxan and other relevant radiochemistry precursors. 
In this context, another objective was the development of a novel approach for the 
preparation of [carbonyl-"C]amides that did not require ["C]acid chlorides. The 
application of this methodology should allow the fast, reproducible and efficient 
radiosynthesis of [carbonyl-''C]Flesinoxan and other [carbonyl-"C]amides. 
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Chanter 2 Materials and Methods 
2.1. Materials 
The following compounds were provided by Target Molecules (Southampton, United 
Kingdom): 
(+)-4-Propyl-3,4,4a, 5,6,1 Ob-hexahydro-2H-naphtho[l, 2-b] [1,4]oxazin-9-ol I(+)- 
P14NO], (+)-4-ethyl-3,4,4a, 5,6, I Ob-hexahydro-2H-naphtho[ I 2-b] [1,4]oxazin-9-ol 
(EHNO) and (+)-4-acetyl-3 4,4a, 5 6,1 Ob-hexahydro-9-triisopropylsilyloxy-2H- 
naphtho[1,2-b][1,4]oxazine (compound 3.14 ). 
The pure (S) enantiomer of benzoic acid (5 -amino -2,3 -dihydro -benzo [ 1,4] dioxin-2 - 
yl)methyl ester (compound 4.1) was provided by Solvay Pharmaceuticals (Brussels, 
Belgium). 
All other chemicals were obtained from Sigma-Aldrich (Gillingham, UK) and used 
without further purification. All solvents were high performance liquid chromatography 
(HPLQ grade and purchased from Fisher Scientific (Loughborough, UK). 
2.2 Methods 
2.2.1. Chromatography systems 
Preparative thin layer chromatography (TLC) was performed using aluminium plates 
with silica gel coating (250 [im layer, 60 A pore size, fluorescent indicator) obtained 
from Whatman International Limited (Maidstone, UK). Radio-TLC was determined 
with a Packard Instant Imager electronic autoradiography apparatus (Packard 
Instrument Company, Connecticut, USA). 
Silica gel (70-230 mesh, 60 A) for manual flash chromatography was obtained from 
Sigma-Aldrich. Besides that, a CombiFlash Companions automated flash 
chromatography device (Isco Inc., Nebraska, USA) equipped with pre-packed silica gel 
columns (35-60 ýtm average particle size, polypropylene construction with Luer lock 
connections) was used for diverse purifications. 
High performance liquid chromatography (HPLQ and radio-HPLC analysis was 
performed on a System Goldo system consisting of a Binary Gradient 125 pump, a 
Diode Array 168 detector (all from Beckman Coulter, High Wycombe, UK), a Model 
7725i injector (Rheodyne, California, USA), and a radioactivity detector (BiOSCanTM 
flow count, Nal(TI) crystal, 20 mm diameter, Lablogic Systems Limited, Sheffield, 
UK). Columns used for identification of standards and separation of radioactive 
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products were: Phenomenex Luna C 18(2) 5ýtrn analytical column (250 mm x 4.6 mm), 
100 A pore size and Phenomenex Luna C18(2) 10ýtm semi-preparative column (250 
mrn x 10 mm), 100 A pore size. Both were purchased from Phenomenex (California, 
USA). 
Preparative HPLC was carried out on an Agilent 1200 Series chromatograph consisting 
of a preparative peristaltic pump (Agilent product number G1361A), a2 position /6 
port valve (Agilent product number GI 158A), an analytical Rheodyne 7725i injector, a 
preparative Rheodyne 3725i-038 injector, a fraction collector (Agilent product number 
G1364B) and a diode-array detector (Agilent product number G1315B). The system 
was controlled by Agilent ChemStation software. The column used was a Phenomenex 
Luna C 18 (2) 5 ýtrn (AxiaTM packed, 75 mm x30 mm), 100 A pore size. 
2.2.2. Structure characterisation 
Infrared spectra were performed on neat samples with a Spectrum BX FT-IR 
spectrometer (Perkin Elmer Instruments, Massachusetts, USA). Transmittance (% T) 
was plotted vs cm-1. 
Nuclear magnetic resonance spectra (NMR) were obtained at ambient temperature for 
solutions of compounds in suitable deuterated solvents using a Bruker AM 400 
spectrometer ('H: 250.13 MHz; 
13C 
: 62.90 MHz) or a JEOL GX500 instrument (1H: 
500 MHz). Chemicals shifts are reported in ppm (6) relative to residual solvent peaks. 
Abbreviations used: s= singlet, bs = broad singlet, d= doublet, dd = double doublet, t 
= triplet, dt = double triplet, tt = triple triplet, q= quartet, quin = quintet, sex = sextet, 
sep = septet. 
GC-MS separations were carried out on an Agilent 6890 gas chromatograph coupled to 
an Agilent 5973 mass spectrometer in electron ionisation mode (El). The system was 
controlled by MSD Productivity Chemstation software. The columns used were: 
Phenomenex Zebron ZB-624 (6 % cyanopropylphenyl-94 % dimethylpolysiloxane), 30 
m length, 0.53 mm ID, 3 ýtm film thickness. Agilent HP-5ms (5 % phenyl-95 % 
dimethylpolysiloxane), 30 m length, 0.25 mm ID, 0.25 4m film thickness. 
Accurate mass spectra (HR-MS) were performed by Mass Spectrometry Services at the 
School of Pharmacy (London, UK). HR-MS were measured using a Thenno-Quest 
Navigator mass spectrometer operated under electrospray ionisation (ESI). 
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Melting points were determined on a Stuart Scientific SMPI melting point apparatus 
(Merck, West Drayton, UK). 
2.2.3. Radioactivity measurements 
Radioactivity was measured with a high-pressure re-entrant ionisation chamber IG 12 
(Centronics Ltd) filled with argon (20 bar) with accompanying picoamperimeter CP 10 
(Cooknell Electronics Ltd, Weymouth, UK) or by a sodium iodide well counter (EG & 
G Instruments, Massachusetts, USA). Both instruments had been pre-calibrated at the 
National Physical Laboratory (Teddington, Middlesex, UK). Radioactivity 
measurements were corrected for background and for physical decay to a set time. 
2.2.4. Microwave heating 
The coaxial resonance microwave cavity system consisted of two sections separated by 
a pair of brass aperture plates. The small aperture (1.3 cm) between the plates allowed 
the passage of microwave radiation through the cavity and the installation of the 
reaction vessels. Microwave radiation from a magnetron (Microtron 200,200 Watt, 
Electro-Medical Supplies Ltd., Wantage, England) was transmitted to the cavity via a 
coaxial cable. The temperature was monitored using a fibre-optic thennometer Type 
FT13 10 equipped with a fibre-optic sensor FTP3-003H (both manufactured by Takaoka 
Electric Mfg. Co. Ltd., Japan). 
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Chapter 3 Labellinz ofPHNO 
3.1 Introduction 
3.1.1. Dopamine 
Doparnine (DA) is the most abundant catecholarnine in the brain. DA has been 
implicated in a variety of physiological functions and dysfunctions that are involved in 
several disorders, including Parkinson's disease and schizophrenia. 1,2 
The biosynthesis of DA starts from the amino acid tyrosine, which is transported across 
the blood-brain barrier (BBB) by the amino acid transport system. Once in the DA 
nerve terminals, the conversion of tyrosine into L-3,4-dihydroxyphenylalanine (L- 
DOPA) is catalysed by the enzyme tyrosine hydroxylase (TH) (Scheme 3.1). TH is 
considered the rate-limiting enzyme in the biosynthesis of DA and is also present in 
other catecholamine neurons. L-DOPA is decarboxylated by the enzyme aromatic L- 
amino acid decarboxylase (AADC), providing DA. 6- [18 F]Fluoro-DOPA is a substrate 
for AADC and has been used to study presynaptic doparninergic function in humans. 
3 
0 
HO 
H 
Tyrosine 
Tyrosine 
hydroxylase (TH) 
HO 
HO 
H 
L-DOPA 
Arom atic-L-a mino acid 
decarboxylase (AADC) 
HO NH2 
HO 
Dopamine 
Scheme 3.1. Steps in the biosynthesis of dopamine 
(DA). 
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The metabolic breakdown of DA occurs via two parallel pathways (Scheme 3.2). In the 
first route, the enzyme monoamine oxidase (MAO) converts DA into 
dihydroxyphenylacetic acid (DOPAC) by oxidative dearnination. The second pathway 
involves the methylation of DA by catechol-0-methyltransferase (COMT). The 
resulting 3-methoxytyramine is then converted into homovanillic acid (FIVA) by the 
action of the MAO enzyme. The distribution of MAO in the brain has been studied with 
PET using [ 11 C] L-deprenyl and [ 11 C] clorgyline. 4,5 
HO NH2 
HO 
Catechol-O-m ethyl 
transferase (COMT) 
meo NH2 
HO""" 
Dopamine 
3-Methoxytyramine 
Scheme 3.2. Metabolic routes of dopamine. 
3.1.2. Dopamine receptors 
HVA 
Doparninergic signalling commences through the binding of the neurotransmitter to 
receptors that belong to the G-protein coupled receptor (GPCR) family. 6 Dopamine 
receptors are classified into two main groups based on their biochemical and 
pharmacological properties: DI -like receptors and D2-like receptors. 
7,8 
The DI-like group comprises the D, and D5 receptor subtypes. Both receptors stimulate 
the activity of adenylyl cyclase. DI receptors are mainly expressed in the striatum and 
in the cerebral cortex, while D5 receptors are found in striatum, thalamus and the 
hippocampus. D, receptors have been quantified by PET using the antagonist 
["C]SCH23390.9 
The D2, D3 and D4 receptors form the D2-like receptor subfamily. The inhibition of 
adenylyl cyclase activity is a general property of the D2-like receptors. 
10 D2 
postsynaptic receptors are mainly located in the striatum, nucleus accumbens and 
external segment of the globus pallidus. 
1 1,12 This receptor is also expressed 
Monoamino oxidase HO y OH 
(MAO) 
- 
HO I'll 
10 
DOPAC 
Monoamino oxidase meo OH 
(MAO) 
y 
HO 
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presynaptically in the substantia nigra pars compacta and in the ventral tegmental area. 
Furthermore, D2 receptors are also found outside the brain in the pituitary gland, 
vascular system, kidney and retina. 
The D3 receptors are less abundant than the D2 receptors and have a more limited 
distribution within the brain. 13,14 D3-receptor rich areas are found in the limbic striatum 
and efferent structures. D4 receptors are expressed at much lower levels and can be 
found in several brain areas such as frontal cortex, amygdala, olfactory bulb, 
hippocampus and hypothalamus. 15 
3.1.3. Imaging of D2 receptors with PET 
D2 receptors are involved in the pathogenesis of several psychiatric and neurological 
disorders. D2 receptors are also a key target of many therapeutic agents such as 
antipsychotics in schizophrenia and dopamine agonists in Parkinson's disease. 2,16,17 
D2 receptors can exist in two interconvertible affinity states for DA: a state of high 
affinity (D2-high) and a state of low affinity (D2-IOW)- 18 In the high-affinity state, the 
receptor is coupled to the G-protein, which is probably the functional state of the 
receptor. Antagonists bind to the D2-low and D2-high states of the receptor with equal 
affinity, whereas agonists bind preferentially to the D2-high state. 
PET radioligands used to study the brain distribution of D2 receptors show high affinity 
for D2 receptors as well as for D3 receptors. 
19,20 Therefore, images obtained with these 
radioligands reveal the population of both D2 and D3 receptors in the brain. D2-like 
antagonists generally have similar affinities for D2 and D3 receptors, whereas DA 
itself 
and most agonists bind with higher affinity to D3 receptors. 
' 5 
Studies of the D2 receptors utilising PET and SPECT have primarily 
focused on the use 
of antagonists, such as ["C]raclopride, 
21 [18 F]fallypride, 22 [II C]FLB457 23 and 
[1231] IBZM- 24 The attainment of a high signal relies mainly on the fact that antagonists 
have equal binding affinity for receptors in both the high- and 
low-affinity states. The 
use of antagonists to quantify receptor 
levels within the brain has been applied to 
examine the DA system in various psychiatric 
disorders. ' 6 In addition to these studies, 
drug-induced receptor occupancy analysis has been used in the development of 
antipsychotic drugs, themselves 
being antagonists, in order to demonstrate therapeutic 
efficacy. 
25 
However, studies of D2 receptors with antagonist radioligands cannot 
distinguish 
pathological conditions 
in which the proportion of D2-high and D2-IOW states may be 
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26 
altered. The study of neurotransmission is therefore very difficult because endogenous 
DA binds preferentially to receptors in the high-affinity state. 27,28 
The imaging and quantification of the D2-high state with an agonist have some potential 
applications: (1) study of diseases with a strong dopaminergic association, such as 
schizophrenia, manic depression and Parkinson's disease; (2) accurate study of 
doparnine release, since dopamine now competes with a more sensitive PET radiotracer 
that is bound only (or predominantly) to the high-affinity state of the receptor; (3) study 
of therapeutic drugs and anaesthetics that shift D2receptors from the high-affinity state 
to the low-affinity state. 
In recent years, there have been multiple efforts to develop agonist radiotracers for in 
vivo imaging of the D2-high state using PET and SPECT. 
A number of 11C- or 18 F-labelled derivatives of apomorphine and 2-aminotetralin have 
been reported as potential agonist radioligands (Figures 3.1 and 3.2). 29-38 Some of these 
agonists (i. e. [11C]NPA and [11C]NINPA) showed promising results in vivo, 
39-47 
although their use has not been reported in humans yet. The modest signal-to-noise 
ratio observed with these D2/D3 agonists may reduce their potential use in human 
trials. 
48 
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Figure 3.1. PET and SPECT D21D3 agonist radioligands 
based on the aminotetralin 
structure. 
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Figure 3.2. PET D21D3 agonist radioligands based on the apomorphine structure. 
3.1.4. (+)-PHNO 
(+)-4-Propyl-3,4,4a, 5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol, (+)-PHNO, 
was first described in 1984 by Jones et al. as the most potent compound in a series of 
naphth[1,2-b]-1,4-oxazines with D2 agonist activity. 49 (+)-PHNO was tested in Phase II 
clinical trials for treatment of Parkinson's disease under various names 50,51 (dopazinol, 
naxagolide, nazagolide, L 647339, MK 458). However, the drug development was 
abandoned due to the publication of some studies reporting the loss of clinical efficacy 
after long-tem-1 use of (+)_pIINO. 52,53 
The tricyclic oxazine structure of (+)-PHNO is related to ergolines 54 and (R)- 
apornorphine 38 , which are alkaloids with potent 
doparninergic activity. The trans 
arylethylamine substructure contained within the tetracyclic ergoline ring system has 
been viewed as the key element responsible for the interaction of these compounds with 
dopaminergic receptors 54-56 (Figure 3.3). The C, D ring junction in natural ergolines is 
trans and has the R, R configuration. (+)-PHNO has a configuration (laR, 4aR) 
consistent with the chirality of the active isomer of apomorphine. Besides that, the 
intrinsic doparninergic activity of the naphthoxazines was enhanced by an N-propyl 
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substituent and by the appropriate placement of a hydroxyl group on the aromatic 
ring. 49 
HN---% 
/ 
Aid 
R 
Ergoline ring system 
HO 
H 
HO"' 
0 
(+)-PHNO 
1-111' 
Figure 3.3. Structures of some compounds that show agonistic dopaminergic activity. 
The original synthesis of (+)-PHNO started from 7-methoxy-l-tetralone and required a 
complicated resolution to obtain the pharmacologically active enantiomer (Scheme 3.3). 
However, enantio selective routes for the synthesis of (+)-PHNO were later developed 
by Melillo et al. in 1987 due to the potential use of the compound for the treatment of 
Parkinson's disease . 
57 The asymmetric synthesis of (R) -homotyro sine provided the key 
precursor in the production of (+)-PfINO and avoided the separation of unwanted 
enantiomers (Scheme 3.4). 
H3CO 
4 steps 
0 
co N)ýý 
H 
OH 
H3 
Resolution of the active 
Ir enantiomer 
HO"'C 
(+)-PHNO 
5 steps 
H3CO N 
H 
OH 
49 
Scheme 3.3. Multi-step synthesis of (+)-PHNO reported by Jones et al. in 19 4. 
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Scheme 3.4. Enantioselective synthesis of (+)-PHNO using (R)-homotyrosine as the key 
intermediate. 
3.1.5. PET studies with ["C]-(+)-PHNO 
Studies in dogs and rodents showed that [3 H]-(+)-PHNO bound selectively to brain 
areas rich in D2 receptors . 
58,59 Furthermore, [3 H]-(+)-PHNO binding was almost fully 
inhibited in the presence of guanylyl-5'-imidodiphosphate [Gpp(NH)p], a substance 
known to convert the D2-high state into the D2-lOW state. This fact showed that [3 H]- 
(+)-PHNO specifically labelled the high-affinity state of the D2 receptors. Due to these 
advantageous features of (+)-PHNO, Seeman et al. already anticipated in 1993 its 
potential use to image the high-affinity state of the D2 receptors in vivo with PET. 58 
The first preclinical evaluation of ["C]-(+)-PHNO was published by Wilson et al. in 
2005 . 
60 Ex vivo binding of ["C]-(+)-PHNO in rat striaturn was found to be 
stereospecific, with the ["C]-(-)-PHNO enantiomer not showing retention in any brain 
region. The ["C]-(+)-PHNO binding was found to be specific to D2/D3 receptors. The 
signal was almost fully displaceable by D2 antagonists, but it was insensitive to DI, 
norepinephrine or serotonin receptor ligands. Besides that, the specific binding in 
rodent striatuin was susceptible to variations in the levels of endogenous DA. Finally, 
the cerebellum, a brain region with extremely low levels of D2 receptors, showed no 
specific uptake of [ 
11 C] -(+)-PHNO. 
The selective binding Of [IICI-(+)-PHNO to brain areas rich in D21D3 receptors was 
later confirmed in isoflurane-anaesthetised cats. 
48 This study also suggeste t at [ 11 C]- 
(+)-PHNO was more sensitive to DA fluctuations than [1 1 C]raclopride and [ 11 C]-(-)- 
steps 
H3CO NHC02CH 3 
OH 
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NPA. However, the use of volatile anaesthetics (i. e. isoflurane) perturbs the receptor/G- 
protein interactions, modifying the proportion of receptors configured in the high- 
affinity state. 61,62 Therefore, the interpretation of those animal PET results involving 
anesthesia should be viewed with caution. 
The first PET study using ["C]-(+)-PHNO in human healthy volunteers was reported 
by Willeit et al. in 2006.63 The obtained images showed excellent delineation of brain 
structures known to be rich in D2/D3 receptors. 11,12,64 The highest levels of radioactivity 
accumulation were measured in the caudate, putamen and in the globus pallidus 
externus. Within the striatum, radioactivity accumulation was most prominent in ventral 
striatal regions. In contrast, considerably lower uptake of radioactivity was observable 
in more caudal pallidal regions and in the globus pallidus internus. There was also a 
detectable accumulation of ["C]-(+)-PHNO in the substantia nigra/ventral tegmental 
area. Low radioactivity levels were observed throughout cortex and cerebellum. A 
blocking experiment of the ["C]-(+)-PHNO uptake with the D2/D3 receptor antagonist 
haloperidol demonstrated that an important component of the radioactive signal in the 
human striatum represented specific and displaceable binding of ["C]-(+)-PHNO to 
D2/D3 receptors. 
The in vivo distribution pattern of ["C]-(+)-PHNO was contrasted with [11C]raclopride 
scans in two subjects. The anatomical distribution of ["C]-(+)-PHNO binding was 
comparable to that of ["C]raclopride. However, within the striatal complex, striking 
differences between ["C]-(+)-PHNO and ["C]raclopride labelling were noticeable. 
["C]-(+)-PHNO appeared to preferentially bind to ventro-medial parts of the striaturn, 
while ["CIraclopride binding was more pronounced in the dorsal part of the striatum. 
There was also a consistently higher degree of ["C]-(+)-PHNO binding to the globus 
pallidus externus. Besides that, the kinetics of the [11 C]-(+)-PHNO uptake 
in this region 
appeared to be different from those obtained in both caudate and putamen, with a 
relatively slower radioactivity washout. Considerable globus pallidus 
binding has also 
been reported in a human postmortem study using the D2/D3 agonist radioligand 
L3 H]N- 
n-propylnorapomorphine. 
65 
The D3 to D2 receptor density ratio is higher in globus pallidus compared to ventral and 
dorsal striatal regions. 
" Hence, the unusual high binding of ["C]-(+)-PHNO in the 
66 
globus pallidus could be related to a possible selectivity 
for D3 receptors. This 
hypothesis was demonstrated in baboon experiments using the selective 
D3 Partial 
agonist BP 897.67 The administration of 
BP 897 reduced ["C]-(+)-PHNO binding in the 
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ventral striaturn, dorsal striaturn and particularly in the globus pallidus. These results 
suggested that the ["C]-(+)-PHNO distribution pattern was due to its preferential 
binding to D3 receptors over D2 receptors and to the fact that the relative density of D3 
receptors is high in the globus pallidus compared to D2receptors. 
68,69 
The sensitivity of the [I 'C]-(+)-PHNO binding to competition with endogenous DA has 
been studied in humans. 70 The subjects underwent ["C]-(+)-PHNO scans after 
administration of the DA-releasing agent D-amphetamine. The results suggested that 
the radioligand displacement correlated almost linearly with serum D-amphetamine 
levels. ["C]-(+)-PHNO was more sensitive to endogenous competition with DA than 
D2/D3 receptor antagonists. 
Vasdev et al. have described the radiolabelling and in vivo evaluation of the fluorinated 
(+)-PHNO derivative [18 F]F-PHN071 (Scheme 3.5). The radioligand showed an in vitro 
affinity for the D2-high receptors comparable to that of (+)-PHNO (K high = 0.4 nM for 
F-PHNO, Ki high = 0.7 nM for (+)-PHNO). However, [18 F]F-PH'NO did not show 
specific binding in the rodent brain and was rapidly cleared. This lack of in vivo 
selective binding has been attributed to the effect of fluorine on the amine basicity, 
which is a crucial factor for the receptor activation. 30,72-74 
11 
BrCH2CH2CH2 18 F 
HO NH DMSO / KI / 150 OC HO NF 
00 
3.1 1 18 FIF-PHNO 
Scheme 3.5. Radiosynthesis of 8 F]F-PHNO by alkylation of amine 3.1 with 
P8 F]fluoropropyl bromide. 
3.1.6. Radiosynthesis of ["C]-(+)-PHNO 
The labelling of racemic PHNO with a positron emitter was first described in 1995 by 
Brown et al. 
75 Carbon-11 was introduced in the propyl group of the molecule by 
reaction of the racemic N-despropyl precursor (±)-2.1 with [1-"C]iodopropane 
(Scheme 3.6). [1-"Cliodopropane was prepared by the Grignard carboxylation, 
reduction, iodination sequence reported by Langstrom. 
76 The alkylation reaction 
required heating at 130 
T and long reaction times due to the low reactivity of [1- 
"C]iodopropane. The radiochemical yields of ["C]-(±)-PHNO were rather poor (2-5 % 
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at EOS from[ II Cl C02) and were not sufficient or reproducible enough to evaluate this 
radioligand in vivo. 
HO NH 
0 -'J 
(±)-3.1 
CH3CH21 1 CH21 
III 
CH2CH2CH3 
NaHC03 / DMF 
HO 
0N 
-1", Ii 
1 11 Cl-(±)-PHNO 
Scheme 3.6. Labelling of racemic PHNO with []-"C]iodopropane. 
Two years later, the same group published an improved method for labelling the active 
(+)-enantiomer of PHNO . 
77 The procedure involved 11 C-amidation of substrate 3.1 with 
[carbonyl-"C]propionyl chloride followed by lithium aluminiurn hydride (LAH) 
reduction of the carbonyl group (Scheme 3.7). The ["C]acid chloride was produced 
either in solution or in a polypropylene loop. 78,79 [carbonyl-"C]Propionyl chloride was 
purified by distillation due to its moderate boiling point (77-79 OQ- The intermediate 
labelled amide 3.2 was finally reduced with lithium aluminium hydride to give [1, C]- 
(+)-PHNO. The highest radiochemical yields of [IIC]-(+)-PHNO were obtained when 
the ["C]propionyl chloride was synthesised in the loop (ca. 20 % at EOS from 
[11CIC02)- 
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Scheme 3.7. Radiosynthesis of P'C]-(+)-PHNO using [carbonyl-1, C]propionyl 
60,77 
chloride. 
The PET group at the University of Toronto recently reported the radiolabelling of (+)- 
PHNO with carbon- II as well as the biological evaluation of the ligand in vitro and in 
vivo. 60 Their initial attempts for the radiosynthesis of ["C]-(+)-PHNO involved the 
alkylation of the secondary amine precursor with [1-IIC]iodopropane. However, this 
approach was abandoned due to the large amounts of by-products obtained during the 
radiosynthesis. 
A 11 C-acylation/reduction method similar to Brown's route was therefore used for the 
preparation of ["C]-(+)-PHNO. The treatment of an ethylmagnesium bromide diethyl, 
ether/THF solution with ["C]carbon dioxide followed by addition of phthaloyl 
dichloride and 2,6-di-tert-butylpyridine gave [carbonyl-"C]propionyl chloride. 78 The 
[carbonyl- 11 C] acid chloride was then purified by distillation in 70 % radiochemical 
yield. The 11 C-acylation of the PHNO precursor occurred rapidly and was followed by 
reduction of the carbonyl group with LiAIH4 in THE However, the analysis of the 
reaction mixture revealed the presence of a polar by-product (identified as [I- 
"C]propanol) as well as ["C]-(+)-PHNO. This unwanted material was observed in 
significant amounts in some of the experiments and the authors proposed a number of 
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possible explanations (Scheme 3.8). Accordingly, [1-"C]propanol could be derived 
from reductive cleavage of the intermediate amide 3.2, from reduction of unreacted 
[carbonyl-IIC]propionyl chloride or from the reduction of the labelled ester 3.3. 
However, the most likely source of [I-11C]propanol was the reductive cleavage of the 
ester. Although acid chlorides have lower reactivity towards phenols compared with 
aliphatic alcohols, phenol acylation is promoted by base catalysis via deprotonation of 
the phenol. In fact, mixtures of 0-acylated and N-acylated products have been reported 
in the labelling with [carbonyl- 11 C] acid chlorides of other structures containing a 
80,81 secondary amine and an unprotected phenol. 
0 
HO N 
0 
3.2 
3.1 + CH3CH211COCI 
(DIPEA / THF) 
NH 
LiAIH4/THF 
imm. 3.1 CH3CH211CH20H 
Unreacted 
LiAIH4/THF 
110 CH3CH2 CH20H 
CH3CH2"COCI 
LiAIH4 / THF 
_ 3.1 + CH3CH211CH20H 
3.3 
Scheme 3.8. Sources ofpossible by-products in the acylation-reduction radiosynthesis 
of PIC]-(+)-PHNO. 
Wilson et al. Obtained ["C]-(+)-PHNO in 10 
% radiochemical yield after reversed 
phase HPLC purification. 
The radiochemical purity of the product was higher than 99 
% and the specific activity was 
50 ± 16.6 GBq/ýtmol. The total synthesis time was 40 
- 60 min. 
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3.1.7. Novel approach for the "Glabelling of (+)-PHNO 
Many D2 agonists, including (+)-PfINO, contain an N-propyl substituent. As mentioned 
above, this side chain has been labelled with carbon-11 using [1-"C]iodopropane or 
through the arnidation-reduction protocol. 35 However, both routes show certain 
drawbacks. 
The use of [1-"C]iodopropane usually gives low radiochemical yields and other [I- 
"C]alkyl iodides such as ["C]iodomethane are always produced during its 
radiosynthesis. 82,83 On the other hand, records at Hammersmith Imanet and other PET 
centres show that the radiosynthesis of ["C]acid chlorides is low yielding, unreliable 
and difficult to adapt to commercial synthesis modules. 
Therefore, a new radiosynthesis route was devised for the labelling of (+)-PHNO with 
carbon-1 1 in the position 3 of the N-propyl chain (Scheme 3.9). 
0 
PGO 
0 
3.4 3.5 
Carbonyl 
reduction 
HO 
[3-11CIPHNO 
PGO 
0 
3.6 
Scheme 3.9. Proposed introduction of carbon-H in the position 3' of the 
PHNO N- 
propyl chain. (PG = Protecting group) 
The new approach would involve the 
11 C-methylation of the carbon next to the carbonyl 
group of the N-acetyl precursor 
3.4 to obtain the [3-11 C]propanamide 3.5. The pKa of 
i) Strong base 
rl 
CH3 
0, PGO N 
CH31 
0 
Phenol 
deprotection CH3 
PGO N 
0 
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the hydrogens next to the amide carbonyl group is around 28-3 0.84 A strong base such 
as lithium diisopropylamide (LDA), lithium bis(trimethylsilyl) amide (LHMDS) or 
lithium 2,2,6,6-tetramethylpiperidide would be required for the formation of the amide 
enolate. Also, the initial N-acetyl precursor 3.4 must have the phenolic function 
protected under these conditions to avoid the formation of the 0-methylated product. 
The carbonyl group of the intermediate 3.5 must be reduced to the amine 3.6. [3 -11 C] - 
(+)-PHNO should be obtained by prompt removal of the phenol protective group. 
The feasibility of this strategy has been demonstrated in other compounds. For 
example, Dar et al. recently reported the use of LDA for the generation of N-acetyl 
amide enolates (Scheme 3.10). 
85 After the nucleophilic attack of the amide carbanion 
on cyclohexyl phenyl ketone, the resulting amides were reduced with BH3-SMe2 to 
yield aminoalcohols. 
i) LDA 
ii) 
c 
OH 0 
UR 
BH3 * SMe2 
OH 
N 
L-1-, 
lý 
R 
Scheme 3.10. Enolates of cyclic N-acetylpiperidines were treated with carbonyl 
electrophiles to yield propionam ides. These intermediates were reacted with a reducing 
agent to provide aminoalcohols. 
Ideally, the [3-"C]-(+)-PHNO radiosynthesis should be done in a one-pot protocol 
in 
order to be implemented on a commercial 
11 C-methylation module. The utilisation of 
["C]iodomethane in the radiosynthesis of (+)-PHNO instead of the unreliable and 
low 
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yielding ["C]acid chloride distillation would also facilitate the preparation of this 
radioligand in other PET centres. 
3.2. Results and discussion 
3.2.1. Chemistry on model compounds 
3.2.1.1. Development of the labelling strategy using a model compound 
The [3-"C]-(+)-PHNO N-acetyl precursor is a highly valuable molecule due to its 
enantiomeric purity and complex synthesis (vide infra). Therefore, the project started 
with the selection of N-acetyl-1,2,3,4-tetrahydroisoquinoline as an appropriate model 
compound for the development of the 1 'C-methylation/reduction strategy. This simple 
N-acetyl tertiary arnide resembled the structure of the (+)-PHNO precursor 3.4 and 
could be easily synthesised from cheap commercial chemicals. Moreover, the reactions 
could be monitored by TLC or HPLC due to the presence of an aromatic ring in the 
molecule. 
3.2.1.2. Synthesis of N-acetyl-1,2,3,4-tetrahydroisoquinoline and N-propionyl- 
1,2,3,4-tetrahydroisoquinoline (compounds 3.8 and 1.2) 
N-Acetyl-1,2,3,4-tetrahydroisoquinoline 3.8 has been prepared from 1,2,3,4- 
tetrahydroisoquinoline ( 3.7 ) via several methods. 86-89 Substrates other than 3.7 have 
also been used to prepare compound 3.8.90 
The method of Aubert 89 was used with some modifications for the synthesis of 3.8 
(Scheme 3.11). Amine 3.7 was acylated by acetyl chloride in the presence of 
triethylamine and the reaction was completed after stirring the reaction mixture 
for two 
hours at room temperature. After acid-base extraction, the crude amide was purified 
with flash chromatography, providing the off-white crystalline solid 
3.8 in reasonable 
yields (55-60 %). The purity of 3.8 was >99 % as shown 
by HPLC analysis. 
3.7 
cl R 
Et3N 
GIIIIIIIiyR 
3.8 Rý CH3 
3.9 R= CH3CH2 
Scheme 3.11. Syntheses off-acetyl and N-propionyl-1,2,3,4-tetrahydroisoquinoline. 
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N-Propionyl-1,2,3,4-tetrahydroisoquinoline 3.9 was obtained by acylation using 
propionyl chloride and the reaction yields were slightly higher in this case (75 %). The 
N-propionyl amide was also prepared using the mixed phosphinic anhydride method 
(Scheme 3.12). 91 In this procedure, amine 3.7 was added over a solution of propionic 
acid diphenylphosphinyl ester prepared in situ and the reaction mixture was stirred 
overnight at room temperature. Compound 3.9 was obtained in excellent yield after 
flash chromatography purification (88 % yield). This result proved the versatility of the 
mixed phosphinic anhydride method in the synthesis of aromatic and aliphatic amides. 
NH 
0 
HO"'Jýý 
3.9 3.7 
Et3N, Dpp-Cl 
Scheme 3.12. Synthesis of 2.9 using diphenylphosphinic chloride. 
The purity of arnides 3.8 and 3.9 deteriorated within two weeks upon storage at room 
temperature. HPLC analysis confirmed the appearance of prominent polar by-products 
in both cases. However, storage of the compounds at -20 T under an argon atmosphere 
maintained their integrity for months. 
The efficient separation of 3.8 and 3.9 by reverse-phase HPLC was easily achieved 
using diverse mobile phases (Table 3.1). 
Table 3.1. HPLC retention times of amides 3.8 and 3.9 in different mobile phases (17ow 
rate =I mIlmin, wavelength = 254 nm). 
Retention time ofL. 8 Retention time of 3.9 
Mobile phase (min) (min) 
50 % (NH4)2HP040.05 M-50 % 
acetonitrile' 
5.1 7.2 
60 % (NH4)2HP040.05 M-40 % 
3.9 6.0 
acetonitrile b 
70 % water/TFA-30 % 
acetonitrile/TFA 
b, c 
7.0 12.3 
aPhenomenex Luna CI 8(2) column, 5 pm particle size (250 mm x 4.6 mm) 
b Phenomenex Luna CI 8(2) column, 5 pm particle size (150 mm x 4.6 mm) 
co. I% TFA (trifluoroacetic acid) 
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3.2.1.3. Synthesis of N-propionyl-1,2,3,4-tetrahydroisoquinoline (compound 3. 1-9) 
through methylation of the cc carbon in N-acetyl-1,2,3,4-tetrahydroisoquinoline 
(compound 2.8D 
The fon-nation of 11 C-C bonds at a carbonyl cc-position through nucleophilic carbanion 
alkylation has been generally used in radiosynthesis to prepare [3-11C]amino acids. 82 ' 92- 
99 The precursors usually contain the carboxylic acid protected as an ester and the 
amino ftinctionality protected as an imine. Only a few strong bases such as NaOH, 
KOH, BuLi and LDA have been used in carbon- II chemistry to form the enolates. 
Modestly electrophilic reactants such as alkyl iodides are not sufficiently reactive to 
combine with neutral enol tautomers, but the increased nucleophilicity of the enolate 
anion conjugate base permits such reactions to take place (Scheme 3.13). Both the 
oxygen and the carbon are nucleophilic, but the carbon is usually the most nucleophilic 
site in the enolate. As with other carbon nucleophiles, the electron-rich carbanion 
attacks the electrophilic carbon of the halide to yield solely the C-alkylation material. 
0 
R1, Base 
, RI, N'Jý'E) 
R2 R2 
08 
RI, 
N 
I 
K2 
Rl"N R' 
1 
H2 
C-alkylation 
Scheme 3.13. Possible alkylation products of tertiary amide enolate anions. 
O-alkylation 
The initial experiments exploring the non-radioactive methylation of the N-acetyl amide 
3.8 were carried out using LDA or LHMDS as the base (Scheme 3.14). LDA could be 
purchased in two different specifications: 1.8 M solution in THF/heptane/ethylbenzene 
(containing 0.5 % LiBr stabiliser) and 2M solution in THF/heptane/ethylbenzene 
(containing 0.5 % Mg(N'Pr)2 stabiliser). On the other hand, LHMDS was obtained as a 
IM solution in THF without additives. 
Amide 3.8 was dissolved in anhydrous THF and the flask containing the starting 
material was kept at low temperature (40 OC or 0 OC) during the addition of the base. A 
slight excess of base was used to account for possible partial hydrolysis of the reagents 
during storage or transfers. 30 to 45 minutes were allowed for the generation of the 
lithium enolate, followed by addition of iodomethane. The alkylation was allowed to 
proceed for 30 minutes before the reaction mixture was worked up. The crude material 
OR' 
RI, 
not N 
1 
R2 
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was analysed by GC-MS and HPLC, confirming the presence of the desired N- 
propionyl amide 3.9. 
r, -,, ") LDA or LHMDS 8+ 8- 
N CH3-1 
3.9 0 Ou 
3.8 + Lil 
Scheme 3.14. General conditions usedfor the methylation of the a-carbon in 3.8. 
HPLC samples were taken at different time points in order to monitor the reaction. 
Only compound 3.8 was detected in samples taken before the addition of the alkylating 
agent. Samples taken after the addition of iodomethane showed no starting material but 
the appearance of three new peaks (Figure 3.4). The most polar product was 
iodomethane, which was normally added in excess and gave very intense UV peaks. 
The peak at 6.8 minutes was identified as the N-propionyl amide 3.9 and the small trace 
at 8.6 minutes was most likely to be the dialkylated N-isobutyryl amide. Disubstituted 
products have been reported in enolate methylations utilising more than one equivalent 
of base. 100 Once a small amount of methylated product 3.9 was formed, it was 
surrounded by a relatively high concentration of a strong base (i. e. the remaining 
enolate anion) that could remove another cc-proton, giving a new enolate anion that 
could be methylated again (Scheme 3.15). However, the dialkylated product was only 
found in small amounts. The rate of the proton abstraction from the cc-carbon in 3.9 was 
probably decreased due to reduced carbanion stability and to the increase in the steric 
hindrance suffered by the bulky bases. 
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Figure 3.4. HPLC trace of the synthesis of N-propionyl amide 3.9 through methylation 
of 3.8. Column: Phenomenex Luna C18(2) 5 pm particle size (250 mm x 4.6 mm), 50 % 
(NH4)2HP04 0.05 M-50 % acetonitrile, wavelength = 254 nm, flow rate =I mIlmin. 
Base 
Ny CH31 
0 
3.8 
3.9 
+ 
cJCy 
IIe 
CH31 
N-isobutyryl-1,2,3,4-tetrahyd roisoq u inoline 
Scheme 3.15. The acid-base proton transfer between alkylated products and unreacted 
enolate anion can give a new enolate anion that isfurther methylated 
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Both LDA and LHMDS were suitable bases in the enolate methylation of amide 3.8 at 
millimolar scale. After work-up, all the samples showed the presence of 3.9 and 
complete consumption of the starting material. However, initial experiments using 
smaller amounts of 3.8 (1-4 mg) showed a prompt decomposition of the acetyl amide in 
the presence of both strong bases. This behaviour was completely unpredicted due to 
the simplicity of the model compound structure. 
Derivative 3.8 underwent quick breakdown when treated with one equivalent of LDA 
or LHMDS at 0T (Figure 3.5, data for LDA not shown) and multiple polar by- 
products were observed shortly after the addition of the base. The same stability 
decrease appeared when 3.8 and LDA were mixed at -78 T, but the treatment of 
compound 3.8, with LHMDS at -78 T kept the amide intact for times up to 30 minutes. 
The use of LDA for the methylation reaction was therefore abandoned. Only LHMDS 
was employed in the development of the methylation-reduction procedure at the 
micromolar scale. 
100 
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Figure 3.5. Stability of compound 3.8 when mixed with one equivalent of LHMDS at 
-78 and 0 
OC 
Subsequent work showed that enolate generation of 3.8 employing LHMDS at -78 
T 
3.9 followed by iodomethane addition gave satisfactory yields of N-propionyl amide - 
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and complete consumption of the starting material. However, cleaner reaction mixtures 
were obtained when LHMDS was added to a solution containing precursor 3.8 and 
iodomethane. 
In the first procedure (pre-formation of enolate followed by iodomethane addition), the 
enolate species had the opportunity to form aggregated complexes., 01-103 The 
monoalkylated product 3.9 was close to neighbouring enolates and subsequent 
intermolecular proton transfer between an enolate and product 3.9 gave the substituted 
enolate, which could then undergo a second alkylation reaction (section 3.2.1.3. ). 
In the alternative protocol, the base was added to a mixture of the N-acetyl amide 3.8 
and the electrophile. In this case, the methylation reaction competed effectively with the 
formation of aggregated complexes and the amount of dialkylated product obtained was 
effectively minimised. 
3.2.1.4. Synthesis of N-ethyl-1,2,3,4-tetrahydroisoquinoline (compound 3.10 and 
N-propyl-1,2,3,4-tetrahydroisoquinoline (compound 3.11 by reduction of the 
amide moiety 
The arnide carbonyl is one of the most difficult functional groups to reduce. 
Nevertheless, several reagents have been used to achieve this transformation in 
disubstituted amides. 104 
Slurries of LAH are capable of reducing virtually all polarised organic functional 
groups. Therefore, LAH has been the reagent of choice for amide reductions in carbon- 
II radiochemistry. 
3 2,3 4,3 5,60,7 7,80,81,105 The use of BH3-SMe2 for the reduction of an 
intermediate propionyl amide has also been reported in the radiosynthesis of ["C]-(±)- 
pramipexole. 
36 
Most LAH reductions begin with the coordination of lithium to the carbonyl oxygen 
and transfer of the nucleophilic hydride (polarised 6- relative to aluminium) to the 
electrophilic carbonyl group (polarised 8+ relative to oxygen) (Scheme 3.16). However, 
amides do not react with LAH in the same way as other carbonyl derivatives do. The 
initial transfer of hydride to the amide forms an intermediate complex that suffers 
alkoxyalurninate elimination, leading to the formation of an iminium salt. The addition 
of another equivalent of hydride gives the amine as the final product. 
' 06-108 
110 
ChaDter 
-3 Labellina ofPHNO 
R2 
H 
H-A HH 
Al H LP /(D 
R, 
ýq 
R, 
N' 14ICK - 
HIHI 
R2 R2 
Alkoxyaluminate 
intermediates 
a 
Elimination of 
alkoxyalurninate H /Rl 10ý N, (@ 
R2 
Iminium salt 
LiAIH4 
10- 
H-AIH3 
II 
H, R, 
ý=ýo 
R2 
HHR, 
Y--N , 
R2 
Amine 
Scheme 3.16. Mechanism ofN-acetyl amide reduction with lithium aluminium hydride. 
In this work, the protocols used for the carbonyl reduction of amides 3.8 and 3.9 with 
LAH were identical (Scheme 3.17). A nitrogen-purged flask was charged with the 
amide (in anhydrous THF) and lithium aluminium hydride in THF (2 equivalents) was 
carefully added at room temperature. The reaction mixture was then heated at 60 OC and 
finally, the LiAlH4excess was carefully quenched with aqueous sodium hydroxide. The 
purification of the crude material was performed by column chromatography. The use 
of basic alumina as the solid phase instead of silica gel gave excellent results and 
avoided the addition of triethylamine or ammonia to the mobile phase. Amines 3.10 and 
3.11 were isolated as colourless oils in good yields (50-70 %). Both compounds were 
fully characterised by chromatographic and spectroscopic methods. Amines 3.10 and 
3.11 were also prepared by alkylation of 1,2,3,4-tetrahydroisoquinoline with iodoethane 
and 1-iodopropane respectively, but the reaction yields were somewhat lower (10-15 
LAH (2 equivalents) 
ýc 
or 3.8 or3.9 Oc THF / 60 
3.10 3.11 
Scheme 3.17. Synthesis ofN-ethyl-1,2,3,4-tetrahydroisoquinoline (3.10 ) andN-propyl- 
1,2,3,4-tetrahydroisoquinoline ( 3.11 ) by LAH reduction of the corresponding amides. 
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3.2-1.5. Temperature as a parameter in the reduction of N-propionyl-1,2,3,4- 
tetrahydroisoquinoline 
A series of experiments was designed to assess the impact of reaction temperature in 
the conversion of amide 3.9 into amine 3.11. Compound 3.9 was reacted with an excess 
of lithium aluminium. hydride (2 equivalents) and the reaction temperatures studied 
ranged from 0T to 60 T. Samples were taken at various time points and were 
analysed by reverse-phase HPLC. The results obtained at the different temperatures are 
summarised in Figure 3.6. 
100 
90 
80 
70 
60 
50 
40 
30 
20 
10 
0 
10 15 20 25 30 35 
Time (min) 
* 60 degrees 
-W- 40 degrees 
20 degrees 
0 degrees 
Figure 3.6. Analytical yields of amine 3.11 obtained at various temperatures. Samples 
were analysed by HPLC. Column: Phenomenex Luna C. 18(2)(150 mm x 
4.6 mm) 5, um 
particle size, wavelength = 254 nm, mobile phase = 50 
% (NH4)2HP04 0.05 M-50 % 
acetonitrile, flow =I mllmin. 
The HPLC yields of amine 3.11 remained low when the amide reduction was carried 
out at 0 T. The amine yield did not increase with time and most of 
the UV area 
corresponded to unidentified polar 
by-products (retention time = 2-3 minutes). 
Interestingly, no starting amide 3.9 was observed at any time point. 
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The yields of 3.11 obtained at room temperature were higher than at 0 OC. However, the 
reaction rate at this temperature was still too slow and inefficient to be applied to 
carbon- II radiochemistry. A significant proportion of polar traces (5 5% of total UV 
area) was observed even 45 minutes after LAH addition. 
Heating the reaction mixture at 40 T gave excellent results and the formation of amine 
3.111 mainly occurred between the I min and 15 min time points. Polar by-products only 
represented a small proportion of the total UV area (15-20 %) 15 min after LAH 
addition. As heating seemed crucial for a quick and efficient reduction of the amide 
moiety, the reaction was also studied at 60 T. Analysis of the sample at I min after 
LAH addition showed a very small amide 3.9 peak, and similar percentages of polar 
traces and amine 3.11 (Figure 3.7). In contrast, a massive increase in the area of the 
product 3.11 was observed in the sample taken at 5 min. The polar peak also decreased 
significantly during this time period and may represent an intermediate in the reaction. 
There was a 10 % higher conversion in 5 min at 60 OC compared to the experiment at 
40 OC. 
RQ CIO 
3.11 
Reduction time 1 min 
LReductb 
IN 
3.11 
FP-olar httermediat7es 
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Figure 3.7. HPLC chromatograms of the amide 3.9 LAH reduction at 60 OC Samples C.;, 
withdrawn at I min and 5 min showed an increase in the area ofproduct 3.11 and a 
reduction in the area of the polar material. 
In summary, heating was required for the expeditious reduction of the carbonyl moiety 
in substrate 3.9. Heating increased the conversion rate of the amide into the amine 3.11. 
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Possible decomposition of the product occurred only after prolonged heating (45 min 
reaction, data not shown) at the highest temperature tested (60 OC), but those conditions 
were not to be applied to carbon- 11 radiochemistry. The polar species observed at 
different time points are most likely intermediates in the amide reduction. These traces 
disappeared after prolonged heating at 40 T or 60 T, whereas they remained in 
significant proportion at lower temperatures. 
3.2.1.6. Background to the one-pot synthesis of N-propyl-1,2,3,4- 
tetrahydroisoquinoline (compound 2.11) 
Direct treatment of the crude mixture with LAH after the methylation of amide 3.8 
(section 3.2.1.3) only gave minute amounts of amine 3.11 and the main HPLC peak 
corresponded to an unidentified polar by-product. Therefore, the reaction should be 
quenched after the methylation stage. Enolate alkylation reactions involving lithium 
amides are normally neutralised with aqueous saturated ammonium chloride solutions. 
However, aqueous solutions are not compatible with LAH and ammonium chloride is 
barely soluble in organic solvents. Therefore, an alternative method for deactivating the 
base before the carbonyl reduction was sought. Furthermore, the quenching protocol 
should be easily incorporated into a radiochemistry procedure. 
Two options were studied for the base neutralisation: the use of a silica Sep-Pak 
cartridge and the addition of protic reagents, i. e. methanol and nitromethane. 
3.2.1.7. Synthesis of N-propyl-1,2,3,4-tetrahydroisoquinoline (compound 3.11 
through the Sep-Pak method 
Silica gel is a fairly acidic reagent and due to the small scale of the studied reactions, a 
silica Sep-Pak cartridge would contain enough material to trap the excess of base 
derived from the methylation step. Both the alkylation and reduction steps required 
anhydrous THF as the solvent. N-Propionyl amide 3.9 was hardly retained on a silica 
TLC plate with THF as the mobile phase (Rf = 0.87). Consequently, a minimum 
amount of solvent should be required to flush the product out of the silica cartridge. 
Compound 3.9 was dissolved in THF and the resulting solution was injected onto a 
light silica Sep-Pak that had been pre-conditioned with THF. Extra THF was used to 
completely flush the amide out. Most of the product was 
in the fractions containing the 
initial solution volume as established by HPLC. Amide 3.9 was still present 
in the 
following fractions, although in much lower concentrations. This experiment showed 
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that 3.9 could be recovered in good yields from a silica Sep-Pak using a small volume 
of THE 
Precursor 3.8 was treated with LHMDS and iodomethane at -78 OC and the crude 
reaction mixture was then injected onto a silica Sep-Pak (Scheme 3.18). Fractions were 
then collected and analysed by HPLC. Chromatograms of the reaction mixtures 
obtained before and after the Sep-Pak step were virtually identical and showed traces of 
iodomethane, product 3.9 and a small N-acetyl amide signal. Fractions containing 
amide 3.9 were treated with an excess of LAH at 60 OC and the crude reduced material 
was analysed by GC-MS and HPLC (Figure 3.8). Both techniques confirmed the 
presence of amine 3.11 as the main product. 
3.8 
CH319 -78 OC 
op 
LHMDS (I equiv) 
3.9 
i) Silica Sep-Pak 
ii) LiAlH4 (excess) 
60 OC, 30 min 
3.11 
Scheme 3.18. Synthesis of amine 3.11 through the methylation-reduction route. A silica 
gel Sep-Pak cartridge was used to trap LHMDS. 
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Figure 3.8. HPLC chromatogram of the crude amine 3.11. Silica Sep-Pak purification 
was used before the reduction step. 
3.2.1.8. One-pot synthesis of N-p ro pyl- 1,2,3,4-tetrahyd ro iso q uin o line (compound 
3.11 
The use of a silica Sep-Pak to neutralise LHMDS was successful and allowed the 
synthesis of amine 3.11 from amide 3.8. However, the introduction of an additional 
silica gel cartridge on an automated radiochemistry module would not be 
straightforward. The addition of a chemical that reacted with the base surplus after the 
methylation step and still allowed the carbonyl reduction would be more desirable. 
Methanol (pKa = 15.5) and nitromethane (pKa = 10.2) are protic solvents that should 
neutralise the base used for the methylation. Both methanol and nitromethane react with 
lithium aluminium hydride, decreasing the reducing power of the parent compound 
(Scheme 3.19). 107,109,110 However, these solvents could be evaporated before the 
addition of LAH. 
LiAIH4 +4 CH30H op- LiAI(OCH3)4 +4 H2 
3 LiAIH4 +2 CH3NO2 op- LiAI(CH3N)2 +2 LiA'02 +6 H2 
Scheme 3.19. Reactions of lithium aluminium hydride with methanol and nitromethane. 
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Methanol and nitromethane were directly reacted with LHMDS to check for the 
formation of the protonated amine HN[Si(CH3)312. The mixture nitromethane/LHMDS 
gave a white precipitate, whereas a clear solution was obtained after mixing anhydrous 
methanol and LHMDS. Both mixtures were analysed by GC-MS and the bis- 
(trimethylsilyl)amine peak (M = 161) was observed in both cases. Thus nitromethane 
and methanol were both able to efficiently neutralise LHMDS. 
N-Acetyl amide 3.8, was treated at low temperature with iodomethane and LHMDS. 
After one minute, the reaction mixture was neutralised with neat methanol or 
nitromethane. Lithium alurninium hydride was added and the mixture was heated at 60 
T for 30 minutes (Scheme 3.20). The excess of quenching reagent reacts with LAH 
and may decrease the reducing power of the metal hydride. Therefore, a large excess of 
LAH was used in the reaction. 
I CH319 -78 
OC 
N,, 
Ir 
LHMDS (1 equivalent) 
0 
3.8 3.9 
i) CH30H or CH3NO2 
(3 equiv) 
ii) LiAIH4 (10 equiv) 
60 OC, 30 min 
3.11 
Scheme 3.20. One-pot synthesis of amine 3.11 through the methylation-reduction route. 
Analysis of the reaction mixture after the reduction stage showed that 
both methanol 
and nitromethane were equally effective in the neutralisation of 
LHMDS. The 
conjugated acid of LHMDS was the strongest peak 
in the GC-MS spectra (M = 161). 
The peak of amine 3.11 was also present. These same results were also confirmed 
by 
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HPLC analysis of the crude reaction mixture. Thus, the methylation-reduction took 
place under these reaction conditions. 
3.2.2. Radiochemistry on model compounds 
3.2.2.1. Radiosynthesis and analysis of [11 C1 iodomethane 
[11C]Iodomethane was prepared from [11C]carbon dioxide by reduction with lithium 
aluminium hydride followed by treatment with hydriodic acid'" (Scheme 3.21) using 
the automated synthesis system depicted in Figure 3.9. 
II LiAIH4 0.1 M THF 
v- 
Hlaq 57 %II 
C021N2 
r. t. 
P- UAI(O CH3)(OCH3)3 
160 OC Am- CH31 
Scheme 3.2 1. Radiosynthesis of P1 Qiodomethane ftom P1 Qcarbon dioxide. 
A solution of lithium aluminium hydride in THF was added to the [1, C]iodomethane 
vessel immediately before the cryogenic trapping of [ 11 C] carbon dioxide in the hot cell. 
Though diethyl ether also dissolves LAH, its use can lead to the formation of 
[11C]iodoethane as a by-product. ' 12 Hence, THF solutions of LAH were used on all 
occasions. LAH readily reacts with atmospheric carbon dioxide contributing to the 
isotopic dilution of [11C]iodomethane (Scheme 3.22). Therefore, the minimum amount 
of LAH that still gave good yields of [11C]methanol was used in the preparations in 
order to achieve high specific radioactivity. 
4 C02 +3 LiAIH4 No- LiAI(OCH3)4 +2 UA102 
Scheme 3.22. Reaction of carbon dioxide with lithium aluminium hydride. 
The solvent was evaporated after the formation of the labelled alkoxyaluminate, since 
the addition of hydriodic acid onto the hot vessel containing LAH and the 
IIC- 
alkoxyalurninate may cause an explosion. Thus, the ["C]iodomethane vessel was 
cooled down to room temperature before such addition. The acid transformed the 
radioactive organometallic complex into ["C]iodomethane, which was purified by 
distillation (iodomethane b. p. 41-43 'C) and collected in the 1 IC-methylation vessel. A 
cartridge containing sodium hydroxide pellets was incorporated into the distillation line 
in order to remove any traces of hydroiodic acid and water. The distilled radioactive 
material was trapped at 0 OC in a sealed Wheaton vial containing ethanol or THE The 
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identity of the radioactive distillate was confirmed by co-elution with non-radioactive 
iodomethane (Figure 3.10). The "C-methylation rig produced ["C]iodomethane in 
satisfactory radiochemical yields (n = 3,60-70 % from [11CIC02, decay-corrected at 
end of synthesis) after the tuning of the nitrogen flows and the reaction temperatures. 
The radiochernical purity of ["C]iodomethane was 98-100 %. No decomposition of 
["C]iodomethane was observed in samples taken one hour after distillation. The total 
synthesis time for [ 11 C] iodomethane was 13 minutes from EOB. 
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Figure 3.10. Radio-HPLC chromatogram of P'C]iodomethane spiked with cold 
standard The conditions used in the analysis were: Phenomenex Luna C18(2) column 
(250 mm x 4.6 min x5 micron), mobile phase = 50 % water-50 % acetonitrile, 
wavelength = 254 nm, flow =I ml/min. 
3.2.2.2. Radiosynthesis of N-([3-1 1 C] p ropionyl)- 1,2,3,4-tetrahyd roiso quino line 
(compound 3.12) using LDA 
The use of LDA for the 11 C-methylation of N-acetyl amide 3.8 (Scheme 3.23) resulted 
in the degradation of both the precursor and the labelled amide 3.12, even when the 
reaction was carried out at -78 T. The highest radiochemical yields of amide 3.12 (35- 
45 % analytical yields) were obtained using a slight excess of base. Nevertheless, the 
reaction yields were not consistent and polar radioactive by-products were always 
obtained. 
In conclusion, the results obtained in the non-radioactive LDA methylations (section 
3.2.1.3. ) were confirmed in the carbon- 11 chemistry. The labelled amide 3.12 was 
obtained, although with unreliable radiochemical yields. Breakdown of precursor and 
labelled product was always observed. 
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3.8 
CH315 -78 
OC 
Do- 
Base (LDA or LHMDS) 
CH3 
0 
3.12 
Scheme 3.23. "C-Methylation ofN-acetyl-1,2,3,4-tetrahydroisoquinoline. 
3.2.2.3. Radiosynthesis of N-([3-"C]propionyl)-1,2,3,4-tetrahydroisoquinoline 
(compound 3.12 using LHMDS 
["C]Iodomethane was distilled into a vial containing N-acetyl arnide 3.8 in anhydrous 
THF at -78 T. One equivalent of LHMDS was then added to the reaction vessel and 
samples were withdrawn at different time points. Acetic acid in methanol was used to 
quench the aliquots. Only a single phase was attained after the addition of acetic acid to 
the reaction mixture. Acetic acid was therefore preferred to the aqueous NH4Cl as 
neutralising agent. 
Samples taken one minute after addition of LHMDS indicated only one radioactive 
compound and this peak was identified as labelled amide 3.12 by HPLC co-elution with 
the non-radioactive standard (Figure 3.11). The UV chromatograms also revealed that 
3.8, was still intact after being in contact with the base at low temperature for one 
minute. On the other hand, a growing degradation of the starting material was observed 
when the reaction times were increased (3 min, 5 min and 10 min). The radiochemical 
purity of the labelled amide also decreased with time and a radioactive hydrophobic by- 
product was detected 3-4 minutes after 3.12. 
The 11 C-methylation of 3.8 proceeded quantitatively at -78 T within one minute. The 
analytical radiochernical yields of labelled amide 3.12 were always higher than 95 % (n 
= 6) and no remaining ["C]iodomethane was detected in any of the experiments. 
Consequently, the reaction was not studied at higher temperatures. 
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Figure 3.11. Typical radio-HPLC chromatogram of labelled amide 3.12 prepared by 
"C-methylation ofN-acetyl amide 3.8. 
3.2.2.4. Radiosynthesis of N-([3-"Clpropionyl)-1,2,3,4-tetrahydroisoquinoline 
(compound 3.12 and reaction work-up using a silica Sep-Pak cartridge 
["C]Iodomethane was distilled into a Wheaton vial containing a THF solution of 3.8 at 
-78 T. The whole reaction mixture was injected into a silica Sep-Pak cartridge one 
minute after the addition of LHMDS. The radioactive products were eluted with THF 
and the radioactivity of the fractions was measured. Most of the reactivity was eluted in 
the first fraction (Table 3.2) and the analytical radiochemical yields of propionyl amide 
3.12 in the collected fractions were identical to those found in samples quenched with 
acetic acid/methanol, i. e. 90-100 %. 
Table 3.2. Radioactivity distribution of amide 3.12 after the silica Sep-Pak stage. 
Volume (MI) Radioactivity (016) 
Fraction 1 0.2 a+0.5 84.9 
Fraction 2 0.5 8.5 
Fraction 3 0.5 1.4 
Vial and Sep- 
- 5.2 
Pak 
'Volume of the reaction mixture injected into the silica cartridge 
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In summary, a Sep-Pak cartridge containing silica gel was successfully used for the 
trapping of LHMDS. The labelled product 3.12 was almost quantitatively eluted by a 
small volume of THF and the use of the Sep-Pak cartridge did not cause any adverse 
effect on the radiochernical yields. 
3.2.2.5. Radiosynthesis of N-([3-1 'Clpropyl)-1,2,3,4-tetrahydroisoquinoline 
(compound 3.13 (Sep-Pak method) 
N-([3 -11 C] Propyl) - 1,2,3,4-tetrahydroisoquino line ( 3.13 ) was obtained in low yields 
(10-20 %) when excess LAH was directly added to the reaction mixture containing 
propionyl arnide 3.12 and LHMDS. The major radioactive peak always corresponded to 
a polar compound eluting at around 2 minutes (75-85 % of the total radioactive area) 
and no other major radioactive by-products were generally observed (Figure 3.12). The 
trace of 3.10, the reduced non-radioactive starting material, eluted at 4.7 min. However, 
prominent UV peaks corresponding to polar products were also detected. 
0 
BioScan Dot 169 
Retention Týne Retention Tirne 
Area Percent 
r- 
. 014- . cn 
3.10 UV absorbance 
. 012- 
C14 
. 
DID- 
. 008 
Dw- CH3 
3.13 
Ra(Boacfivity D04 
...... 13 14 V 12389 I'l 1'2 
Mnutes 
Figure 3.12. Radio-HPLC trace of amine 3.13 obtained when LHMDS was not 
neutralised before the addition of LAH. 
The emergence of these by-products was possibly caused by the concomitant presence 
of LHMDS and LAH and had also been observed in non-radioactive experiments 
(section 3.2.1.6. ). The excess of base used for the enolate generation required 
neutralisation before the addition of LAH in order to achieve the effective reduction of 
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the labelled amide 3.12. Silica Sep-Pak work-up after the formation of 3.12 could 
provide a simple way to deactivate the base due to the acidic nature of silica gel. LAH 
could then be added into the eluate fraction containing the labelled intermediate 
(Scheme 3.24). 
3.8 
CHA -78 
OC 
Do- 
LHMDS U- I N 
CH3 
0 
3.12 
i) Silica Sep-Pak 
ii) LiAIH4 (excess) 
60 OC, 3-7 min 
CH3 
3.13 
Scheme 3.24. Radiosynthesis of labelled amine 3.13 involving silica Sep-Pak cartridge 
neutralisation of the base. 
Compound 3.12 was synthesised as described in section 3.2.2.3. by addition of LHMDS 
to a solution containing precursor 3.8 and ["C]iodomethane at -78'C. The reaction 
mixture was withdrawn from the reaction vessel with a syringe and was injected into 
the silica cartridge. Extra THF was also injected and the eluate was collected in a dry 
Wheaton vial sealed with a Teflon septum. A solution of LAH in THF was added to the 
eluate at room temperature. The reaction vial required venting with a needle during the 
LAH addition due to the evolvement of hydrogen gas. The mixture was then heated (60 
'C) and samples were analysed by reverse-phase HPLC. The labelled amine 3.13 was 
obtained in excellent analytical yields (n = 6,77-97 %) and amine 3.10 was normally 
the major trace observed in the UV chromatograms (Figure 3.13). Therefore, this 
protocol gave 3.13 exclusively, with no formation of unwanted by-products. 
Samples were taken at different time points with the aim of determining the optimal 
reaction time of the carbonyl reduction step (Figure 3.14). 
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Figure 3.13. Typical radio-HPLC profile of amine 3.13 spiked with non-radioactive 
standard The product was prepared using the Sep-Pak method 
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Figure 3.14. Effect of the LAH reduction reaction time on the radiochemical yields of 
amine 3.13. The reaction temperature was 60 T. 
The reaction was complete in approximately 7 minutes after the addition of LAH. 
Longer reaction times did not improve the radiochemical yields of 3.13 and samples 
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taken at 7 minutes showed a 10-20 % increase in the labelled amine yields compared 
with samples withdrawn at shorter time points. The area of a polar radioactive side 
product (retention time = 2.3 min) diminished when the reaction times were increased 
(Figure 3.15). Similar by-products were also observed in non-radioactive experiments 
and could be related to an intermediate in the amide reduction. During the 
radiosynthesis, LAH was added to the reaction mixture at room temperature and the 
vial was then placed in a heating block at 60 OC. The Wheaton glass vial reached 60 T 
in approximately two minutes. Therefore, the use of higher temperatures may have 
reduced the reaction time necessary in this step. 
u1 h4wes 
Figure 3.15. Comparison of radio-HPLC chromatograms at different reaction times in 
the LAH reduction step. The area of the polar radioactive peaks diminished and the 
area of amine 3.13 raised when the reduction time was 
increasedftom 2 minutes to 7 
minutes. 
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3.2.2.6. One-pot radiosynthesis of N-Q3 C1 propyl)- 1,2,3 4-tetrahydroisoqu in o line 
(compound 3.13 
As mentioned earlier, the use of a silica cartridge to remove the excess of LHMDS 
enabled the radiosynthesis of the labelled N-propyl amine 3.13 in remarkable yields. 
However, the application of the protocol to an automated rig would be costly and 
complicated. Hence, anhydrous methanol was tested as a possible substitute of silica gel 
in the neutralisation of LHMDS (Scheme 3.25). 
3.8 
it (--'H311-78 "C 
10. 
LHMDS 
CH3 
0 
3.12 
i) CH30H 
ii) LiAIH4 (excess) 
60 OC, 7 min 
CH3 
Scheme 3.25. One-pot 
tetrahydroisoquinoline. 
radiosynthesis 
3.13 
of N- ([3 -II C]propyl)-1,2,3,4- 
The radiosynthesis of the labelled amide 3.12 was carried out as described in section 
3.2.2.3. One minute after the addition of LHMDS at -78 T, the reaction mixture was 
quenched with anhydrous methanol. The reaction vial was then allowed to warm up to 
room temperature. Excess LAH was added and the reaction was heated at 60 T for 7 
minutes. The analytical radiochemical yields of amine 3.13, were 76-82 % (n = 6) 
(Figure 3.16). 
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Figure 3.16 Typical radio-HPLC Profile of amine 3.13. The product was prepared 
using the one-pot method 
One of the difficulties encountered in the reaction was the addition of small amounts of 
neat methanol. Volumes of around 1-2 ýd of quenching reagent were required at the 
radiochemistry scale. Huge variations in the radiochernical yields of 3.13 were observed 
in the initial experiments, probably due to partial or inaccurate addition of methanol. 
Furthermore, the addition of such volumes would be complex to automate and would 
create reliability problems in the protocol. A means to circumvent this inconvenience 
was the dilution of the quenching material with the reaction solvent (anhydrous THF). 
Excess methanol (3 equivalents) was used in the LHMDS neutralisation step. This 
surplus of methanol reacted with LAH, decreasing the reducing power of the metal 
hydride. 107,109,1 10 Therefore, a greater excess of LAH was employed in the one-pot 
procedure compared to the Sep-Pak method. However, evaporation of methanol prior to 
the addition of LAH could be implemented in an automated module, thus decreasing 
the amount of LAH required in the reduction step. 
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3.2.3. Non-radioactive chemistry involving the PHNO precursor 
3.2.3.1. Selection of the protecting group for the PHNO precursor 
The protecting group of the phenol moiety of the N-acetyl PHNO precursor (see section 
3.1.7. ) had to withstand the strong basic conditions of the 11 C-methylation and had to be 
easily removed later on in the radiosynthesis. Silyl ethers have been increasingly used 
to protect alcohols in complex organic syntheses due to their ease of introduction and 
removal. 1 13 The most common protective silyl ethers are (in order of increasing 
stability): trimethylsilyl ethers JMS), tert-butyldimethylsilyl ethers (TBDMS) and 
triisopropylsilyl ethers (TIPS). 
The trimethylsilyl group can be introduced in a molecule bearing a phenolic 
functionality by a large number of silylating agents. However, it is the most labile silyl 
ether and could be cleaved in the "C-methylation step. The TBDMS and TIPS groups 
are both considerably more stable to hydrolysis than TMS. The greater bulkiness of the 
TIPS group makes it more robust than the TBDMS group and was therefore the 
preferred choice for this project. 
Aryl TIPS ethers are inert in the presence of numerous strong bases such as NaH, KH, 
LDA, LiN(TMS)2, NaN(TMS)2, hydroxides, alkoxides, organometallic reagents (BuLi) 
and Grignard reagents. ' 14 The TIPS protective group is also compatible with strong 
reducing reagents (LAH, boranes), although LAH is known to cleave the 0-TIPS bond 
under certain conditions. ' 15 Besides that, TIPS ethers are rapidly cleaved by fluoride- 
containing reagents such as tetrabutylammonium fluoride, caesium fluoride or various 
adducts of HF. 1 16 
(+)-4-Acetyl-3,4,4a, 5 6,1 Ob-hexahydro-9-triisopropylsilyloxy-2H-naphtho [ 1,2- 
b][1,4]oxazine ( 3.14 ) was considered a suitable precursor for the radiosynthesis of [3- 
"C]-(+)-PHNO (Scheme 3.26). A small amount of this protected precursor as well as a 
(+)-PHNO sample could be obtained from a commercial source (see Experimental 
section). The optimisation of the methylation, amide reduction and 
TIPS deprotection 
were first studied at the micromolar scale using non-radioactive conditions. 
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Scheme 3.26 Selected one-pot radiosynthesis of [3-"C]-(+)-PHNO utilising a TIPS- 
protected precursor. 
3.2.3.2. HPLC analysis of (+)-4-acetyl-3,4,4a, 5,6,10b-hexahydro-9- 
triisopropylsilyloxy-2H-naphtho[1,2-b][1,4]oxazine (compound 3.14 
A suitable HPLC method for the adequate detection of the N-acetyl protected precursor 
3.14 had to be developed. Wilson et al. reported an analytical method for the detection 
of (+)-PHNO using an aqueous ammonium formate-acetonitrile mobile phase and a 
reverse-phase column. 60 However, it was found here that the TIPS-protected precursor 
3.14 was retained in the column for very long times under those HPLC conditions. This 
was due to the highly hydrophobic nature of the triisopropylsilyl group. 
High percentages of organic phase and the use of a short reverse-phase column allowed 
the elution of the compound 3.14 at retention times that were appropriate for carbon- II 
radiochemistry (Table 3.3). The amide 3.14 had maximal UV absorbance at 205 nm and 
280 nm. Chromatograms were recorded at both wavelengths, although the use of the 
280 nm channel avoided the detection of signals arising from solvents and from other 
unidentified traces. 
3.15 
HAII-14 IM in THF 
60 'C 
1.119 
TBAF 
TIPSO"' N 
0 
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Table 3.3. HPLC retention times of the N-acetyl precursor 3.14 in different columns 
and mobile phases. Wavelength = 280 nm. Flow rate =I ml/min. 
Mobile phase 
Column (016 waterITFA-% 
CH3CNITFA) 
A1 25-75 
20-80 
A1 18-82 
B1 25-75 
B1 20-80 
B1 18-82 
Retention time (min) 
17.7 
12.8 
11.1 
6.4 
4.7 
4.2 
Column A. - Phenomenex Luna CI 8(2) (150 mm x 4.6 mm) 5 pm particle size 
Column B. - Phenomenex Luna CI 8(2) (50 mm x 4.6 mm) 3 pm particle size 
3.2.3.3. HPLC analysis of (+)-4-ethyl-3,4,4a, 5,6,10b-hexahydro-2H-naphtho[1,2- 
b][1,4]oxazin-9-ol (EHNO) and (+)-4-propyl-3,4,4a, 5,6,10b-hexahydro-2H- 
naphtho[1,2-bj[1,4joxazin-9-ol (PHNO) 
The main non-radioactive product expected in the methylation-reduction-deprotection 
[3-"C]-(+)-PHNO radiosynthesis ought to be (+)-4-ethyl-3,4,4a, 5,6,10b-hexahydro- 
2H-naphtho[1,2-b][1,4]oxazin-9-oI (EHNO). Hence, both compounds must be 
effectively separated by analytical and semi-preparative HPLC. Due to the low pKa of 
phenols, the pH of the mobile phase had to be moderately acidic. A gradient system 
employing ammonium formate-acetonitrile as the mobile phase resulted in the 
successful separation of PHNO and EHNO using a reverse-phase analytical column 
(Figure 3.17). The pH of the mobile phase was adjusted with acetic acid (PH = 4.5) and 
the retention time difference between the two compounds was approximately 2 minutes. 
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Figure 3.17. Efficient separation of EHNO and PHNO using a gradient method in a Cy 
reverse-phase analytical HPLC column (details in the Experimental Section). 
A different gradient method was established to allow the effective separation of EHNO 
and PHNO using aC 18 semi-preparative column, as shown in Figure 3.18. This method 
was also useful to analyse iodomethane and the starting material 3.14'. The very high 
percentage of acetonitrile necessary for the elution of the TIPS-protected compound 
highlights the polarity difference between the triisopropylsilyl ether and the free 
phenols. 
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Figure 3.18. Separation of 3.14, EHNO and PHNO in a reverse-phase semi- 
preparative HPLC column (details in the Experimental Section). 
3.2.3.4. Stability of (+)-4-acetyl-3,4,4a, 5,6,10b-hexahydro-9-triisopropylsilyloxy- 
2H-naphtho[1,2-b][1,4]oxazine (compound 2.14D in the presence of base at low 
temperature 
The N-acetyl precursor 3.14 was dissolved in anhydrous THF and the resulting solution 
was cooled to -78 T. The base (LDA or LHMDS) was added to the reaction mixture 
and samples were analysed by HPLC at various time points (Figure 3.19), showing that 
substrate 3.14 did not undergo degradation at that temperature. The same experiment 
was repeated at 0 T. In this case, LHMDS induced the partial decomposition of 
compound 3.14. Two new peaks were detected and the magnitude of these by-products 
increased when more than one equivalent of LHMDS was added to the reaction 
mixture. In contrast with the results obtained with N-acetyl- 1,2,3,4- 
tetrahydroi soquino lines, LDA did not cause the breakdown of the naphthoxazine 3.14 
at any of the temperatures studied. Thus, both bases could be potentially used at -78 
T 
for the generation of the PHNO precursor enolate. 
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Figure 3.19. Stability of precursor 3.14 in the presence of one equivalent of base at 
-7 OC as measured by HPLC 
3.2.3.5. Synthesis of (+)-4-propionyl-3,4,4a, 5,6,10b-hexahydro-9- 
triisopropylsilyloxy-2H-naphtho[l, 2-b][1,4]oxazine (compound 3.17 through cc 
carbon methylation of compound 3.14 
The use of LHMDS for the methylation of precursor 3.14 did not provide adequate 
yields of compound 3.17 (Scheme 3.27). Excess LHMDS was added to a solution of 
iodomethane and precursor 3.14 at -78 OC and the analysis of the reaction mixture 
revealed the presence of considerable amounts of starting material even 15 minutes 
after addition of the base. 
0 
TIPSO 
3.14 
i) CH311THF 
TIPSO 
ii) LHMDS or LDA 
3.17 
Scheme 3.27. Methylation of the N-acetyl derivative 3.14 using different lithium amides. C-1 
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The yields of 3.17 did not improve appreciably when the methylation was performed at 
a higher temperature (0 'Q using LHMDS. Incomplete alkylation was again observed 
at this temperature, suggesting that the base is not as efficient in the generation of the 
3.14 enolate as it was in the case of N-acetyl-1,2,3,4-tetrahydroisoquinoline. The 
increased complexity and bulkiness of the TIPS-protected molecule may have been 
responsible for this reduction in reactivity. 
The addition of LDA to a cold (-78 OC) solution of iodomethane and 3.14 gave yields of 
N-propionyl product nearly identical to those obtained with LHMDS (50-60 % 
conversion). Increases in the reaction times did not improve the yield of 3.17, and after 
15 minutes, the ratio of N-acetyl to N-propionyl material was only 1 to 1.5. However, 
very different results were attained when this reaction was performed at 0T (Figure 
3.20). At this temperature, the starting material was completely consumed 5 minutes 
after the addition of LDA. Small percentages of possible dialkylated product were also 
detected two minutes after the elution of compound 3.17. 
The difference in the methylation rate at different temperatures was tested in an 
experiment combining low temperature and a warming up period. Compound 3.14 was 
mixed with an excess of iodomethane and LDA. The mixture was kept at -78 T and 
two samples were withdrawn I minute and 5 minutes after addition of the base. The 
HPLC analysis of those samples showed considerable amounts of unreacted starting 
material. The cold bath was removed and a new sample was taken 10 minutes later. A 
total consumption of the N-acetyl compound was observed in this last sample, as well 
as a marked increase in the iodide peak that confirmed the occurrence of the 
methylation. Product 3.17 was obtained in 95 % yield as shown by HPLC 
(Figure 3.21). 
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Figure 3.20. Formation of N-propionyl amide 3.17 from compound 
3.14 at different 
temperatures using LDAICH3I 
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Figure 3.21. HPLC chromatograin ofproplonyl amide 3.17 prepared by methylation of 
compound 3.14. Column: Phenoinenex Lima C, 18(2)(50 mm x 4.6 mm) 3 um particle 
size. Mobile phase. - 25 % waterITFA- 75 % CH3CNITFA. Flow I mIlmin. Wavelength: 
280 nm. 
3.2.3.6. Unexpected results in the reduction of the carbonyl group in (+)-4-acetyl- 
3,4,4a, 5,6,1 Ob-hexahydro-9-triiso pro py 13 ilyloxy-2H-naphtho[1,2-b][1,4]oxazine 
(compound 3.14 
The pure standard for the N-propionyl amide 3.17 could not be obtained from 
commercial sources. Therefore, the study of the carbonyl reduction with LAH was 
carried out on precursor 3.14. The application of the LAH reduction protocol outlined 
in section 3.2.1.4. on compound 3.14 should provide the reduced and protected 
intermediate 3.18 (Scheme 3.28). The deprotected phenol, EHNO, should then be 
obtained by addition of tetrabutylammonium fluoride (TBAF) or another source of 
fluoride to 3.18. 
During the course of the reduction experiments, the presence of the reduced 
intermediate 3.18 was monitored by HPLC using diverse columns and mobile phases. 
The reduced intermediate was expected to elute shortly after the N-acetyl starting 
material, as in the case of the 1,2, '),, -teti-,. i'iý-droisoqtiiiiolii-ies. However, such a trace 
was only observed occasionally. The niain trace al\\, ays corresponded to the reduced 
and unprotected product E14NO. Complete disappearance of the starting amide was 
TnA. 0 1 
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always observed. Besides that, the analysis of samples taken before and after the 
addition of TBAF to the reaction mixture provided similar chromatograms. Therefore, 
not only did LAH reduce the amide group, but it also cleaved the TIPS ether under the 
reaction conditions. LAH in THF at reflux was known to cleave an 0-TIPS ether 
vicinal to an alcohol, amine, or other group capable of binding an aluminium hydride 
moiety. 1 15 In this case, the presence of a large excess of LAH may have been 
responsible for the unexpected silyl ether cleavage. TBAF addition was avoided as a 
result of the concomitant removal of the TIPS group by LAH and this fact led to the 
simplification of the protocol for the radiosynthesis of PHNO. 
0 
TIPSO 
3.14 3.18 
TBAFinTHF 
HO 
EHNO 
Scheme 3.28. Possible outcomes after the treatment of compound 3.14 with LAH. - 
Simple reduction of the carbonyl moiety to form 3.18 or reduction plus cleavage of the 
TIPSprotecting group to give EHNO. 
3.2.3.7. Synthesis of EHNO through the one-pot enolate formation-reduction- 
deprotection protocol 
The one-pot approach that was to be applied for the radiosynthesis of [3-11C]PHNO 
was studied under non-radioactive conditions. However, the addition of iodomethane 
was omitted and the final product should then be EHNO instead of PHNO (Scheme 
3.29). 
LDA was added to a solution of 3.14 in THF at 0 OC and was immediately neutralised 
with an excess of anhydrous methanol. LAH was finally added and the reaction mixture 
was heated at 60 T. Samples were withdrawn at different time points after the addition 
LAH (10 equiv) 
o-- TIPSW- 
60 OC 
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of LAH and were analysed by HPLC. No starting material or other hydrophobic peaks 
that could correspond to the reduced and protected intermediate 3.18 were observed in 
any of the samples. ERNO was obtained in high purity and no by-products were 
detected (Figure 3.22). These experiments confirmed that the methanol effectively 
quenched the LDA and still allowed the quantitative reduction-deprotection of the 
starting material by LAH. 
0 
TIPSO N 
0 -IJ 
3.14 
i) LDA (3 equiv), 0 OC 
00- 
ii) CH30H (5 equiv), 0 OC 
iii) LiAIH4 (10 equiv), 60 OC 
HO N 
EHNO 
Scheme 3.29. Treatment of compound 3.14 with LAH after enolatelbase quenching 
leads to the formation ofEHNO. 
01- 
Mnutes 
Figure 3.22. HPLC analysis of crude EHNO formed after treatment with LDA, 
methanol and LAH. The chromatogram was obtained using the analytical conditions 
described in section 3.2-3-3. 
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3.2-3.8. Quenching and solubilisation of lithium aluminium hydride 
In organic chemistry, the quenching of LAH can be done by an array of methods. ' 17 
However, this task must be carried out carefully due to the high reactivity of this 
chemical. LAH deactivation by addition of water or basic aqueous solutions produces 
inorganic aluminium precipitates that can be filtered off. The organic product can then 
be recovered by extraction with a suitable solvent. Shi et al. 32 used this work-up in the 
radiosynthesis of three D2 PET agonists. However, the extraction step at the 
radiochemistry scale is not easily amenable to automated protocols. The attaim-nent of a 
homogeneous solution after the deactivation of the LAH is therefore more convenient 
in radiochemistry. Methanol was employed to obtain a solution after the LAH reduction 
step in the radiosyntheses of [11C]diprenorphine, 80 ["C]buprenorphinel 05 and 
[11C]cyclorphan .81A silica gel cartridge followed by normal-phase 
HPLC were then 
used to isolate the pure radioligands. 
Acidic work-up of LAH is nevertheless the most common practice in PET 
radiochemistry. 35,60 Aqueous HCl is normally added after evaporation of the reaction 
solvent and dissolves the aluminium salts. The crude solution can then be filtered with a 
solid-phase cartridge or it can be directly injected into a reverse-phase HPLC column. 
The aluminiurn precipitates can be dissolved at very high and very low pH and in this 
work, a solution of LAH in THF (0.2 M, 0.25 ml) was deactivated with the reagents 
listed on Table 3.4 (clear solutions were obtained in all cases). Small volumes of diluted 
hydrochloric acid were sufficient to dissolve the aluminate salts. Concentrated sodium 
hydroxide (on its own or combined with EDTA) also dissolved the precipitate, although 
larger volumes were needed. Interestingly, a small volume of TBAF also provided a 
clear solution. It should be noted that smaller volumes of reagents may be required 
if 
the THF is evaporated before the LAH quenching. 
Table 3.4. Summary of the conditions used to quench and to dissolve 0.25 ml of LiAlH4 
in THF (0.2 M) - 
Basic conditions I Acidic conditions 
1.5 M NaOH (2 ml) 
6.2 5M NaOH (0.5 ml) + 0.1 M EDTA disodium salt (2 ml) 
6.25 M NaOH (0.3 ml) + 0.1 M EDTA trisodium salt (2 ml) 
IM TBAF in THF (0.3 ml) 
0.5 M HUI (U. ý mi) 
IM HCI (0.3 ml) 
140 
C 
r'T I 
, voter 3 Labellink ofPHNO 
3.2.4. Radiosynthesis of [3-1 1 Cl-(+)-PHNO 
3.2.4.1. Radiosynthesis of (+)-4-([3-"Clpropionyl)-3,4,4a, 5,6,10b-hexahydro-9- 
triisopropylsilyloxy-2H-naphtho[1,2-bl[1,4]oxazine (compound 3.15 
Precursor 3.14 was provided as an oil that needed to be aliquoted before the beginning 
of the radiosyntheses. A known weight of the precursor was dissolved in a volatile 
solvent such as dichloromethane or THF and the total volume was equally distributed 
into Wheaton vials. Aliquots contained 2.5 ± 0.3 mg (6.2 ± 0.7 ýtrnol) of compound 
3.14. 
The experiments carried out with the non-radioactive PHNO precursor (section 3.2.3.5. ) 
showed that LDA was superior to LHMDS in the formation of the acetyl compound 
3.14 enolate. Therefore, commercial solutions of LDA were used in the initial 
radiosyntheses of 3.15 (Scheme 3.30). 
0 
TIPSO 
3.14 
CH31 / Base CH3 
TIP 
0 
3.15 
Scheme 3.30. Radiosynthesis of compound 3.15 through the IIC-methylation of the N- 
acetyl precursor 3.14. 
Different amounts of LDA (1-15 equivalents) were added to a THF solution containing 
the starting material and [1 1 C]iodomethane. The experiments were performed over a 
range of temperatures (-78 OC to 25 OC). Although the N-acetyl precursor 3.14 did not 
suffer degradation under the conditions examined, compound 3.15 was not obtained in 
any of the radiosyntheses and ["C]iodomethane was never detected. A highly polar 
radioactive peak eluting before [ 11 C] iodomethane was observed instead. 
Some commercial solutions of LDA contain a small percentage of LiBr that may 
convert [ 11 C]iodomethane into ["C]bromomethane. 
1 18 This halogen exchange would 
not be significant in large-scale experiments, but it may be critical at the carbon- 11 
scale. However, the use of LDA containing a different stabiliser or freshly prepared 
LDA did not provide the labelled product 3.15 either. The use of LDA and ["C]methyl 
triflate or ["C]iodomethane produced in a different rig also failed to give compound 
3.15. 
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Other strong bases tested for the enolate formation were: NaH, potassium tert-butoxide 
and NaNH2 (in combination with a crown ether to increase their solubility in THF). 
Nevertheless, substrate 3.14 was unstable in the presence of these reagents and no 
labelled product was attained. 
The next option explored was the use of LHMDS. This base was very effective in the 
"C-methylation of N-acetyl- 1,2,3,4 -tetrahydroisoquino line (section 3.2.2.3. ), although 
the non-radioactive results obtained with 3.14 were somewhat mediocre. In order to 
increase the reproducibility in the base addition, diluted solutions of LHMDS in 
inhibitor-free THF were used in the radiochemistry. 
LHMDS was added to a THF solution containing 3.14 and [1 'C]iodomethane at -78 OC. 
The chromatographic analysis of the reaction mixture showed that most of the 
radioactivity corresponded to unreacted ["C]iodomethane (70-90 % of total area). An 
unidentified radioactive polar peak (10-20 %, retention time = 0.9 min) and the labelled 
product 3.15 (5-10 %) were also detected. This outcome was in agreement with the 
non-radioactive results obtained at -78 OC. At such low temperature, the non- 
radioactive methylation reaction was also found to be slow and incomplete. 
The same LHMDS procedure was repeated at - 40 OC and the analysis of samples taken 
2 min after addition of the base showed the amide 3.15 in yields up to 28 %. However, 
the yield of 3.15 did not improve with longer reaction times. 
The significant covalent character in the metal-oxygen bond of lithium enolates retards 
the electrophilic attack. Additives that coordinate with the lithium cation, such as 1,2- 
dimethoxyethane (DME) or tetramethylenediamine (TMEDA), reduce the aggregation 
of the enolate and increase its reactivity (Figure 3.23). These chelating 
ligands also 
enhance the polarity of the solvent, thereby speeding up theSN2 alkylation step. 
ON 
DME TMEDA 
Figure 3.23. Additives that stabilise the lithium cation by coordination. 
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The addition of LHMDS at - 40 T to a TMEDA/THF solution containing precursor 
3.14 and ["C]iodomethane provided the labelled product 3.15 in 21 % yield. On the 
other hand, the use of DME/THF as the reaction solvent only gave a highly polar 
radioactive by-product. Therefore, the use of these chelating ligands did not improve 
the radiochemical yields of 3.15 (Table 3.5). 
Table 3.5. Additive effect on the radiochemical yield of 3.15 using LHMDS at -40 OC 
Additive I r. c. y. ofproduct 3.15 
None 28% 
TMEDA a 21% 
DMEa 0% 
'The reaction solvent was 50 % THF-50 % additive 
The radiosynthesis of 3.15 was also carried out at 0 T. LHMDS was added to an ice- 
chilled solution containing [ 11 C] iodomethane and precursor 3.14. The reaction mixture 
was quenched after 2 minutes and the radiochemical yields of [3-11 C]propionyl product 
3.15 were up to 51 %. The UV trace showed two remarkable by-products at 2.7 min and 
4.2 min. These degradation products had already been observed in non-radioactive tests 
when compound 3.14 was in contact with LHMDS at 0 OC (section 3.2.3.4. ). 
Nevertheless, the formation of the by-products was greatly reduced at lower 
temperatures. 
3.2.4.2. Effect of the purification of the starting material in the radiochemical 
yields of (+)-4-([3-"Clpropionyl)-3,4,4a, 5,6,10b-hexahydro-9-triisopropylsilyloxy- 
2H-naphtho[1,2-bl[1,4]oxazine (compound 3.15 
Although 1H NMR analysis of 3.14 did not show any impurity, the HPLC trace of the 
acetyl precursor 3.14 contained a minor polar peak at 0.6 min. The presence of that 
polar unknown product in the starting material was also confirmed 
by TLC. That 
impurity may have been responsible to some extent for the moderate yields in the 
IIC_ 
methylation. Hence, two methods were utilised 
for the purification of compound 3.14: 
reverse-phase preparative HPLC and chromatography using a short silica gel column. 
Precursor 3.14 was purified using a C18 preparative HPLC column and the fraction 
containing the pure material was eluted with a mobile phase of 
95 % acetonitrile-5 % 
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water. The solvent was evaporated off and the residue was dissolved in ethyl acetate. 
The organic phase was washed with brine to remove the remaining water and the 
solvent was thoroughly evaporated under vacuo. Despite these efforts, the precursor 
purified by preparative HPLC gave disappointing yields of labelled product 3.15. The 
presence of water traces in the reaction mixture might have been accountable for these 
poor results. 
The starting material 3.14 was also purified by silica gel chromatography, using either a 
manually-packed column or a silica Sep-Pak cartridge. Ethyl acetate, diethyl ether, 
dichloromethane and THF were suitable solvents for this purification. The purified 
material was almost colourless and the precursor aliquots were kept under argon at -20 
OC. However, not all the solvents used for the purification of 3.14 were suitable for the 
radiochemistry. Solvents used for chromatography were mixed with [IIC]iodomethane 
and LHMDS. HPLC analysis revealed that ["C]iodomethane remained intact when 
solvents without additives (inhibitor-free anhydrous THF and anhydrous ethyl acetate) 
were used, but solvents containing stabilisers (anhydrous diethyl ether, anhydrous THF 
and dichloromethane) degraded ["C]iodomethane substantially. A polar radioactive 
species was the main product instead of [ 11 C] iodomethane (Figure 3.24). 
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Figure 3.24. ý'C]Iodomethane suffered substantial degradation when mixed with 
LHMDS in certain anhydrous solvents that contained additives (diethyl ether, THF and 
dichloromethane). 
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The radiochemical yields of 3.15 were greatly enhanced when starting material purified 
by silica gel chromatography and the appropriate solvent were utilised. The product 
3.15 was routinely obtained in 60-70 % analytical yield (n = 20) (Figure 3.25). Aliquots 
purified using a short silica gel column or a silica Sep-Pak produced similar results. The 
isolated radiochemical yield of product 3.15 was 50-55 % (decay-corrected, calculated 
from the initial radioactivity of C] iodomethane) and the radiochemical purity was > 
99%. 
k4nuies 
Figure 3.25. Typical radio-HPLC of IIC-methylated product 3.15. Column: C? 
Phenomenex Luna C18(2)(50 mm x 4.6 mm) 3 pm particle size. Mobile phase: 20 % 
waterITFA-80 % CH3CNITFA. Flow I ml/min. Wavelength: 280 nm. 
3.2.4.3. Adaptation of the "C-methylation protocol to the requirements of 
automated radiosynthesis modules 
Although the labelled compound 3.15 had been obtained in adequate radiochemical 
yield, the total reaction volume had to be increased to at least 200 ýtl in order to carry 
out the "C-methylation step on an automated radiosynthesis module. Besides that, the 
addition of the base prior to the start of the distillation of Cliodomethane would also 
simplify the automation requirements. 
These demands were satisfied by adjustments in the "C-methylation step. An increase 
in the total volume required the use of more base in order to obtain the labelled product 
at reasonable times. This parameter was examined adding 
1-4 equivalents of LHMDS at 
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0 OC to a THF solution of precursor 3.14 and [1 'C]iodomethane (Figure 3.26). The final 
reaction volume was 200 ýd and the highest 11 C-methylation yields were obtained with 
2.5 equivalents of base. Further increases in the amount of base used did not improve 
the radiochemical yields, probably due to the competing degradation of the precursor. 
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Figure 3.26 Radiochemical yields of amide 3.15 using increasing amounts of base at 
0 OC The reaction volume was 0.2 ml. 
The stability of precursor 3.14 in the presence of LHMDS was limited at 0 T, but no 
decomposition was observed at lower temperatures. Hence, reaction mixtures 
containing 3.14 and 2.5 equivalents of LHMDS were kept at -78 T for up to 20 
minutes and were then allowed to warm up for 5 minutes before adding 
["C]iodomethane. The reaction was neutralised after 2 minutes and the analytical 
radiochernical yields of 3.15 were between 65 % and 85 % (Figure 3.27). 
This latter "C-methylation procedure satisfied the two conditions required by the 
automation, i. e. the reaction volume was at least 200 ýtl and the base was added to the 
reaction vial before the start of the [ 
11 C] iodomethane synthesis. 
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Figure 3.27. Radio-HPLC chromatogram of compound 3.15 when prepared by a 
radiosynthetic method suitable for automation. Column: Phenomenex Luna C18(2) (50 
mm x 4.6 mm) 3 pm particle size. Mobile phase: 20 % waterITFA-80 % CH3CNITFA. 
Flow: I ml/min. Wavelength: 280 nm. 
3.2.4.4. One-pot radiosynthesis of (+)-4-([3- 11 Clpropyl)-3,4,4a, 5,6,10b-hexahydro- 
2H-naphtho[1,2-bl[1,4]oxazin-9-oI ([3-"C]-(+)-PHNO) 
The one-pot radiosynthesis of [3-"C]-(+)-PHNO (Scheme 3.31) was developed in 
parallel with the optimisation of the "C-methylation step. After confirming the 
presence of the labelled intermediate 3.15 in adequate yields, the reaction mixture was 
quenched with an excess of anhydrous methanol. This reagent was diluted in THF to 
allow the handling of that solution in the future automated process. 
Both the reduction of the amide group and the removal of the TIPS protecting group in 
compound 3.15 were achieved by a LAH solution. A 3-fold excess of LAH compared 
to methanol was added and the reaction mixture was then heated at 60 OC for 7 minutes. 
The purification of the reaction mixture was carried out using a semi-preparative 
reverse-phase column and the gradient system described in section 3.2.3.3. The 
analytical radiochemical yields of [3 -11 C] -(+)-PHNO prepared by the one-pot procedure 
were up to 60 % (n = 5) (Figure 3.28). The identity of [3-"C]-(+)-PHNO was 
confirmed by co-elution with non-radioactive PHNO using various HPLC systems. The 
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analytical radiochemical yields of intermediate 3.15 were similar to the final [3-"C]- 
(+)-PHNO yields, indicating the quantitative conversion of 3.15 ' 
into [3-"C]-(+)- 
PHNO. The reduction-deprotection step was therefore rather clean and fast and did not 
affect the C-N bond. 
i) CH31/LH M DS CH3 TIPSO TIPSO N'j 
ii) CH30H/THF 
00 
3.14 3.15 
LiA1H4 IM in THF 
60 Y, 7 min 
c 
HO, - 
H3 
0 
13-"C]-(+)-PHNO 
Scheme 3.31. One-pot procedure for the radiosynthesis of [3-"C]-(+)-PHNO. 
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Figure 3.28. [3-"C]-(+)-PHNO trace spiked with non-radioactive standard The semi- 
preparative gradient method described in section 3.2.3.3. was usedfor the analysis of 
the reaction mixture. 
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3.3. Automated synthesis of [3-"C]-(+)-PHNO and biological 
evaluation 
The automated radiosynthesis of [3-"C]-(+)-PHNO was carried out by the 
Hammersmith Imanet Development Group (led by Mr. D. R. Turton) using a 11C- 
methylation rig (made in-house) with facility to perform product separation and 
formulation of the labelled product. [3-"C]-(+)-PHNO was prepared as described in 
this thesis and the reaction mixture was worked up using hydrochloric acid and was 
purified following the method reported by Wilson et al. 60 Decay-corrected 
radiochemical yields (EO S) were 15 -17 % from [ 
11 C] iodomethane (n > 40) and the total 
radiosynthesis time was 60 minutes (from [I ICIC02 trapping). The average specific 
activity (EOS) of [3-11 C]-(+)-PHNO was 69 GBq/ýtmol (n = 9). These values are higher 
than those reported by Wilson et al. and can be significantly increased in the future if 
[11 C]iodomethane produced from [ 11 C]methane is used in the radiosynthesis. 
Furthermore, a patent application covering the radiosynthesis of [3-"C]-(+)-PHNO 
described in this thesis has been filed. 
The biological evaluation of the radioligand was performed by the Hammersmith 
Imanet Biology Group (Dr. E. Hirani, Ms. R. Ahmad) and Dr. A. Egerton (Imperial 
College) on adult male Sprague Dawley rats. Ex vivo biodistribution studies were 
carried out as described by Hume et al. 119 High levels of radioactivity were measured in 
the rat brain after intravenous injection of [3-"C]-(+)-PHNO, confirming the 
radioligand passage through the blood-brain barrier. The highest radioactivity uptake 
was observed in brain areas rich in D2/3 receptors such as striaturn, olfactory tubercles 
and olfactory bulbs (Figure 3.29). Cerebellum showed the lowest radioligand uptake of 
all brain areas studied and the obtained specific binding ratios agreed with those 
obtained for [1 'C]-(+)-PHNO by Wilson et al. 
60 
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Figure 3.29. Radioactive content in rat brain areas with high levels of D213 receptors 
(striata, oýfactory tubercles, olfactory bulbs) and cerebellum as afunction of time after 
intravenous injection of [3-"C]-(+)-PHNO. 
Rat plasma and brain extract were analysed with HPLC at different time points after 
radioligand administration (Figure 3.30). [3-"C]-(+)-PHNO underwent fast metabolic 
breakdown in plasma, although only a polar metabolite was observed (Figure 3.3 1). On 
the other hand, the parent compound represented over 97 % of the radioactivity in the 
rat brain extract. These results confirmed that [3-"C]-(+)-PHNO (radioligand labelled 
in position 3 of the N-propyl chain) has the same metabolic behaviour in vivo as ["C]- 
(+)-PHNO (radioligand labelled in position I of the N-propyl chain). 60 
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Figure 3.30. Unmetabolised [3-"C]-(+)-PHNO in rat brain extract and plasma as a 
function of time. 
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Figure 3.31. Radio-HPLC chromatograms of rat plasma (2 min after radioligand 
injection) and brain extract (10 min after radioligand injection). 
PET images were obtained using a quad-HIDAC small animal tomograph (Oxford 
Positron Systems, Weston-on-the-Green, UK). [3-"C]-(+)-PHNO (10 MBq) was 
administered as a bolus dose via the lateral tail vein and data were acquired for 60 
minutes. Scan sinograms were then reconstructed and images were transferred to 
AnalyzeS image analysis software 120 for volume of interest (VOI) analysis, as 
described by Houston et al. 12 1 The images showed the selective binding of [3 -11 C] -(+)- 
PHNO in the rat striata (Figure 3.32). The striata were identified by dissecting and 
counting the region of interest after the scan and by using a VOI template 
based on the 
stereotaxic coordinates of the rat brain. 
a P-1 
I Cl-(+)-PHNO 
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13 
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indicated) ftom average image volumes obtained from quad-HIDAC scans and 
Analyze* software. The hot spots represent the rat striata (confirmed by using a VOI 
template based on the stereotaxic coordinates ofthe rat brain) 
3.4. Conclusions and future work 
-N-([3- 
I 'C]propyl)-1,2,3,4-tetrahydroisoquinoline was prepared using a simple two-step 
procedure. The lithium enolate of the N-acetyl precursor 3.8 was alkylated by 
["C]iodomethane almost instantaneously at low temperature. The excess of base was 
quenched either by methanol or by a silica Sep-Pak cartridge. Subsequent addition of 
LAH to the reaction mixture provided the labelled N-propyl amine 3.13 in excellent 
yields (76-82 %). 
This radiosynthesis represents the first alkylation with ["C]iodomethane of a carbon 
next to an amide carbonyl group. 
-[3-"C]-(+)-PHNO was prepared in a one-pot protocol that involved the 
"C- 
methylation of compound 3.14 followed by treatment of the labelled intermediate with 
LAH excess. The latter reagent reduced the carbonyl group and cleaved the 
triisopropylsilyl protecting group, simplifying the synthesis of the radioligand. The 
method was easily implemented on an automated 
1 'C-methylation module, providing 
the radioligand reliably and in high isolated yields (15-17 %). 
-The specific activity of [3-11 C]-(+)-PHNO 
(69 ± 27 GBq/ýtmol) is higher than the 
value reported by Wilson et al. for [II Cl-(+)-PHNO (50 ± 16.6 Gl3q/ýtmol) and can be 
significantly increased in the future if C]iodomethane produced from ["C]methane is 
used in the radiosynthesis. 
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-A patent application covering the radiosynthesis of [3 C] -(+)-PHNO described in this 
thesis has been filed. 
-The in vivo behaviour and metabolism of PHNO labelled in position I (["C]-(+)- 
PHNO) or in position 3 ([3-1'C]-(+)-PHNO) of the N-propyl chain appear to be the 
same. 
-The future work related to this proj ect will involve the evaluation of [3 -11 C] -(+)-PHNO 
in humans as well as the search for a new N-acetyl precursor that is in solid state at 
room temperature (the current precursor is an oil that needs aliquoting before 
radiosyntheses). 
3.5. Experimental 
Materials 
The following compounds were provided by Target Molecules (Southampton, United 
Kingdom): 
(+)-4-Propyl-3,4,4a, 5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-oI [(+)- 
PHNO], (+)-4-ethyl-3,4,4a, 5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-oI 
(ERNO) and (+)-4-acetyl-3,4,4a, 5,6, l Ob-hexahydro-9-triisopropylsilyloxy-2H- 
naphtho [ 1,2-b] [ 1,4] oxazine (compound 3.14). 
All other chemicals were obtained from Sigma-Aldrich (Gillingham, UK). All solvents 
were high performance liquid chromatography (HPLQ grade and purchased from 
Fisher Scientific (Loughborough, UK). 
Chemis 
Synthesis of N-acetyl-1,2,3,4-tetrahydroisoquinoline (compound 1, D 
Triethylamine (1.75 ml, 12.5 mmol) was added under a nitrogen stream to a solution of 
1,2,3,4-tetrahydroisoquinoline (0.62 ml, 5 mmol) in 20 ml of anhydrous 
dichloromethane. The mixture was kept in an ice/acetone bath while acetyl chloride 
(0.42 ml, 6 mmol) was added dropwise over a 10 minute period. The flask was then 
kept stirring at room temperature for 2-3 hours. The obtained orange or yellowish slurry 
was washed with hydrochloric acid 10 % v/v (2 x 15 ml), sodium carbonate 10 % w/w 
solution (2 x 15 ml) and brine (I x 20 ml). The organic phase was finally dried over 
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magnesium sulphate and was filtered. The residue was purified with flash 
chromatography (silica gel, petroleum ether-ethyl acetate 1: 1, Rf = 0.48), obtaining the 
final product as an off-white solid (569 mg, 65 % yield). 
HPLC: Phenomenex Luna C18(2) column (150 min x 4.6 mm x5 micron), 70 % water 
(0-1 % TFA)-30 % acetonitrile (0.1 % TFA), flow =1 ml/min, wavelength = 220 and 
254 rim, retention time = 7.0 min. 
I H-NMR (500 MHz, CDC13) 8 (ppm) (2 conformers): 2.18 (3 H, s, CH3), 2.85-2.91 (2 
H, in, ArCH2CH2N), 3.68-3.82 (2 H, m, ArCH2CH2N), 4.62-4.73 (2 H, in, ArCH2N), 
7.12-7.21 (4 H, m, C6H4). 
13 C-NMR (62.9 MHz, CDC13) 8 (ppm) (2 conformers): 21.7 and 21.9 (CHA 2 8.6 and 
29.5 (ArCH2CH2N), 39.7,44.1,44.2 and 48.2 (ArCH2CH2N and ArCHN, 126.1, 
126.59 126.6,126.8,127.1,127.5,128.4,129.6,132.5,133.5,134.1 and 135.2 (QH4)ý 
169.8 and 169.9 (CO). 
IR (v,,, ax, cm-1): 3000-2850,1636 (C=O), 1434,1250,1224. 
GC-MS: 175 (M), 132 (M-CH3CO)+, 117 (M-C2H4NO)+, 104 (M-C3H7NO)+, 77 
(C6H5+), 63,5 1ý 43 (CH3CO+)- 
Synthesis of N-propionyl-1,2,3,4-tetrahydroisoquinoline (compound 3. (acid L92) 
chloride method) 
Triethylamine (1.75 ml, 12.5 mmol) was added under a nitrogen stream to a solution of 
1,, 2,3,4-tetrahydroisoquinoline (0.62 ml, 5 mmol) in 20 ml of anhydrous 
dichloromethane. The mixture was kept in an ice/acetone bath while propionyl chloride 
(0.52 ml, 6 mmol) was added dropwise over a 10 minute period. The flask was then 
kept stirring at room temperature for 2-3 hours, obtaining a yellow slurry which was 
washed with hydrochloric acid 10 % v/v (2 x 15 ml), sodium carbonate 10 % w/w 
solution (2 x 15 ml) and brine (I x 20 ml). The organic phase was finally dried over 
magnesium sulphate and was filtered. The residue was purified using flash 
chromatography (silica gel, petroleum ether-ethyl acetate 1: 1, Rf = 0.3 8), obtaining the 
title compound as a colourless oil (705 mg, 75 % yield). 
HPLC: Phenomenex Luna C18(2) column (150 min x 4.6 mm x5 micron), 70 % water 
(0.1 % TFA)-3 0% acetonitrile (0.1 % TFA), flow =I ml/min, wavelength = 220 and 
254 nm, retention time = 12.3 min. 
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'H-NMR (500 MHz, CDC13) 8 (ppm) (2 conformers): 1.18 (3 H, t, J=7.2 Hz, CH3), 
2.38 (2 H, q, J=7.2 Hz, COCH2), 2.88 (2 H, m, ArCH2CH2N), 3.67-3.83 (2 H, m, 
ArCH2CH2N), 4.60-4.70 (2 H, m, ArCH2N), 7.05-7-15 (4 H, m, C6H4)- 
13C-NMR (62.9 MHz, CDC13) 8 (PPM) (2 conformers): 9.47 and 9.56 (CHA 2 6.9 and 
27.1 (CH2CO), 28.6 and 29.6 (ArCH2CH2N), 39.7,43.2,44.3 and 47.3 (ArCH2CH2N 
and ArCHN, 126.1,126.4,126.5,126.6,126.7,126.9,128.4,129.1,132.8,133.8, 
134.2 and 135.2 (C6H4)5 169.8 and 169.9 (CO). 
IR (v,,,,,,, cm-1): 3000-2850,1646 (C=O), 1584,1498 (C=C), 1434,1372,1212. 
GC-MS: 189 (M), 174 (M-CH3)+ý 160,132 (M-C2H5CO)+, 117 (M-C3H6NO) +, 104 
(M-C4H7NO)+, 77(C6H5+), 51. 
Synthesis of N-propionyl-1,2,3,4-tetrahydroisoquinoline (compound L2) 
(diphenylphosphinic chloride method) 
Propionic acid (0.6 ml, 8 mmol) was added under a nitrogen stream to an oven-dried 
round-bottomed flask and was diluted with anhydrous dichloromethane (45 ml). An 
excess of triethylamine (2.8 ml, 20 mmol) was added and the mixture was kept in an 
ice/acetone bath for a few minutes. Diphenylphosphinic chloride (1.91 ml, 10 mmol) 
was added dropwise over a 15 minute period and then, 1,2,3,4-tetrahydroisoquinoline 
(I ml, 8 mmol) was added into the reaction flask under vigorous stirring, obtaining a 
yellow solution that was kept in the ice/acetone bath for ten minutes and at room 
temperature overnight. The reaction mixture was extracted with sodium 
hydrogencarbonate (0.2 M, 2x 40 ml), hydrochloric acid (0.2 M, 2x 40 ml) and was 
washed with brine. After drying over magnesium sulphate and evaporation of the 
solvent, the crude product was purified by flash chromatography (silica gel, diethyl 
ether Rf = 0.59), yielding the title compound as a colourless oil (1.34 gq 88 %). 
) through Synthesis of N-propionyl-1,2,3,4-tetrahydroisoquinoline (compound j.. 9 
methylation of the oc carbon in N-acetyl-1,2,3,4-tetrahydroisoquinoline (1.8 ) 
A nitrogen-purged two-necked flask was charged with N-acetyl-1,2,3,4- 
tetrahydroisoquinoline (17.5 mg, 0.1 mmol) and 3 ml of anhydrous THE The flask was 
kept in an ice/salt bath while LDA or LHMDS (0.2-0.3 mmol) were added dropwise. 
After 30 minutes, iodomethane (20 ýtI3 0.3 mmol) was added. The reaction was kept in 
the ice/salt bath for 30 minutes and at room temperature for 15 minutes before the 
work-up. The solvent was evaporated off under vacuum and saturated aqueous 
NH4CI 
155 
C 0"1 a ter 3 Labeffinz ofPHNO 
(20 ml) was added to quench the excess of base. The product was extracted with ethyl 
acetate (3 x 20 ml) and the organic phases were washed with brine (I x 20 ml) and 
dried over magnesium sulphate, obtaining 3.9 as a colourless oil (15.5 mg, 82 % yield). 
Synthesis of N-ethyl-1,2,3,4-tetrahydroisoquinoline (compound 3.10 
A nitrogen-purged flask was charged with N-acetyl-1,2,3,4-tetrahydroisoquinoline 
(87.5 mg, 0.5 mmol) and 5 ml of anhydrous THF. Lithium aluminium hydride (I M in 
THF, 0.8 ml, 0.8 mmol) was carefully added at room temperature. The reaction mixture 
was heated at 60 T for one hour and a white slurry was formed. The solvent was then 
evaporated under vacuum and the flask was kept in an ice bath. The excess LiAlH4was 
quenched by the addition of aqueous sodium hydroxide (10 % w/w, 5 ml). The reduced 
product was extracted with diethyl ether (3 x 15 ml) and the organic phases were 
washed with brine (2 x 15 ml) and were dried over magnesium sulphate. Purification of 
the crude material was achieved by flash chromatography (basic alumina, petroleum 
ether-ethyl acetate 20: 1, Rf = 0.40), obtaining the title compound as a colourless oil (60 
mg, 74 % yield). 
HPLC: Phenomenex Luna C18(2) column (150 mm x 4.6 mm x5 micron), 50 % 
(NH4)2HP04 0.05 M-50 % acetonitrile, flow =I ml/min, wavelength = 254 run, 
retention time = 4.0 min. 
'H-NMR (500 MHz, CDC13) 8 (PPM): 1.11 (3 H, t, J=7.2 Hz, CH3), 2.50 (2 H, q, J 
7.2 Hz, NCH2CHA 2.65 (2 H, t, J=5.9 Hz, ArCH2CH2N), 2.84 (2 H, t, J=5.9 Hz, 
ArCH2CH2N), 3.55 (2 H, s, ArCH2N), 6.92-7.03 (4 H, m, C6H4). 
13C-NMR (62.9 MHz, CDC13) 8 (PPM): 12.4 (CHA 29.1 (NCH2CH3)5 50.5 
(ArCH2CH2N), 52.2 (ArCH2CH2N), 55.8 (ArCH2N), 125.7,126.5,127.2,128.8,134.3, 
134.9 (C6H4)- 
IR (v,,,,,, , cm-1): 
2970-2860,1452,740. 
GC-MS (m/z): 161 (M), 160,146 (M-CH3)+ý 132 
(M-C2H5)+i, 117 (M-C2H6N)+, 104 
(M-C3H7N)+, 91,77 (C6H5+)- 
Synthesis of N-propyl-1,29394-tetrahydroisoquinoline (compound 
3.11 
N-propionyl-1,2,3,4-tetrahydroisoquinoline (102.6 mg, 0.54 Mmol) was dissolved 
in 5 
ml anhydrous THF in a nitrogen-purged 
flask. Lithium aluminium hydride (1 M in 
THF, I ml, I mmol) was added dropwise at room temperature, 
forming a white slurry 
that was heated to 60 
OC for one hour. The solvent was evaporated and a sodium 
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hydroxide 10 % w/w solution (10 ml) was added. The product was extracted with 
diethyl ether (3 x 15 ml) and the organic phases were washed with brine and were dried 
over magnesium sulphate. Purification of the crude mixture was achieved using flash 
chromatography (basic alumina, petroleum ether-ethyl acetate 20: 1, Rf = 0.45), yielding 
the title compound as a colourless oil (43 mg, 45 % yield). 
HPLC: Phenomenex Luna C18(2) column (150 mm x 4.6 mm x5 micron), 50 % 
(NH4)2HP04 0.05 M-50 % acetonitrile, flow =I ml/min, wavelength = 254 nm, 
retention time = 7.2 min. 
I H-NMR (500 MHz, CDC13) 6 (PPM): 1.06 (3 H, t, J=7.2 Hz, CH3), 1.69 (2 H, sex, J 
7.2 Hz, CH3CH2CH2N), 2.51 (2 H, t, J=7.2 Hz, CH3CH2CH2N), 2.65 (2 H, t, J=5.9 
Hz, ArCH2CH2N), 2.84 (2 H, t, J=5.9 Hz, ArCH2CH2N), 3.55 (2 H, s, ArCH2N), 6-92- 
7.03 (4 H, m, C6H4). 
13C-NMR (62.9 MHz, CDC13) 6 (PPM): 14.2 (CHA 29.2 (CH3CH2CH2N), 29.5 
(CH3CH2CH2N), 47.5 (ArCH2CH2N), 51.2 (ArCH2CH2N), 56.8 (ArCH2N), 125.6, 
126.0) 126.8) 128.8,134.4ý 135.4 (C6H4)- 
IR (v,,,,, x , cm-1): 2950-2860,1464,740. 
GC-MS (m/z): 175 (M)+, 174,146 (M-C2HO+ý 132 (M-C3H7)+5 117 (M-C3H8N), 104, 
91,77 (C6H5+)- 
Synthesis of N-propyl-1,2,3,4-tetrahydroisoquinoline (compound 3.11 from 
compound 3.8 using the Sep-Pak method 
A solution of N-acetyl-1,2,3,4-tetrahydroisoquinoline (17.5 mg, 0.1 mmol) in 
anhydrous THF (3 ml) was cooled down using an ice bath. LDA 2M (0.1 ml, 0.2 
mmol) was added dropwise and the mixture was kept in the ice bath for 30 minutes. An 
excess of iodomethane (20 ýtl, 0.3 mmol) was finally added dropwise. After 15 minutes, 
the reaction mixture was passed through a light silica Sep-Pak that had been pre- 
conditioned with THF (15 ml). Extra THF (3 ml) was used to elute the N-propyl- 
1,2,3,4-tetrahydroisoquinoline product. The eluate fractions were added to a solution of 
IM LiAlH4 in THF (I ml, I mmol) and the reaction was heated at 60 T. The solvent 
was evaporated off after one hour and the excess LiAlH4 was carefully quenched with 
aqueous NaOH (10 % w/w, 15 ml). The resulting slurry was extracted with 
dichloromethane or diethyl ether (3 x 15 ml) and the organic phases were washed with 
brine (2 x 20 ml), dried over magnesium sulphate and filtered. Purification of the crude 
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material was carried out using flash chromatography (basic alumina, petroleum ether- 
ethyl acetate 20: 1, Rf = 0.45), obtaining 3.11 as a colourless oil (6.2 mg, 35% yield). 
Synthesis of (+)-4-propionyl-3,4,4a, 5,6,10b-hexahydro-9-triisopropylsilyloxy-2H- 
naphtho[1,2-bl[1,4]oxazine (compound 3.17 through methylation of the cc carbon 
in the N-acetyl precursor 3.14 
Compound 3.14, (2.4 mg, 5.9 ýtmol) was dissolved with anhydrous THF (0.1 ml) in a 
Wheaton vial. An excess of iodomethane (I M in THF, 17.7 ýLl, 17.7 ýtmol) was added 
to the solution and the vial was placed in an ice bath. A solution of 1.8 M LDA (18 ý11, 
10 [tmol) was slowly added into the reaction mixture. Analytical samples were 
quenched with a 0.1 M solution of acetic acid in methanol (0.1 ml) and HPLC mobile 
phase (0.2 ml). The samples were then analysed using the following HPLC conditions: 
Phenomenex Luna C 18(2) column (50 mm x 4.6 mm x5 micron) , wavelength = 280 
nim, mobile phase 20 % water containing 0.1 % TFA-80 % acetonitrile containing 0.1 
% TFA, flow rate I ml/min. Retention time of compound 3.14 = 4.7 min. Retention 
time of compound 3.17 = 6.5 min. 
Synthesis of (+)-4-ethyl-3,4,4a, 5,6,10b-hexahydro-2H-naphtho[1,2-bl[1,4]oxazin-9- 
ol (EHNO) from the N-acetyl precursor 3.14 (deprotection-reduction) 
Precursor 3.14 (2 mg, 5 ýtmol) was placed in a Wheaton vial and was dissolved using 
anhydrous THF (0.1 ml). The reaction vessel was immersed in an ice bath and 1.8 M 
LDA (8.3 ýtl, 15 ptmol) was added dropwise. An excess of 1M anhydrous methanol in 
THF (25 ýil, 25 ptmol) was immediately used to quench the base and finally aIM 
solution of LiAlH4 in TFIF (50 ýtl, 50 ýtmol) was added into the vial. The reaction 
mixture was heated at 60 T and samples were quenched with HPLC mobile phase (0.2 
ml) and two drops of acetic acid (sample pH = 4-5). The identity of the product was 
confirmed by HPLC co-elution with the EHNO standard. 
Analytical samples were analysed using the following HPLC conditions: 
Phenomenex. Luna C 18 (2) column (5 0 mm x 4.6 mm x5 micron), mobile phase = water 
(0.1 % TFA)-acetonitrile (0.1 % TFA), wavelength = 280 nm, flow =I ml/min. 
Gradient system 1: 
0-5 minutes: 20 % aqueous-80 % organic 
5-10 minutes: from 20 % aqueous to 5% aqueous 
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10-38 minutes: 5% aqueous-95 % organic 
Semi-preparative Phenomenex Luna 10ýt C18(2) column (250 x 10 mm), 100 A pore 
size, mobile phase = 0.1 M aqueous ammonium formate (adjusted to pH = 4.5 with 
acetic acid)- acetonitrile , wavelength = 280 run, flow =3 ml/min. 
Gradient system II: 
0-1 minutes: 75 % aqueous-25 % organic 
1-6 minutes: from 75 % aqueous to 55 % aqueous 
6-10 minutes: from 55 % aqueous to 5% aqueous 
10-45 minutes: 5% aqueous- 95 % organic 
Radiochemistrv 
Production of ["C]carbon dioxide 
Carbon- II was produced as [ 11 C] carbon dioxide by the 14 N(p, oc) 11 C nuclear reaction 122 
using the Scanditronix MC40 or the GE PETtrace cyclotron. The target gas (nitrogen 
containing 0.5 % 160-oxygen, 200 psi, 14 bar) was irradiated by 19 MeV protons (10 
ýtA beam current). 
Synthesis of ["Cliodomethane from [I 1C]carbon dioxide 
The synthesis of ["C]iodomethane from ["C]carbon dioxide was carried out as 
described by Luthra et al. 123 using the automated synthesis system shown on Figure 3.9. 
The apparatus also had facility for performing "C-methylation reactions followed by 
product separation and formulation of the "C-methylated product. The synthesis 
system was contained in a lead-shielded enclosure (ca 60 mm thickness) with all 
operations controlled externally by a Toshiba EX-40+ programmable logic controller 
(PLC). Each valve was actuated by a low voltage (24 V) output from the PLC. The PLC 
was under the control of a specially written ladder logic programme which determined 
the sequence and timing of the steps in the synthesis. 
Set-up procedure 
The system was set up at least one hour before the expected end of bombardment 
(EOB) time. The [1 'C]iodomethane vessel was connected to the NaOH trap (ca 0.5 g, 3- 
4 pellets) and both were continuously purged through with a nitrogen stream. The 
Teflon loop between valves I and 2 was loaded with hydriodic acid (57 % w/v, 200 [d). 
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The acetyl precursor (compound 3.8 or 2.14! ) was dissolved in inhibitor-free anhydrous 
THF (100-200 ýtl) and was placed into the "C-methylation vessel. Lithium aluminium 
hydride in tetrahydrofuran (0.1 M, 200-300 ýtl) was added to the ["C]iodomethane 
vessel via Tap I thirty seconds before the start of the radiosynthesis. 
Preparation of ["Cliodomethane 
The ["C]carbon dioxide was carried in a nitrogen stream (10-20 ml/min) from the 
cyclotron vault into the hot cell, where it was cryogenically trapped for two minutes in 
a 1/16" stainless steel loop immersed in liquid argon (b. p. = -185.7 OC). The cryotrap 
was then released and the trapped radioactivity was carried by nitrogen gas (5 ml/min) 
into the ["C]iodomethane vessel. THF was then removed by heating the 
["C]iodomethane vessel at 115 OC under a nitrogen flow (37 ml/min, 3 min) (Figure 
3.3 2). The [ 11 C] iodomethane vessel was cooled down to room temperature by a flow of 
compressed air (3 minutes). The hydriodic acid (57 % w/v, 200 ýfl) contained in the 
Teflon loop was added to the reaction mixture, which was then sealed and heated to 160 
for 3 minutes. The produced [11 C]iodomethane was distilled via a nitrogen gas flow 
(5 ml/min, 1 min) into the 11 C-methylation vessel, which was then lowered by a syringe 
drive. 
The total synthesis time for [1 'C]iodomethane was 13 minutes from EOB. 
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Trapping and analysis of ["Cliodomethane 
The radioactive material was distilled into a closed vial containing 0.3 ml ethanol (or 
THF) that was immersed in an acetonitrile/dry ice bath. Samples (25 ýtl diluted in 0.3 
ml mobile phase) were analysed by HPLC showing 98-100% purities in the 
["C]iodomethane. The identity of the radioactive peak was confirmed by co-elution 
with non-radioactive iodomethane using different mobile phases. 
HPLC conditions: Phenomenex Luna C18(2) column (250 mm x 4.6 mm x5 micron), 
wavelength = 254 nm, 50 % water-50 % acetonitrile, flow =I ml/min, retention time = 
8.5 min. 
Radiosynthesis of N-([3- 11 Clpropionyl)-1,2,3,4-tetrahydroisoquinoline (3.12 
["C]Iodomethane was distilled into a closed vial containing of N-acetyl-1,2,3,4- 
tetrahydroi soquino line (4.3 mg, 25 ýtmol) dissolved in inhibitor-free anhydrous THF 
(0.2-0.3 ml). The reaction vial was cooled down to -78 T in an acetone/dry ice bath. 
Finally, aIM solution of lithium bis-(trimethylsilyl)amide in THF (25 ýd, 25 ýtmol) 
was injected dropwise, forming a light brown reaction mixture. Reaction samples (20 
ýtl) were quenched with a 0.1 M solution of acetic acid in methanol (0.1 ml) and HPLC 
mobile phase (0.2 ml) and were then analysed using HPLC. 
HPLC conditions: Phenomenex Luna C 18 (2) column (15 0 mm. x 4.6 mm x5 micron), 
mobile phase = 70 % water containing 0.1 % TFA-30 % acetonitrile containing 0.1 % 
TFA, wavelength = 254 nm, flow =I ml/min. 
The analytical radiochernical yields of 3.12 were 92-98 %. 
L3) Radiosynthesis of N-([3-"Clpropyl)-1,2,3,4-tetrahydroisoquinoline (L. 1 (Sep-Pak 
method) 
["C]Iodomethane was distilled into a closed vial containing of N-acetyl-1,2,3,4- 
tetrahydroisoquinoline (4.3 mg, 25 ýtmol) dissolved in inhibitor-free anhydrous THF 
(0.2-0.3 ml). The reaction vial was cooled down to -78 T in an acetone/dry ice bath. 
Finally, a1M solution of lithium bis-(trimethylsilyl)amide in THF (25 ýtl, 25 ýtmol) 
was injected dropwise. After one minute, the reaction mixture was passed through a 
silica Sep-Pak cartridge that had been pre-conditioned with 
THF (15 ml). Extra THF 
(0.5 ml) was used to elute the radioactive product. A solution of IM LiAlH4 
in THF 
(15 0 ýtl, 15 0 ýtmol) was added to the eluate and the reaction was 
heated at 60 T for 3 -7 
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minutes. Samples were quenched with aqueous sodium hydroxide (0.1 ml, 10 % w/w) 
and diluted with HPLC mobile phase (0.3 ml, 50 % (NH4)2HP04 0.05 M-50 % 
acetonitrile). The samples were analysed by HPLC. 
HPLC conditions: Phenomenex Luna C18(2) column (150 mm x 4.6 mm x5 micron), 
mobile-phase = 50 % (NH4)2HP04 0.05 M-50 % acetonitrile, flow =I ml/min, 
wavelength = 254 nm. 
The analytical radiochernical yields of 3.13 were 75-95 
One-pot radiosynthesis of N-(13- I 'C]propyl)-1,2,3,4-tetrahydroisoquinoline (L. 13 
'C]Iodomethane was distilled over a closed vial containing of N-acetyl-1,2,3,4- 
tetrahydroisoquinoline (2 mg, II Vtmol) dissolved in inhibitor-free anhydrous THF 
(0.2-0.3 ml). The reaction vial was cooled to -78 OC in an acetone/dry ice bath. Finally, 
aIM solution of lithium bis-(trimethylsilyl)amide in THF (11 ýtl, II ýImol) was 
injected dropwise. After one minute, the reaction mixture was quenched with anhydrous 
methanol (I ýtl, 25 ýimol) and was warmed up to room temperature. A solution of IM 
LiAlH4 in THF (0.1 ml, 100 ýtmol) was added and the reaction was heated at 60 T for 
7 minutes. Samples were quenched with aqueous sodium hydroxide (0.1 ml, 10 % w/w) 
and diluted with HPLC mobile phase (0-2 ml, 50 % (NH4)2HP04 0.05 M-50 % 
acetonitrile). The samples were then analysed by HPLC as described above. 
The analytical radiochernical yields of 3.13 were 76-82 %. 
Radiosynthesis of (+)-4-([3- 11 C]propionyl)-3,4,4a, 5,6,10b-hexahydro-9- 
triisopropylsilyloxy-2H-naphtho[1,2-b][1,4]oxazine (2-15 ) 
Procedure 1: 
The acetyl precursor 3.14 (2-3 mg, 5-7.5 ýtmol) was dissolved in 100 ýtl of THF 
(stirring was required). The solution was kept in an acetone/dry ice bath (-78 OC) and a 
0.2 M solution of lithium bis-(trimethylsilyl)amide in THF (2.2-3 equivalents relative to 
the precursor 3.14,55-112 ýtl) was added dropwise. The reaction mixture (a slightly 
yellow solution) was allowed to warm up for 3-7 minutes and 25 ýtl of 
"CH31/THF was 
added. The reaction mixture was neutralised 2 minutes later with 0.2 ml of acetic acid 
(0.2 M in methanol). 
Procedure 2: 
m--ý 
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The acetyl precursor 3.14 (2-3 mg, 5-7.5 ýtmol) was dissolved in 150 ýd of 11CH31/THF 
solution at room temperature (stirring was required). LHMDS (0.2 M in THF, 2.2 
equivalents, 55-82 ýtl) was added dropwise at room temperature and the reaction 
mixture was quenched with 0.2 ml of acetic acid (0.2 M in methanol) two minutes later. 
HPLC conditions: 
Analytical Phenomenex Luna 3ýt C18(2) column (50 x 4.6 mm), 100 A pore size, 
wavelength = 280 nm, flow =I ml/min. Mobile phase: 20 % water (with 0.1 % TFA)- 
80 % acetonitrile (with 0.1 % TFA). 
Semi-preparative Phenomenex Luna 10ýt C18(2) column (250 x 10 mm), 100 A pore 
size, wavelength = 280 nrn, flow =3 ml/min. Mobile phase: 20 % water (with 0.1 % 
TFA)-80 % acetonitrile (with 0.1 % TFA). 
The analytical radiochernical yields of 3.15 were 65-85 %. 
Isolated radiochemical yields of product 3.15 were 50-55 % (from the initial 
[ 11 C] iodomethane activity). 
One-pot radiosynthesis of (+)-4-([3-"C]propyl)-3,4,4a, 5,6,10b-hexahydro-2H- 
naphtho[1,2-bj[1,4]oxazin-9-oI ([3-"C]-(+)-PHNO) 
The acetyl precursor 3.14 (2.6 mg, 6.4 ýtmol) was dissolved in 100 ýtl of THF (stirring 
needed). The solution was kept in an acetone/dry ice bath (-78 OQ and a 0.2 M solution 
of lithium bis-(trimethylsilyl)amide in TFIF (2.5 equivalents, 80 [d) was added 
dropwise. The reaction mixture (a slightly yellow solution) was allowed to warm up for 
3-7 minutes and 25 ýd of "CH31/THF was added. The reaction was quenched after 5 
minutes with anhydrous methanol (0.2 M solution in THF, 5 equivalents, 160 ýtl) and 
lithium aluminium hydride (I M solution in THF, 15 equivalents, 96 ýtl) was added 
dropwise. The reaction vial needed to be vented during this addition due to hydrogen 
formation. After the LiAlH4 addition, the reaction vial was heated at 60 OC for 7 
minutes. Analytical samples (10 ýtl) were quenched with HPLC mobile phase (0.2 ml) 
and two drops of acetic acid. 
HPLC conditions: 
Semi-preparative Phenomenex Luna 10ýt C18(2) column (250 x 10 mm), 100 A pore 
size, wavelength = 280 nm, 3 ml/min. Mobile phase: water/0.1 M ammonium formate 
(adjusted to pH = 4.5 with acetic acid)- acetonitrile. 
Gradient system 11: 
163 
f ha ter 3 Labelli'm THNO 
, ý, ol 
0-1 minutes: 75 % aqueous-25 % organic 
1-6 minutes: from 75 % aqueous to 55 % aqueous 
6-10 minutes: from 55 % aqueous to 5% aqueous 
10-45 minutes: 5% aqueous- 95 % organic 
The analytical radiochernical yields of [3-1 'C]-(+)-PHNO were 55-60 
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4.1. Introduction 
4.1.1. Serotonin 
Serotonin (5-hydroxytryptamine or 5-HT) is a monoamine neurotransmitter that is 
involved in a wide range of physiological roles such as sleep, mood, learning, pain, 
addictions and sexual activity amongst others. 5-HT is also implicated in the etiology 
of numerous mental illnesses such as depression, schizophrenia, migraine, suicidal 
behaviour, autism, eating disorders or obsessive compulsive disorder. ' In fact, some of 
the best-selling drugs worldwide modulate 5-HT activity. 2 
5-HT neurons are located in the raphe nuclei of the dorsal brain stem. 5-HT projections 
are widespread throughout the forebrain, cerebellum and brain stem. Midbrain and 
pontine raphe neurons give rise to innervation of the cerebral cortex, hippocampus, 
basal ganglia, diencephalons and cerebellum, whereas medullary raphe neurons 
predominantly send descending projections to the spinal cord. 3,4 
The biosynthesis of 5-HT starts from the amino acid tryptophan, which is transported 
into the brain by the neutral amino acid transporter. Tryptophan is converted into 5- 
hydroxytryptophan by the tryptophan hydroxylase enzyme within the presynaptic 
terminals (Scheme 4.1). Serotonin is finally obtained by decarboxylation of 5- 
hydroxytryptophan. However, it is not clear what decarboxylase isofonn is involved in 
the serotonin synthesis. The rate of serotonin synthesis has been traced with PET using 
cc-[' 'C]methyl-L-tryptophan. 5-7 
After its release, 5-HT is re-accumulated into the presynaptic terminals by the serotonin 
transporter (SERT). The radioligands 'C]McN-5652 
8 and [11C]DASB 9 allow the in 
vivo imaging of SERT with PET. 
The serotonin metabolic pathway involves the formation of 5-hydroxyindole acetic acid 
(5HIAA), which is catalysed by monoamino oxidase (MAO). 
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Scheme 4.1. Biosynthesis and metabolism of 5-hydroxytryptamine (serotonin). 
4.1.2. Serotonin receptors 
Although 5-HT receptors are mainly found in the central and peripheral nervous 
system, they also exist in non-neuronal tissues such as the gut or the cardiovascular 
system. The 5-HT receptor family is composed of at least fourteen members that have 
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been classified on the basis of their structural and operational features (Table 4.1). 10 All 
5-HT receptors belong to the G-protein coupled receptor superfamily (GPCR), except 
the 5-HT3 subtype, which is a ligand-gated ion channel. ' 1 
Table 4.1. Classification of serotonin receptors. 
G-protein coupled receptors Ligand-gated ion channel 
5-HTI (5-HTIA, 5-HTIBý 5-HTID, 5-HTIE, 5-HTI F)a 
5-HT2 (5-HT2A, 5-HT2B) 5-HT2C)b 
5-HT4C 
5-HT6C 
5-HT7C 
5-HT3 (5-HT3A, 5-HT3Bq 5-HT3C) 
' The signalling pathway consists of adenylyl cyclase inhibition. 
b The signalling pathway consists ofphospholipase C activation. 
' The signalling pathway consists of adenylyl cyclase activation. 
The 5-HTI receptor family includes five molecular subtypes (5-HTIA, 5-HTIBI, 5-HTID5 
5-HTIEand 5-HTIF) that exert their effects through inhibition of adenylyl cyclase. The 
5-HT2 receptor class is composed of three members (5-HT2A, 5-HT2Band 5-HT20 and 
their stimulation increases the hydrolysis of inositol phosphates and raises the cytosolic 
Ca2+ concentration. 5-HT2Areceptors have been imaged with PET using the antagonist 
["C]MDLI00907.12 The 5-HT3 receptor is a transmitter- gated cation channel and 
includes three molecular subtypes (5-HT3A, 5-HT3B, 5-HT3C). 5-HT3 activation has 
pronounced effects on the cardiovascular system, gastrointestinal tract and dopamine 
release. 11 
The 5-HT4,5-HT6 and 5-HT7 receptors are positively coupled to adenylyl cyclase. 5- 
HT4 receptors are found in striatum, heart and digestive tract. 
13 The activation of 5-HT4 
receptors plays an important role in gastrointestinal motility and heart rhythm. 
14 5-HT6 
receptors are only found in the central nervous system and are involved in the control of 
cholinergic function. 15 5-HT7 receptors are found in the limbic system, thalamocortical 
regions and vascular system. 
' 6 This receptor subtype may be involved in affective 
disorders and has a role in the regulation of circadian rhythms and thermoregulation. 
17 
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4.1.3. Imaging of 5-HTIAreceptors with PET antagonists 
The 5-HTIAreceptors are the best characterised of all known serotonin receptors and 
were the first serotonin receptor subtype to be cloned and sequenced. 18,19 Moreover, 5- 
HTIA receptors have been extensively studied due to the early discovery of selective 
agonists and radioligands. 20,21 The 5-HTIAreceptor consists of a protein with 422 amino 
acids with the amino terminus facing the extracellular space and the carboxy tenninus 
facing the cytoplasmic space (Figure 4.1). 2 This receptor has the typical structure of a 
G-protein coupled receptor and contains seven putative transmembrane domains. 22 
5-HTIA receptors are found presynaptically in the raphe nuclei, where they act as 
somatodendritic autoreceptors. These 5-HTIA autoreceptors are involved in the 
regulation of 5-HT cell firing. On the other hand, postsynaptic 5-HTIA receptors act as 
heteroreceptors and are mainly located in hippocampus, septum, amygdala and some 
cortical layers. The lowest densities of 5-HTIA receptors are observed in extrapyramidal 
areas (basal ganglia, substantia nigra) and in the cerebellum. 3,4 
DH 
IC Intrucellubu loop IC-3 
FT--ml Tr-ansmembr-ane domain 
y N- glycosylation site 
Site for protein kinase mediated phosphorylation 
Putative palmitoylation site 
Figure 4.1. Schematic representation of the 5-HT]Areceptor. 
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There is substantial evidence from postmortem studies to correlate abnormal levels of 
brain 5-HTIA receptor density to neuropsychiatric diseases . 
23,24 Reductions in 5-HTIA 
receptor density have been found in precortical regions of patients suffering from 
depression 25,26 or Alzheimer's disease. 27-29 In contrast, increases in receptor density in 
prefrontal cortex of schizophrenic subjects have been reported using postmortem 
techniques. 30-32 
Some antagonist PET radioligands have been developed for the imaging and 
quantification of 5-HTIAreceptors in humans (Figure 4.2). 33 
0 C113 OH 
N ýC-0 J/ 
Labelled positions: 
10-methyl-"CIWAY-100635 
icarbonyl-"CIWAY-100635 
OCH3 
N 18 F 
0ý- 
H2T 
1 11 CIDWAY 
q 
--41': ýo '? 
F 
P_[18 FIMPPF 
Figure 4.2. PET 5-HT]Aantagonists. 
1 11 CINAD-299 
WAY-100635 is an antagonist at both presynaptic 5-HTIA autoreceptors and 
postsynaptic 5-HTIA receptors. 34 [0-methyl-"C]WAY-100635 was the first PET 
radioligand used to image the 5-HTIA in vivo. 35 Monkey studies showed that [0-methyl- 
"C]WAY-100635 accumulated in brain areas with high density of 5-HTIA receptors. 
36 
Furthermore, pre-treatment of the animals with 5-HTIAagonists and 5-HTlAantagonists 
blocked [0-methyl- 11 CIWAY-100635 uptake, demonstrating the selective binding of 
the radioligand to 5-HTIA receptors. [0-methyl-"C]WAY-100635 also allowed the 
visualisation of 5-HTIAin the living human brain. 37 However, the extensive formation 
of lipophilic metabolites made difficult the quantification of 5-HTIAreceptors in man. 
38 
[0-methyl-"C]WAY-100634 was found to be a prominent metabolite that entered the 
brain and contributed to the radioactive signal observed (Scheme 4.2). 
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This problem was overcome by labelling WAY-100635 in the carbonyl position. 
39 
Images obtained with [carbonyl-"C]WAY-100635 showed lower non-specific binding 
40,41 and higher cortex-to-cerebellum ratios than [0-methyl- 11 C] WAY- 10063 5. 
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Scheme 4.2. Metabolites obtained ftom [0-methyl-"C]WAY-100635 and [carbonyl- 
"C]WAY-100635 in humans. 
Metabolite analysis in humans after the administration of [carbonyl-"C]WAY-100635 
proved a significant presence of [carboxy- 11 C] cyclohexanecarboxylic acid. On the other 
hand, [carbonyl-"C]desmethyl-WAY-100635 was only a minor metabolite in human 
plasma. 42 
Although [carbonyl-"C]WAY-100635 generates outstanding images of 5-HTIA 
receptors in human brain, it is metabolised very quickly and the radioligand binding is 
hardly affected by fluctuations of intrasynaptic serotonin concentrations. Besides that, 
its current radiosynthesis is rather demanding. 
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The desmethyl analogue of [carbonyl-"C]WAY-100635 (["C]DWAY) has been 
evaluated in animals (rats and primates) in vivo and in the human brain in vitro. 43 The 
radioligand had a good brain penetration and bound specifically to 5-HTIA receptors. 
Moreover, [11C]DWAY showed better kinetics and metabolism properties than 
[carbonyl-"C]WAY-100635, which may facilitate the biomathematical modelling of 
the radioligand. Several other structural analogues of WAY-100635 less prone to 
metabolic degradation have been reported. 29,34,44,45 However, most of these compounds 
have shown limited success in vivo. 
["C]NAD-299 is a silent 5-HTIAantagonist that has been labelled using ["C]cyanide 
as the primary radioactive precursor. 46 This radioligand showed rapid uptake in monkey 
brains and its binding to neocortex and raphe nuclei was 5-HTIA specific, as 
demonstrated by competition experiments with WAY-100635.47 Post-mortem 
autoradiography in human brain also showed accumulation of ["C]NAD-299 in areas 
with high 5-HTIAreceptor density. 46 On the other hand, the fast metabolism suffered by 
this radioligand in vivo may undermine its possible human use. 48 
Although the high-affinity ligand [carbonyl-"C]WAY-100635 and its derivative 
[carbonyl- 11 C] DWAY both produce excellent images of 5 -HTIAreceptor distribution in 
living brain, their use requires an on-site cyclotron due to the short half-life of carbon- 
11. This problem has been overcome by the development of P_[18 F]MPPF, a selective 
5-HTIA antagonist labelled with fluorine-18 . 
49 Animal studies showed that p- 
[18 F]MPPF accumulated specifically in hippocampus and cerebral cortex. 49-52 However, 
the radioligand brain uptake was much lower compared to [carbonyl-''C]WAY- 
53 100635, due to the efflux action of the P-glycoprotein on P_[18 F]MPPF. Human 
studies employing P_ [ 
18 F]MPPF have also been reported and the radioactivity binding 
pattern corresponded to the known localisation of 5-HTIA receptors in the brain. 
54,55 
However 'P_[18 F]MPPF suffered from fast brain washout and fast metabolism. 
Rat studies have shown that the desmethyl analogue of P_[18 F]MPPF, p-[ 
18 F]DMPPF, 
has better brain penetration and more favourable metabolic characteristics than p- 
[18 F]MPPF . 
56 
4.1.4. Imaging of 5-HTIAreceptors with PET agonists 
5-HTIAreceptors can exist in high-affinity (coupled to G-protein) and low-affinity (free 
receptor) states. Agonists bind exclusively to the G-protein- coupled form, whereas 
antagonists bind homogeneously to both . 
57 An effective 5-HTIAPET agonist would 
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provide a means to measure the high-affinity state/low-affinity state ratio in vivo, which 
may be altered in certain neurological conditions. Furthermore, 5-HTIA receptor 
occupancies by agonist drugs are not correctly measured by PET antagonists. 58 The use 
of an agonist PET radioligand could measure the drug occupancy of only the high- 
affinity receptors, which is a more meaningful clinical measure. Besides that, current 5- 
HTIAantagonist radioligands do not seem to be very sensitive to competition with 
endogenous serotonin. Changes in the intrasynaptic levels of serotonin may occur in 
response to spontaneous emotional reactions such as anxiety, depression and coping 
with pain. 59 PET agonists are more responsive to variations in neurotransmitter 
concentrations than antagonists. 60 
Numerous efforts have been directed towards the radiosynthesis and biological 
evaluation of potential 5-HTIAPET and SPECT agonists. Many of these radioligands 
were based on the structure of 8-hydroxy-2-(dipropylamino)tetralin (8-OH-DPAT), the 
first selective 5-HTIAagonist discovered (Figure 4.3 ). 20 
1 125 IIBH-8-MeO-N-PAT 
OH IICH2CH2CH3 
1 11 CI-8-OH-DPAT 
II 
N 
["C]-(+)-S20499 I Cl-(±)-8-OH-PPSNIAT 
Figure 4.3. Potential PET and SPECT 5-HTIA agonists containing the aminotetralin 
structure. 
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Gozlan et al. described in 1988 the evaluation of the 5-HTIAagonist [ 125 I]BH-8-MeO- 
N-PAT . 
61 In vitro autoradiography of [125 I]BH-8-MeO-N-PAT demonstrated the 
binding of this radioligand to areas with high 5-HTIAreceptor densities. However, this 
potential 5-HTIAradioligand has not been evaluated in vivo yet. 
Zhuang et al. reported in 1993 that racemic [1251] -trans- 8 -OH-PIPAT bound with high 
affinity to 5-HTIAreceptors in rats. 62 The same authors showed that the (R)-isomer was 
a partial agonist and had higher affinity for 5-HTIA receptors than the (S)-isomer. 63 
However, the evaluation of the [1231] -(R)-trans-8-OH-PIPAT enantiomer in vivo has not 
been reported yet. 
The carbon-I I derivative of 8-OH-DPAT, ["C]-8-OH-DPAT, was prepared by Thorell 
et al. using [1-1 C]propyl iodide and microwave heating, but no PET studies have been 
reported so far. 64 
LY274601 is a full agonist that shows high affinity (Ki = 0.6 nM) and selectivity for 5- 
HTIA receptors. 65 The only difference between LY274601 and 8-OH-DPAT is the 
substitution of the hydroxyl by a methylthio group. Suehiro et al. synthesised and 
evaluated ["C]LY274601 in living mice brain. 66 The radioligand crossed the BBB and 
accumulated in regions known to have high densities of 5-HTIA receptor sites, and 
blocking experiments with 8-OH-DPAT showed that the binding was specific to 5- 
HTIA receptors. However, [I'C]LY274601 suffered from extensive metabolism, rapid 
washout and considerable non-specific binding. 
OSU 191 is a highly potent and selective 5-HTIAagonist (IC50for 5-HTIA = 1.2 nM). 
67 
Halldin et al. reported the radiosynthesis of [propyl-"C]OSU 191, although the 
radioligand was not further evaluated. 
68 
Both [11C]-(±)-8-OH-PPSMAT and ["C]-(+)-S20499 displayed high in vitro affinity 
for 5-HTIAreceptors (Ki = 0.9 nM and Ki = 0.19 nM respectively) . 
69Despite exhibiting 
high brain uptake in rats, both radioligands failed to accumulate selectively in regions 
containing high 5-HTIAreceptor densities. 
There are also other 5-HTIAagonists with structures not based on that of 8-OH-DPAT 
that have been labelled with a positron emitter (Figure 4.4). Hwang et al. prepared and 
evaluated in rodents the potent (Ki = 0.5 nM) 5-HTIA agonist [18 F]-(-)-FBP. 
70,71 The 
radioligand exhibited high brain uptake, but the binding was not consistent with the 
distribution of 5-HTIAreceptors in the rat brain. 
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Figure 4.4. Potential PET and SPECT 5-HTIA agonists that do not include the 
aminotetralin moiety. 
S14506 has been described as one of the most potent and selective 5-HTIA receptor 
agonists (Ki = 0.98 nM). 72-74 Lu et aL reported the labelling of S14506 in different 
positions with carbon- II and fluorine- 18 . 
75However, these radioligands have not been 
evaluated with PET yet. 
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["CIORG-13502 is a potent (Ki = 0.04 nM) and selective 5-HTIApartial agonist that 
was evaluated in rats. 76 The brain uptake of the radioligand was high, but the 
radioactivity was distributed homogeneously throughout the brain. The partial agonist 
characteristics of this radioligand may explain its unsuitability to image 5-HTIA 
receptors in vivo. 
Vandecapelle et al. reported the assessment of the full 5-HTlAagonist [18 F]ORG-13063 
and its radioiodinated analogue [1231] ORG-13063 in ViVo. 77,78 Biodistribution studies of 
[1231] ORG-13063 in rats and rabbits were rather disappointing, maybe due to the high 
lipophilicity of this radioligand (clogP = 3.88) . 
79 [18 F]ORG-13063 showed acceptable 
brain uptake although the specificity of the radioligand binding was not investigated. 
The radioligand 81 ý3-[4-(2-[' 'C]methoxyphenyl)piperazin-1-yl]-2- 
hydroxypropylloxylthiochroman (["C]Thiochroman) behaved as an agonist at the 
presynaptic 5-HTIA receptors and as an antagonist at the postsynaptic 5-HTIA 
80 receptors. ["C]Thiochroman was evaluated in vivo in rats and a cat. However, the 
labelled compound was not suitable for the visualisation of 5-HTIA receptors in vivo. 
The partial agonistic properties of ["C]Thiochroman or its insufficient brain 
penetration may explain the radioligand failure. 
The benzamide (S)-PPMMB is an agonist with moderate affinity (Ki = 4.3 nM) and 
high selectivity for 5-HTIA receptors. 81 Fujio et al. have reported the biological 
82 
evaluation of ["C]-(S)-PPMMB in mice and rats. The radioligand showed certain 
accumulation in the hippocampus, although the cerebellum uptake was also high. 
Furthermore, pre-treatment of the animals with 5-HTIA agonists and antagonists did not 
affect the brain distribution of ["C]-(S)-PPMMB. 
The apornorphine derivative (R)- 11 -hydroxy- I 0-methylapomorphine (MHA) is a potent 
(Ki = 0.45 nM) and selective 5-HTIA agonist. 83 In primates, [11C]MHA showed 
excellent brain uptake and preferential binding to regions rich in 5-HTIA receptors. 59,84 
On the other hand, the brain washout was very fast and the non-specific binding was 
high. 
2-f 4-[4-(7-methoxynaphthalen- I -yl)piperazin- I -yl]butyll-4-methyl-2H-[1 2,4]triazine- 
3.5-dione (MPT or F 11461) is a ligand with high affinity for the 5-HTIAreceptor (Ki = 
1.4 nM) and with an adequate lipophilicity (logP,, t = 2.2). 
85,86 MPT also has nanomolar 
affinity for the 5-HT7and the D4 receptors, but these receptors are found in the brain in 
very low densities. 87 The [35 S]GTP7S binding and cyclic adenosine monophosphate 
(cAMP) formation assays confinned the agonistic properties of MPT. Kumar et al. 
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have recently reported the radiosynthesis and in vivo validation of [1, C]MPT in 
baboons. 87,88 ["C]MPT bound specifically to brain regions possessing high 5-HTI A 
receptor densities such as hippocampus, amygdala, cingulated, cortical areas and dorsal 
raphe nucleus. The lowest binding of [11C]MPT occurred in the cerebellum. Blocking 
studies with WAY-100635 and 8-OH-DPAT demonstrated the specificity of the 
[11C]MPT binding to 5-HTIA receptors and pre-treatment of the baboons with 
MDLI00907 (a 5-HT2A antagonist) or haloperidol (a D2/3 antagonist) did not affect 
[11C]MPT binding in the regions of interest. The radioligand underwent fast 
metabolism, although only polar metabolites were observed. Hence, ["C]MPT 
represented the first promising 5-HTIAPET agonist. 
["C]MMT and ["C]MMP are phenyl analogues of [11C]MPT that have also been 
assessed in vivo in primates. [1 'C]MMT is a high affinity (Ki = 1.1 nM) and selective 5- 
HTIAagonist. However, baboon scans showed that this radioligand did not accumulate 
in brain areas with high 5-HTIA receptor levels . 
89 In contrast, ["C]MMP (Ki = 0.15 
nM) bound specifically to 5-HTIA receptor-enriched brain regions and showed more 
favourable kinetic properties than [ 11 C] MPT. 90 
4.1.5. Flesinoxan: a 5-HTlAagonist candidate for PET studies 
Arylpiperazines have found therapeutic applications as antibacterials, antidepressants, 
antitussives or anxiolytics. 91 More importantly, the arylpiperazine scaffold is active 
towards many 5-HT receptor subtypes. 92-95 
For this project, the candidate of choice was Flesinoxan, R-(+)-N-[2-[4-(2,3-dihydro-2- 
hydroxymethyl- 1,4-benzodioxin-5-yl)- I -piperazinyl] ethyl] -4-fluorobenzamide (Figure 
4 96 
. 5). Although 
first reported as an antihypertensive compound, Flesinoxan is now in 
phase III clinical trials as an antidepressant and an anxiolytic agent. 97-99 
OH 
CN3 
N 
N, 
lr 
Flesinoxan 
Figure 4.5. Structure of the 5-HT]Aagonist Flesinoxan. 
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Several reports have shown that Flesinoxan is a potent agonist at the 5-HTIA 
receptors. 
100-103 
Furthermore, this compound displays subnanomolar affinity for the 5- 
HTIAreceptors, but contrary to other agonists, it does not display great affinity for D2 
receptors (Table 4.2). 92,99,1 01 Kuipers et al. reported the structure- affinity relationships 
of several Flesinoxan analogues and found that the selectivity of Flesinoxan for 5-HTIA 
versus D2 receptors was derived from the arylpiperazine aromatic ring substitution. 92 
The N4- [(p-fluorobenzoyl)amino] ethyl- moiety was found to be mainly a spacer and 
was not likely to interact with the 5-HTIAreceptor. 
Despite being a substrate for P-glycoprotein, Flesinoxan crosses the blood-brain barrier 
in rats and man. 
100,104 Interestingly, the drug does not have pharmacologically active 
metabolites. 
105 
Table 4.2. Affinities of Flesinoxan to different receptors in rat brain homogenates. 99,101 
4.1.6. Aims and objectives of the project 
0 The radiolabelling of the 5-HTIA agonist Flesinoxan with a positron- 
emitting radionuclide for subsequent biological evaluation in vivo. 
9 The organic synthesis, characterisation and chromatographic analysis of 
Flesinoxan and other relevant precursors and reference materials. 
4.1.7. Radiolabelling strategies for Flesinoxan 
Two main strategies were considered in order to introduce a positron emitter in the 
molecule without altering the original structure (Figure 4.6). Labelling the para 
position of the benzamide ring with fluorine-18 would provide [18 F]Flesinoxan and 
labelling the carbonyl position of the amide group with carbon-11 would yield 
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[carbonyl-"C]Flesinoxan. Labelling in different positions may also give more 
information about the radioligand metabolism in ViVO. 
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[carbonyl- 11 CIFIesinoxan 
Figure 4.6 Feasible positionsfor the radiolabelling of Flesinoxan. 
4.2. Fluorine-18 strategy 
4.2.1. Approach to the radiosynthesis of [ 18 F]Flesinoxan 
Radioligands for the central nervous system must be prepared in high specific activities 
to avoid the saturation of receptors with non-radioactive tracer. In the case of fluorine- 
18, this can only be achieved with the use of no-carrier-added [18F]fluoride. The direct 
replacement of a leaving group by fluorine-18 is the most frequent method for the 
preparation of 18 F-radiopharmaceuticals and is amenable to automation. Therefore, the 
selected approach for the incorporation of fluorine-18 into the benzamide scaffold of 
Flesinoxan was an aromatic nucleophilic substitution (Scheme 4.3). The nitro 
functionality and other good leaving groups are displaced by [18 F]fluoride in this kind 
of reactions. 106 Moreover, the additional amido moiety acts as a moderate electron- 
withdrawing group and facilitates the [18 F]fluoride attack. 107 The hydroxyl group 
should be protected during the radioactive fluorination and the protecting group should 
be removed rapidly and quantitatively after the formation of the 4- [18 F]benzamide. 
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Scheme 4.3. Proposed radiosynthesis of P8 F]Flesinoxan. (PG = Protecting group). 
4.2.2. Results and discussion for the fluorine-18 strategy 
4.2.2.1. Chemistry 
4.2.2.1.1. Synthesis of Flesinoxan and the nitro-Flesinoxan precursor 
Flesinoxan is not commercially available, although its synthesis has been described in 
patent and scientific literature. 96,108 
In this work, the starting material for the synthesis of Flesinoxan and the nitro 
radiochemistry precursor was the chiral aniline 4.1 (Scheme 4.4). The hydroxyl group 
in 4.1 was protected as a benzoate ester. However, published Flesinoxan syntheses used 
the acetate group to protect the alcohol. 
OBz 
0 
NH2 
4.1 
(CICH2CH2)2NH2-HCI 
Chlorobenzene / reflux / 72 hours 
OBz 
0 
pq 
N 
H-HCI 
4.2 
Scheme 4.4. Synthesis of the arylpiperazine 4.2 ftom the chiral aniline 4.1 and bis-(2- 
chloroethyl)amine. 
In this work, the arylpiperazine 4.2 was prepared by dialkylation of compound 4.1 with 
bis-(2-chloroethyl)amine hydrochloride. The aniline 4.1 was dissolved in anhydrous 
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chlorobenzene under nitrogen followed by the addition of the dialkylating reagent. The 
reaction was then refluxed for three days at 135-140 OC. The piperazine 4.2 precipitated 
after cooling down the reaction mixture and the solid was washed with chlorobenzene. 
The arylpiperazine 4.2 was obtained as the hydrochloride salt in good yields (75-95 %). 
However, reliable yields were only attained when the chemicals were added in the 
correct order. Failure to follow the mentioned procedure did lead to low product yields 
and to the formation of unidentified by-products. Furthermore, no yield enhancement 
occurred when basic potassium carbonate was added to the reaction mixture, as 
suggested elsewhere. 109,110 p-Toluenesulphonic acid has also been suggested as a 
suitable catalyst in piperazine ring formations. "' However, multiple unwanted products 
were obtained here when the alkylation of 4.1 was performed under acid catalysis. 
The compound 4.2 was fully characterised by mass spectrometry, infrared 
spectroscopy, 1H NMR and 13 C NMR. The piperazine ring formation was confirmed by 
the characteristic broad singlet at 6 3.39 ppm in the 1H NMR spectrum of 4.2. 
The Flesinoxan literature reported two options for the extension of arylpiperazines with 
the N4- [(p-fluorobenzoyl)amino] ethyl chain: aziridine ring-opening and 2-oxazoline 
ring-opening (Scheme 4.5). 
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Scheme 4.5. Amide 4.4 can be obtained by alkylation of arylpiperazine 4.3 with N-(4- 
fluorobenzoyl)aziridine or with 2-(p-fluorophenyl)-2-oxazoline, 4.5. 
Ennis and Ghazal obtained the benzamide 4.4 by reaction of the intermediate 4.3 with 
N-(4-fluorobenzoyl)aziridine in the absence of acid catalysis. 108,112 A similar procedure 
was used by Kuipers et al. to prepare some Flesinoxan analogues. 92 However, this route 
was not attempted in this work due to the involvement of hazardous aziridines in the 
synthesis of N-(4-fluorobenzoyl)aziridine. 113 
The patented procedure for the production of Flesinoxan involves the ring-opening of 
2-(p-fluorophenyl)-2-oxazoline (., L. 5) by the nucleophilic nitrogen of the piperazine 4.3. 
Hence, this option was explored in this work. 
The oxazoline 4.5 and the nitro analogue 4.6 were easily prepared from the 
corresponding acid chlorides and 2-(chloroethyl)amine (Scheme 4.6). 
96 Compounds 4.5 
and 4.6 were isolated in acceptable yields (60-70 %) as crystalline solids. 
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2-(Chloroethyl)amine 
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R= N02 ý 4-6 
Scheme 4.6. Synthesis of 2-(p-fluorophenyl)-2-oxazoline (1.5) and 2-(p-nitrophenyl)-2- 
oxazoline (L. 6D. 
2-Oxazolines are versatile heterocycles that have found extensive application in organic 
synthesis, asymmetric synthesis, macromolecular and coordination chemistry. 
114-118 
Several nucleophiles can attack the C(5) position of the 2-oxazoline ring, leading to 
C(5)-O(I) bond cleavage (Scheme 4.7). 1 19-121 
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Scheme 4.7. The nucleophilic ring-opening of 2-oxazolines occurs at the 5-position and 
yields 8-substituted ethylcarboxam ides. 
The ring-opening of 2-oxazolines by primary and secondary amines is catalysed by 
Bronsted and Lewis acids. 122-124 The presence of catalytic amounts of acid allows the 
formation of highly reactive oxazolinium species and amines add irreversibly at the 5- 
position of the oxazolinium intermediate to yield N-(2-aminoethyl)carboxamides. 
The hydrochloride salt of the arylpiperazine 4.2 was reacted in refluxing chlorobenzene 
with the oxazolines 4.5 or 4.6.96 Mass spectrometry of the crude reaction mixture 
revealed several unidentified products, but it failed to show the peaks of the benzamides 
4.7 or 4.8. On the other hand, a black gum was recovered when a catalytic amount of p- 
toluenesulphonic acid was included in the reaction between 4.2 and 4.6.124 The viscous 
material obtained may have been poly [N-(4-nitrobenzoyl)ethylene imine] (Scheme 
4.8), ' 18 since 2-oxazolines with electron-withdrawing groups at the 2-position (such as 
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4.5, and A-6) are known to undergo cationic ring-opening isomerisation 
polymerisations. ' 
25 
N 
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R =F, 4.7 
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Scheme 4.8. The reaction of arylpiperazine 4.2 with heterocycles 4.5 or 4.6 did not 
yield benzamides. 
In summary, the reported method for the ring-opening of 2-oxazolines by amines could 
not be reproduced satisfactorily in this case. The high temperatures (160-200 OC) 
demanded for this reaction caused decomposition and possible polymerisation of the 
reagents. In contrast, lower reaction temperatures (130-140 'C) did not produce any 
alkylation product. 
An alternative route for the synthesis of benzamides 4.7 or 4.8 was devised. This 
approach was based on the alkylation of intermediate 4.2 with the N-(2- 
haloethyl)benzamides 4.9 and 4.10 (Scheme 4.9). 
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Scheme 4.9. Synthesis of the benzamides 4.7 and 4.8 through alkylation with the N-(2- 
chloroethyl) benzam ides 4.9 and 4.10. 
N-(2-chloroethyl)-4-fluorobenzamide (compound 4.2) was prepared following the 
method described by El Ahmad et al. 70 A dichloromethane solution of 4-fluorobenzoyl 
chloride was added onto an aqueous solution containing 2-(chloroethyl)amine and 
potassium carbonate. The yield of benzamide 4.9 was excellent (94 %). 2-Oxazoline 4.5 
was a minor by-product of this reaction, although it could be easily separated from 4.9 
using flash chromatography. N-(2-chloroethyl)-4-nitrobenzamide ( 4.10 ) was prepared 
using the same methodology. However, the reaction solvent was THF or acetone due to 
the extremely low solubility of 4-nitrobenzoyl chloride in dichloromethane. The 
benzamide 4.10 was obtained in acceptable yields (35-45 %), although TLC revealed 
the presence of oxazoline 4.6 and unreacted acid chloride in the crude reaction mixture. 
The compound 4.10 was also synthesised by a different method (Method B, Scheme 
4.9). 126 In this case, a solution of 4-nitrobenzoyl chloride in toluene was added to 
aqueous 2-(chloroethyl)amine. An ice-cold NaOH solution was then slowly added and 
the benzamide 4.10 eventually precipitated out of the reaction mixture. The reaction 
yields were higher with this latter method (77 %). 
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The hydrochloride salt of arylpiperazine 4.2 was converted to the free base using 
dichloromethane and aqueous sodium carbonate. After extraction and evaporation of 
the solvent, the free base was dissolved in anhydrous acetonitrile and an excess of base 
was added. 127 Both potassium carbonate and triethylamine worked equally well in this 
reaction. Finally, the N-(2-haloethyl)benzamides 4.9 or 4.10 were added and the 
reaction mixture was heated at 80 T for 12-14 hours. After purification, the fluoro and 
nitro products 4.7 and 4.8 were obtained in 15-25 % yield. The addition of catalytic 
amounts of Nal usually activates alkylation reactions. However, in this work Nal only 
enhanced the formation of the unwanted oxazolines 4.5 and 4.6. 
The last step to synthesise the 5-HTIAagonist Flesinoxan and the nitro analogue (nitro- 
Flesinoxan) was the O-deacylation of the intermediates 4.7 and 4.8 (Scheme 4.10). 
(I 
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CN 
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N 
H ýýNy, 
ýýý 
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i) NaOCH3 / CH30H 
ii) Acidic Dowex resin (H+) 
R =F, 4.7 R=F, Flesinoxan 
R= N02,4.8 R= N02, nitro-Fiesinoxan 
Scheme 4.10. O-Debenzoylation of intermediates 4.7 and 4.8 under basic conditions 
provided Flesinoxan and nitro-Flesinoxan. 
O-Debenzoylations are usually performed under basic conditions, 
128-130 
although neutral 
and acidic conditions have also been described. 
131,132 The deprotection of the alcoholic 
group in 4.7 and 4.8 was achieved quickly and quantitatively using a suspension of 
sodium methoxide in methanol/dichloromethane. 
133 The ester cleavage was followed by 
neutralisation of the reaction mixture with an acidic cation exchange resin. The crude 
products were filtered and purified by flash chromatography, giving Flesinoxan and the 
nitro-Flesinoxan precursor in 90-95 % yield. Both products were fully characterised 
spectroscopically and by elemental analysis. The alcohol infrared absorption band at 
3400 cm-1 observed in the products and the disappearance of the 
1H and 13 C NMR 
benzoate signals confirmed the complete removal of the protecting group. 
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The deprotection step was studied in detail using HPLC. Compounds 4.7 or 4.8 (1.8 
ýimol) were dissolved in anhydrous THF and a slurry of NaOMe/MeOH was then added 
(5 ýtmol). Analysis of the crude mixtures after one minute showed no starting 
benzoylated materials (Figure 4.7). Flesinoxan and nitro -Flesinoxan were the main 
products and two other new peaks were observed at 5.4 and 6.9 min in both cases. The 
peak at 6.9 min was likely to correspond to methyl benzoate, the transesterification by- 
product. 
Before NaOCH3 / CH 30 
ýN) 
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0 "ý'OH 
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Figure 4.7. The benzoate group in compound 4.7 was cleaved by sodium methoxide to 
give Flesinoxan. Column: Phenomenex Luna C18(2), 5kan (250 mm x 4.6 mm). Mobile 
phase: 40 % (NH4)2HP04 0.05 M-60 % acetonitrile. Flow rate =I ml / min. 
Wavelength = 254 nm. 
4.2.2.1.2. Synthesis of 4-fluoro-N- [2-(4-phenylpiperazin- 1 -yl) ethyl] benzamide 
(compound 4.11 and 4-nitro-N-[2-(4-phenylpiperazin-1-yl)ethyllbenzamide 
(compound 4.12 
The optimisation of the radiochemistry conditions was developed using the model 
benzamides 4.11 and 4.12 in order to save the valuable material 4.8.1 -Phenylpiperazine 
was reacted with the N-(2-haloethyl)benzamides 4.9 or 4.10 under basic conditions and 
the products 4.11 and 4.12 were obtained as crystalline solids in 30-40 
% yields 
(Scheme 4.11). 
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R 
Scheme 4.11. Synthesis of model compounds 4.11 and 4.12ftom I-phenylpiperazine. 
4.2.2.2. Fluorine-18 radiochemistry 
4.2.2.2.1. Chromatographic separation of compounds 4.11 and 4.12 
The adequate separation of fluorine-18 labelled products from their nitro precursors is 
one of the most common challenges in the radiofluorination of aromatic nitro 
compounds. 49,134 In fact, overlapping of the HPLC signals from benzamides 4.11 and 
4.12 was observed in the following mobile phases: water-acetonitrile, water (0.1 % 
TFA)-acetonitrile (0.1 % TFA), ammonium formate 0.1 M-acetonitrile, water-methanol 
(Figure 4.8). 
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Figure 4.8. HPLC chromatogram showing incomplete resolution of compounds 4.11 4z) 
and 4.12. Column: Phenomenex Luna CI 8(2), 5pm, 100 1 pore size, 250 mm x 4.6 mm. 
Mobile phase: 70 % water-30 % acetonitrile. Flow rate =I ml / min. Wavelength 
254 nm. 
Furthermore, the labelled material should ideally elute before the nitro precursor to 
reach high specific activity and to avoid possible contamination from the starting 
material. 135 The only HPLC method tested that provided sufficient peak resolution 
between 4.11 and 4.12 consisted of a gradient programme run on a reverse-phase 
column using aqueous sodium acetate and acetonitrile (Figure 4.9). 
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Figure 4.9. HPLC chromatogram showing adequate peak resolution between fluoro 
benzamide 4.11 and the nitro analogue 4.12. Phenomenex Luna C. 18(2), 5pm, 1004 
pore size, 250 mm x 4.6 mm. Mobile phase: Water (0.05 M NaOAc, pH = 5)- 
Acetonitrile. Gradient system: 30 % to 50 % acetonitrile in 15 minutes. Flow =I ml 
min. Wavelength = 254 nm. 
4.2.2.2.2. Radiosynthesis of 
yl)ethyl]benzamide (compound 4.13 
4- [18 Flfluoro-N-[2-(4-phenylpiperazin-l- 
No-carrier-added [18 F]fluoride was obtained by proton irradiation of a steel and 
titanium target filled with 18 O-enriched water. The aqueous [18F]fluoride anion was then 
transferred to a conical borosilicate vessel (Wheaton vial) containing cesium carbonate 
or potassium carbonate complexed with the aminopolyether Kryptofix 2.2.2. 
(K2.2.2. ). 136 
The counterion of these added cations was the non-nucleophilic carbonate or the less 
basic potassium oxalate . 
135,137 Anhydrous acetonitrile was added to the [18 F]fluoride 
vial and the water/acetonitrile mixture was evaporated to dryness. Three acetonitrile 
addition-evaporation cycles rendered the 
[18 F]fluoride ion reasonably anhydrous and 
reactive. A solution containing the nitro precursor 4.12 was finally added to the dry 
radioactive residue (Scheme 4.12). 
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The radiochemistry was carried out in the following dipolar aprotic solvents: 
dimethylsulfoxide (DMSO), NN-dimethylformamide (DMF) and acetonitrile. 
N 
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H 
0 
4.12 
1 18 FIFluoride 
18 
4.13 
Scheme 4.12. Radiosynthesis of the 4_P8 F]fluorobenzamide 4.13 ftom the nitro 
precursor 4.12. 
Various radiochernical parameters were explored such as solvent, temperature, reaction 
time, heating system, fluorinating complex and base (Table 4.3). Initial 18 F-fluoro-for- 
nitro exchanges were carried out with solutions of 4.12 in anhydrous acetonitrile and 
K[ 18 F]F/K2.2.2/K2CO3 as the fluorinating reagent (Entries 1-4). In this solvent, the 
reaction mixtures quickly turned black upon heating and no radioactive fluorinated 
products other than [18 F]fluoride were detected. In contrast, the radiosynthesis of 4.13 
took place in DMSO using conventional heating (Entries 5-10). However, 
radiochemical yields were low (1.5-6 % yield, decay-corrected) and a minimum 
temperature of 130 OC was required. Prolonged reaction times (30 minutes) slightly 
enhanced the radiochernical yields. 
138 
Microwave technology has become a very powerful tool in radiochemistry. This 
methodology drastically reduces reaction times and often enhances the radiochemical 
yields. A mono-modal microwave cavity adapted for small-scale radiochemistry was 
utilised for the radiosynthesis of 4.13 (Entries 11-15). However, microwave heating 
only had a minor effect on the radiochernical yields (4-6.5 % yield, decay-corrected). 
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Table 4.3. Radiochemical yields and synthesis parameters for the 18 F-labelled 
benzamides studied 
Entry 
number' 
Solvent 
T-1- 
heating 
rocedure 
1 
2 
3 
4 
5 
6 
7 
8 
9b 
1 ob 
11 
12 
13 
14 
15' 
16 
17 
18 
19 
20 d 
21 d 
CH3CN 
CH3CN 
CH3CN 
CH3CN 
DMSO 
DMSO 
DMSO 
DMSO 
DMSO 
DMSO 
DMSO 
DMSO 
DMSO 
DMSO 
DMSO 
DMF 
DMF 
DMF 
DMF 
DMF 
DMSO 
Oil bath 
Oil bath 
Microwaves 
Microwaves 
Oil bath 
Oil bath 
Oil bath 
Oil bath 
Oil bath 
Microwaves 
Microwaves 
Microwaves 
Microwaves 
Microwaves 
Oil bath 
Oil bath 
Microwaves 
Microwaves 
Oil bath 
Microwaves 
Temperature 
( 0c) 
80 
80 
120 
150 
20 
100 
130 
130 
130 
130 
120 
120 
120 
150 
150 
130 
130 
130 
130 
130 
150 
Reaction time 
(min) 
15 
30 
5 
5 
30 
30 
15 
30 
15 
30 
3 
5 
7 
5 
10 
15 
30 
5 
10 
30 
7 
Radiochemical 
yield (01o) 
0 
0 
0 
0 
0 
0 
3 
6 
1.5 
3 
4 
4 
5 
6.5 (4)e 
6 
5 
6 (3)e 
4 
4.5 
<je 
<je 
a K[ 18 FjF1K2.2.2/K2CO3 was used as fluorinating reagent. The reaction substrate was nitro-precursor 
4.12 (2-3mg). 
F -1 CSP8 Thefluorinating reagent was F]F. 
C The base was potassium oxalate instead ofpotassium carbonate. 
d The reaction substrate was 4.8 (3 mg). 
' Decay-corrected isolatedyield 
The use Of CS[18 F]F instead of K[ 18 F]F/Kryptofix 2.2.2. also produced 4.13, although 
not with the efficiency desired (Entries 9-10). Similar radiochemical yields of 4.13 were 
gained when potassium carbonate (Entry 14) or potassium oxalate (Entry 15) were 
utilised in the preparation of the fluorinating complex. DMF was also a suitable solvent 
for the 18 F-fluorination. In this case, the use of microwave heating provided lower 
yields than the classical oil bath procedure. 
Isolated radiochemical yields of 4.13 were 3-4 % (decay-corrected from the initial 
[18 F]fluoride radioactivity) (Figure 4.10). Similar yields have been reported in the 
radiosynthesis of other 4- [18 F]fluorobenzamides from nitro precursors . 
71,139 
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Unreacted 
'OF ftluoride 
UV absorhance (240 nno 
05 10 15 20 25 30 
Time (iidit) 
Figure 4.10. Radio-HPLC chromatogram showing the labelled benzamide 4.13. Most of 
the radioactivity corresponded to P8 F]fluoride. 
4.2.2.2.3. Radiosynthesis of [18 FIFIesinoxan 
The best conditions found for the labelling of 4.13 were applied to the radiosynthesis of 
compound 4.14 from 4.8 (Scheme 4.13). Unfortunately, very poor radiochemical yields 
were obtained (0.5-0.8%, decay-corrected isolated yield) (Table 4.3: Entries 20-21). 
Furthermore, reaction temperatures above 150 T caused partial decomposition of the 
nitro compound 4.8. 
4.13 
(4 % radiochendral yieM) 
Radioactivity 
1 
4.12 
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OBz 
0 
N02 
N 
H 
Ny 
0 
4.8 
K118FIFIK2.2.2. 
DMF or DMSO / 130-150 OC 
Scheme 4.13.18 F-Fluorination of the nitro precursor 4.8. 
OBz 
N 
18 
N 
H 
N 
0 
4.14 
The synthesis of 4- [18 F]fluorobenzamides from nitro precursors by aromatic 
nucleophilic substitution is not always successful and the radiochemical yields can be 
strongly different for close structures (Figure 4.1 1 ). 
51,56,71,75,77,139-141 This reaction 
demands high reaction temperatures that may cause thermal breakdown of the 
substrates. Besides that, interactions between the basic [18 F]fluoride anion and the 
amide proton may also interfere in the fluorination process. 
142 Nevertheless, the 
electronic effects of the molecule substituents should also be taken into account, since 
there are also cases of moderate to good yields in 
18 F-for-nitro exchange reactions of 4- 
nitrobenzamides. 
49,75,77 
In summary, the model benzamide 4.13 was obtained in 3-4 % isolated radiochemical 
yield in a straightforward 18 F-fluorination from the nitro precursor 4.12. The use of 
microwave heating for this labelling reduced the reaction time, although it did not have 
a significant effect on the radiochernical yields. 
The radiosynthesis of [18 F]Flesinoxan via the 
18 F-fluorodenitration of substrate 4.8 was 
found to be not feasible. 
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ýýýýesinoxan 
1 18 FIS14506 74 
37 % r. c. y. (DMSO, 180 OC, 30 min) 
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Figure 4.11. Structures and references of 4-p8F]fluorobenzam ides that have been 
synthesisedftom nitro precursors by aromatic nucleophilic substitution. The reaction 
conditions are also presented (r. c. y. = radiochemical yield, AlfW = microwaves). 
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4.2.2.2.4. Future work and alternative radiosynthesis of [18 FIFIesinoxan 
* N-succinimidyl-4- [18 F]fluorobenzoate ([18 F]SFB) is an active ester that has been 
used for the labelling of proteins, peptides and antibodies with fluorine-18.143-146 
[18 FISFB reacts specifically with amino groups to give 4- [18 F]fluorobenzamides. 
Therefore, this labelled synthon could be applied to the preparation of [18 F]Flesinoxan, 
as depicted on Scheme 4.14. One of the drawbacks of this route is that the three-step 
radiosynthesis of [18 F]SFB requires a sophisticated automation process. However, fully 
automated preparations of [18 F]SFB have been reported recently. 
147-149 
0 
RO 
TfO 
N(CH3)3 
0 4-"-, 0 N 00N 
18 E) i) K2.2.2. / K[ FIF HO BF4 Ný, 
ii) Acid or base 
18 F 
N,, 
0 
18 
1 18 FISFB 
I OH 
CN 
N 
NH2 
1 18 FISFB / Base 
0 
OH 
0 
CN 
18 F 
N 
N, 
ý 
0 
1 18 FIFIesinoxan 
8F Scheme 4.14. Radiosynthesis of N-succinimidyl-4_P ]flUorobenzoate (P8F]SFB) and 
application to the preparation of P8F]Flesinoxan. 
* The development of a single-step preparation of [ 18 F]SFB would be highly valuable. 
The direct 18 F-fluorination of a suitable iodonium salt may provide [18 F]SFB in a much 
simpler protocol (Scheme 4.15). 
150 
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0 
0 
N,, 
0 
18 TfO K2.2.2. /KI F1 F 
18 F 
1 18 FISFB 
18 P8F SFB Scheme 4.15. The F-fluorination of iodonium salts could provide in one 
step. 
9 The causes of the great variability in radiochemical yields reported in the 
radiosynthesis of 2- [18 F] and 4- [18 F]fluorobenzamides from nitro precursors also 
deserve thorough investigation. The possible interaction between the amidic proton and 
[18F]fluoride (hydrogen bonding) needs to be demonstrated, as well as the effect of 
substituents on radiochemical yields. 
4.3. Carbon-11 strategy 
4.3.1. Background: preparation of [carbonyl- I 'Clamides 
4.3.1.1. [carbonyl-11CIAmides from [11CIC02 via ["Clacid chlorides 
The first preparation of a no-carrier-added [ 11 C] acid chloride was reported by Luthra et 
aL in the radiosynthesis of ["C]diprenorphine (Scheme 4.16). 
15 1 The reaction between 
[11CIC02and cyclopropy1magnesium bromide provided a labelled carboxylate that was 
treated with phthaloyl dichloride (PDC) and 2,6-di-tert-butylpyridine (DBTP). The 
resulting ["C]acid chloride, [carbonyl-"C]cyclopropanecarbonyI chloride (b. p. 119 
'C), was distilled into a solution containing an amine precursor. PDC has a high boiling 
point (271 'C) and did not co-distil with the ["C]acid chloride into the second reaction 
mixture. The final reduction of the intermediate amide with LiAlH4 yielded 
["C]diprenorphine. The opiate receptor radioligands ["C]buprenorphine and 
["C]cyclorphan were also labelled using [carbonyl-"C]cyclopropanecarbonyI 
chloride. 152,153 
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Scheme 4.16 Application of [1-11C]cyclopropanecarbonyl chloride 
radiosynthesis of P1 C]diprenorphine. 
to the 
Luthra et aL showed that the procedure utilised in the radiosynthesis of [carbonyl- 
11 C]cyclopropanecarbonyl chloride could also be applied to the preparation of other 
volatile ["C]acid chlorides. 
154 Both alkyl lithium reagents and Grignard reagents 
efficiently reacted with [11CIC02 tOgive labelled carboxylates. 
155,1 56 However, several 
labelled products were obtained when alkyl lithium was used in the 
"C-carboxylation 
207 
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step. This was due to the quick reaction between the alkyl lithium excess and 
["C]carboxylates. 156 Hence, Grignard reagents were strongly preferred in the 
radiosynthesis of [11C]acid chlorides. 
In the "Luthra method", [11C]carboxylates were directly converted into [11C]acid 
chlorides by reaction with a non-volatile acid chloride (PDC) and a hindered base 
(DBTP) was added into the reaction mixture to enhance the radiochemical yields of 
[11C]acid chloride. Nonetheless, some variations of the original procedure have been 
reported. For instance, Ben-David et al. prepared [11C]acryloyl chloride by distilling 
[carboxy- 11 C] acrylic acid through two columns containing polymer-bound reagents 
(PC15 and DBTP respectively). 157 However, the final radiochemical yield of 
[11C]acryloyl chloride was disappointing (less than I %). 
One of the limitations of the "Luthra method" is that only volatile [11C]acid chlorides 
can be produced and that a significant proportion of the labelled material is stuck in the 
tubings during the distillation stage. Despite these drawbacks in the radiosynthesis of 
[11C]acid chlorides, the "Luthra method" has been employed in numerous labellings. 158- 
166 
The radiosynthesis of [11C]acid chlorides with high boiling points requires some 
adaptations in the "Luthra method". Ravert et al. synthesised the non-volatile 
[11C]benzoyl chloride (b. p. 198 T) using the "Luthra method". 167 However, normal- 
phase HPLC was used instead of distillation to separate the [I' C] acid chloride from the 
PDC. Pure [11C]benzoyl chloride was then used to prepare [11C]paclitaxel in 7% 
radiochemical yield. 
Van der Mey et al. prepared 3,5-di(trifluoromethyl)[carbonyl-"C]benzoyI chloride 
from 3,5 -di(trifluoromethyl) [carboxy- 
11 C] benzoic acid using oxalyl chloride (b. p. 62-65 
'Q in dichloromethane. 168 The excess of chlorinating agent was evaporated and the 
["C]acid chloride was reacted one-pot with a secondary amine to give the [carbonyl- 
1 'C]amide product in 45-57 % radiochemical yield (from the [11 C]acid chloride). 
["C]Cyclohexanecarbonyl chloride (b. p. 184 OC) is required for the radiosynthesis of 
[carbonyl-"C]WAY-100635. Hwang et al. prepared this radioligand in a one-pot 
procedure. 169 [11CIC02 was bubbled into a cyclohexylmagnesium chloride solution, 
forming the ["C]carboxymagnesium halide. The excess of Grignard reagent was then 
neutralised by the addition of anhydrous HCI in ether and the 
[carboxy- 
11C]cyclohexanecarboxylic acid was transformed into ["C]cyclohexanecarbonyl 
chloride with thionyl chloride (b. p. 790C). The excess of chlorinating agent was 
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evaporated off and a solution containing the amine precursor (WAY-100634) and 
triethylamine was added to the residue. [carbonyl- 11 C] WAY- 10063 5 was prepared with 
this one-pot protocol in sufficient radiochernical yield and specific activity to allow 
human studies. 
A different approach to the radiosynthesis of [carbonyl-"C]WAY-100635 consisted of 
the preparation of [11C]cyclohexanecarbonyl chloride within the inner surface of a 
polypropylene loop. 170 In this method, [11CIC02was flushed through a tube containing 
a small amount of cyclohexylmagnesium. chloride and the chlorination of the 
[ 11 C] carboxylate was achieved with thionyl chloride. The produced 
[11C]cyclohexanecarbonyl chloride was immediately reacted with a suitable amine to 
provide [carbonyl-'IC]WAY-100635 in 50-70 % radiochernical yield (from the 
[11C]acid chloride). This "loop method" has been successfully applied to the 
radiosynthesis of several other [11C]acid chlorides. 171 
4.3.1.2. Other methods for the radiosynthesis of [carbonyl- I 'Clamides from 
CICIC02 
[carbonyl-"C]Amides have been prepared via the in situ formation of ["C]activated 
esters. For instance, Rogers et al. reported the activation of [carboxy- 1 C]benzoic acids 
with carbonyl diimidazole. 172 The resulting [carbonyl- 11 C]benzoyl imidazolides reacted 
efficiently with piperidine to give [carbonyl-"C]benzamides in 80 % radiochemical 
yield. 
The non-radioactive amides WAY- 10063 5 and p-MPPF were synthesised by activating 
the corresponding carboxylic acids with a polymer- supported carbodiimide resin and 
microwave heating. 1 73 However, the application of this one-pot method to 
radiochemistry has not been reported yet. 
In the radiosynthesis of [carbonyl-"C]amides, ["C]carboxylates are normally used as 
mere intermediates for preparing more activated species such as [ 11 C] acid chlorides or 
[11C]activated esters. Aubert et al. prepared some [carbonyl-11C]amides in acceptable 
radiochemical yields (15-60 %) by direct reaction of [carboxy-"C]carboxymagnesium 
halides with amines (Scheme 4.17). 174 , 175 However, the success of their procedure was 
only limited to the radiosynthesis of a few aliphatic [carbonyl-1, C]amides. Lu et al. 
found that both aromatic and aliphatic [carbonyl-11C]amides could be prepared if this 
direct coupling was carried out with microwave heating. 75,176 Nonetheless, aromatic 
[carboxy-"C]carboxylates were found to be considerably less reactive towards amines 
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than the aliphatic congeners. The authors also showed that primary amines gave much 
higher yields of [carbonyl- 11 C]amides than secondary amines. 
R 11 C02M9X + R'R"NH 
Heat 
10- 
Scheme 4.17. Radiosynthesis of [carbonyl- "Clam ides 
"C]carboxymagnesium halides. 
R 11 CONR'R" 
ftom [carboxy- 
Interestingly, ["C]alkylamines could be obtained if NaBH4 was added to a reaction 
mixture containing aliphatic [carboxy-"C]carboxylates and amines (Scheme 
4.18). 175,177 This reductive amination of carboxylic acids had been reported previously 
in non-radioactive organic chemistry. 178,179 
RC02H + R'R"NH 
NaBH4 
Op- RCH2NR'R" 
R 11 C02MgBr + R'R"NH 
NaBH4 
Ow R"CH2NR'R" 
Scheme 4.18. Reductive amination of carboxylic acids and [carboxy- 
"C]carboxymagnesium bromides. 
Lemoucheux et al. prepared ["C]carbamoyl chlorides by reacting ["C]phosgene with 
tertiary amides that contained a 4-methoxybenzyl moiety (Scheme 4.19). 
180,181 The 
["C]carbamoyl chlorides readily reacted with amines and sodium ethoxide to provide 
unsymmetrical ["C]ureas and ["C]carbamates respectively. Besides that, tertiary 
[carbonyl-"C]benzamides were attained in good yields (50-60 % from the 
["C]carbamoyl chloride) when ["C]carbamoyl chlorides were reacted with 
pheny1magnesium bromide or a cyanocuprate. 
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Scheme 4.19. Radiosynthesis of [carbonyl- 11 C]am ides, [carbonyl-1, C]carbamates and 
[carbonyl-"C]unsymmetrical ureas via labelled carbamoyl chlorides. 
4.3.1.3. Radiosynthesis of [carbonyl- 11 Clamides from ["C]CO 
The Uppsala PET group published in 1999 the first radiosynthesis of [carbonyl- 
1 'C]amides using [11C]CO. 
182 The labelled amides were synthesised in a 
microautoclave at high pressure using the following reagents: 
tetrakis(triphenylphosphine)palladium (0), aryl or benzyl halides, an amine and 
[11C]CO (Scheme 4.20). Rahman et al. used aryl triflates instead of aryl halides in these 
palladium-mediated carbonylations (Scheme 4.20). 183,184 However, [carbonyl- 
11C]amides were only obtained if a catalytic amount of lithium bromide was added to 
the reaction mixture. The isolated radiochernical yields of [carbonyl-"C]amides were 
20-78 % and the specific activities were up to 1000 GBq/ýtmol. The atmospheric 
isotopic dilution was insignificant due to the low reactivity and the low concentration of 
carbon monoxide (0.1 ppm) in the air. 
211 
Chapter 4 Labelling qLElesinoxan 
R-X 
I iiclco 
-AM. - [Pd(PPh3)41 
1,4-Dioxane 
R= Aromatic, benzylic 
X= Br, I 
R-"COPd(PPh3)2X 
RjR2NH 
Ow 
N 
I 
K2 
1 11 C]Amides 
Ar-OTf 
'CICO / [Pd(PPh3)41 / LiBr / THF 
RjR2NH 150 OC / 35 MPa 
Scheme 4.20. Radiosynthesis of [carbonyl- Qam ides by palladium-mediated 
carbonylation. 
The yields of [carbonyl- 11 C] amides prepared by the methods described above were very 
poor when unreactive amines such as or indole or anilines were used. However, Karimi 
and Langstr6rn showed that the in situ activation of those amines with lithium 
bis(trimethylsilyl)amide improved considerably the yields of [carbonyl- 11 C] amides .1 
85 
Palladium-mediated carbonylations using [ 11 C] CO can only be applied to aromatic and 
benzylic halides. Organohalides with P-protons bound to sp 3 carbons undergo 
competing P-hydride elimination under those conditions, but Itsenko et al. developed a 
possible solution to this limitation. 186 These authors carried out the photoinitiated 
radical carbonylation of alkyl iodides with [ 11 C] CO in a microautoclave that included a 
sapphire window and a mercury lamp (Scheme 4.21). A solution containing an alkyl 
iodide and an amine was injected into the microautoclave and was pressurised. The 
reaction mixture was then irradiated with the mercury lamp after the [11C]CO trapping 
and the conversion of [ 11 C] CO into the [carbonyl- 11 C] amides was up to 95 %. 
R-1 
RIR2NH / Et3N / 1-Methyl-2-pyrrolidinone 
bl. 
l"CICO/ho/35MPa 
R= alkyl, cycloalkyl 
Scheme 4.21. Radiosynthesis of [carbonyl- C]am ides 
P'C]carbonylation of alkyl iodides. 
N -Rl 
1 
R2 
1 11 ClAmides 
through photoinitiated 
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Simpler procedures for the handling of [11C]CO that do not require specialised 
equipment have been described by Gee et al. 187,188 The basis of their method was the 
use of a ["C]BH3-COcomplex instead of [11C]CO (Scheme 4.22). ["C]BH3-COwas 
easily prepared by passing [11C]CO through a borane/THF solution and the labelled 
synthon allowed the formation of [carbonyl-1 I C]amides by palladium-mediated 
carbonylations. 
BH3 - THF 
11C]CO 
Am- ["CICO-BH3 
0 
HN 11 'CICO- BH3 / THF-I %water 
C", 
N 
Pd (0) cat. / Et3N/ Heat 
H 
a20 
Scheme 4.22. Use of P'CJBH3-CO in palladium-mediated carbonylations. 
4.3.1.4. Novel approach to the preparation of [carbonyl-1 I Clamides 
Palladium-mediated reactions with organohalides and [11C]CO require a special 
technology for [ 11 C] CO trapping and reaction in a microautoclave at high pressure. 
On the other hand, the classical approach to the synthesis of [carbonyl- 11 C] amides from 
[11CICO2 involves the radiosynthesis of ["C]acid chlorides followed by reaction with 
an amine. The production of ["C]acid chlorides requires harsh reagents and the 
formation of very reactive intermediates. Radiosyntheses involving ["C]acid chlorides 
present reliability problems, are relatively long and are also difficult to reproduce. 
Moreover, the equipment required for ["C]acid chloride preparations is not widely 
available. 169 Other strategies for the synthesis of [carbonyl-"C]amides have been 
formulated, but they have showed limited applicability or poor results. 
Significant progress in arnide synthesis has been achieved in recent years due to the 
increasing scientific interest devoted to peptide coupling reactions. 189The development 
of more efficient coupling reagents has made possible the smooth incorporation of non- 
coded and sterically hindered amino acids into peptides. 190,191 However, most of these 
advances have not been translated to radiochernistry yet. 
The main objectives of this work were: 
9 The preparation of [carbonyl- 11 C]amides from[IlCIC02 using fast, reproducible 
and easy to perform methodology. 
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9 The novel approach for the preparation of [carbonyl- 11 C]amides should involve the 
radiosynthesis of ["C]carboxylic-phosphinic mixed anhydrides. 
9 The application of the methodology to the efficient radiosynthesis of [carbonyl- 
"C]Flesinoxan. 
4.3.1.5. Carboxylic-phosphinic mixed anhydrides 
A vast number of peptide coupling reagents have been developed in recent years, 
including onium-type reagents (phosphonium, uronium, immonium, imidazolium), 
carbodiimides and acid halides. 
189,192-201 
Organophosphorus reagents have also become popular in peptide coupling reactions 
and can be divided into two types: phosphoric acid derivatives and phosphinic acid 
derivatives (Figure 4.12). 
0 
11.,, OR 
OR 
Phosphoric acid derivatives 
0 
jlý, R 
X-P"" 
R 
Phosphinic acid derivatives 
Figure 4.12. Classification of organophosphorous peptide-coupling reagents. 
Diphenylphosphoryl azide (DPPA) and diethylphosphoryl cyanide (DEPQ belong to 
the phosphoric acid family and were the first phosphorous reagents used in peptide 
chemistry. 202,203 These compounds react with carboxylic acids to yield mixed 
carboxylic-phosphoric anhydrides. The regio selectivity of the amine attack on mixed 
carboxylic-phosphoric anhydrides is usually higher than on mixed carbonic anhydrides 
(Scheme 4.23). 
00 
Isobutyl 11 11 11 11 
,,, 
OEt 
CC chloroformate C DEPC 1-11C-10"Ji 11-1 R<ý'ý'O< ""O'Bu IK R OH 10- Rý OEt 
Amine attack Amine attack 
Scheme 4.23. The specificity of the nucleophilic amine attack on mixed carboxylic- 
phosphoric anhydrides leads to higher amide yields. 
A great effort has been devoted to the development of new phosphoric acid derivatives 
(Figure 4.13). 189,204 
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Figure 4.13. Some common phosphoric acid derivatives used in peptide coupling 
reactions. 
Within this reagent family, bis(2-oxo-3-oxazolidinyl)phosphorodiamidic chloride 
(BOP-Cl) has attracted special attention since it was first synthesised in 198 0.205 BOP- 
Cl has shown great efficiency in the acylation of hindered amino acids as well as in 
macrocyclisations. 190,191 Furthermore, BOP-Cl has also been used in esterification 
reactions. 206 Van der Auwera et al. attributed the effectiveness of BOP-Cl in acylation 
reactions to intramolecular base catalysis by the oxazolidinone carbonyl group in the 
mixed anhydride intermediate (Figure 4.14). 207 
oo)----o \\ ,N 
R"" 0 11-1 
p 
N 
0 
R'HN 
H111110 -, - 
Figure 4.14. Intramolecular base catalysis in BOP-Cl mediated acylations. 
However, BOP-Cl also displays certain drawbacks. Primary amines react with BOP-Cl 
to give phosphinamidates. 206 Thus, acceptable amide yields are only obtained by pre- 
activation of the carboxylic acid followed by amine addition. More importantly, BOP- 
Cl displays very poor solubility in organic solvents such as CH202, CH3CN, THF or 
DMF. This insolubility could be a limitation for the use/applicability of BOP-Cl in 
radiochemistry. 
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The development of phosphinic acid derivatives for peptide synthesis started when 
diphenylphosphinic chloride (Dpp-Cl) was first introduced in 1976 . 
208 Dpp-CI is now 
commercially available, although it can also be easily prepared by oxidation of 
diphenylchlorophosphine with oxygen. 209 Dpp-Cl and I-oxo-l-chlorophospholane 
(Cpt-Cl) have become the reagents of choice for peptide couplings within the 
phosphinic acid family (Figure 4.15). 
Ph 
Ph 
Dpp-Cl 
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F O-px 
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Ph 
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H3C-, 11 
H3C " 
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Figure 4.15. Phosphinic acid derivatives used in peptide synthesis. 
MPTO 
Carboxylate anions react more rapidly with phosphinic chloride derivatives than with 
phosphoric acid derivatives to provide carboxylic-phosphinic mixed anhydrides. 210 
These mixed anhydrides are more reactive and significantly less prone to thermal 
disproportionation than carboxylic anhydrides. 211-213 Dpp-carboxylic mixed anhydrides 
are also superior to biscarboxylic anhydrides in terms of regioselectivity towards 
nucleophiles. Mixtures of products are always obtained when amines react with 
carboxylic anhydrides, but amines attack exclusively the carboxyl carbon in Dpp- 
carboxylic mixed anhydrides to give the amide product (Scheme 4.23). 210 
0- 
\ 
ci 
Cpt-Cl 
0 
s ---0 
H3C ý 11 
H3C"" 
P-N 
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Scheme 4.24. Only amides are obtained when Dpp-mixed anhydrides are reacted with 
amines. 
31 P NMR spectroscopy studies have shown that both the Dpp-mixed anhydride 
formation and the subsequent acylation reaction were almost instantaneous. 210,211,214 
Although Dpp-carboxylic mixed anhydrides are normally prepared and reacted with 
amines in situ, these intermediates can be isolated in certain cases as white foams or 
crystalline solids. 211 Moreover, reactions involving Dpp-Cl are normally carried out in 
THF or CH2CI2. which are common solvents in carbon- 11 radiochemistry. 
All these observations encouraged the use of Dpp-Cl in the radiosynthesis of [carbonyl- 
11 C] amides. 
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4.3.2. Results and discussion for the carbon-11 strategy 
4.3.2.1. Chemistry on model compounds 
4.3.2.1.1. Synthesis of 4-fluorobenzoic acid diphenylphosphinyl ester (compound 
4.15 
An excess of Hiinig's base was added to a solution of 4-fluorobenzoic acid in 
anhydrous dichloromethane. Commercial Dpp-CI contains minor amounts of 
210 diphenylphosphinic acid (Dpp-OH) and the symmetrical anhydride (Ph2PO)20 . 
Hence, a slight excess of Dpp-Cl (1.1 equivalents) was used in the synthesis of the 
mixed anhydride 4.15, (Scheme 4.25). After 15 minutes, the reaction was worked up by 
acid-base extraction to remove the unreacted carboxylic acid and the base excess. The 
crude product was washed with diethyl ether and the compound 4.15 was obtained as 
an off-white crystalline solid in high yield (94 %). 
000 
11 11 ýj Ph 
c "'OH 
Dpp-Cl 
c --,, 0 Ph 
DIPEA / CH2CI2 
F 
4.15 
Scheme 4.25. Synthesis of the diphenylphosphinic mixed anhydride derived ftom 4- 
fluorobenzoic acid 
Several TLC conditions were tried to follow the 4.15 formation such as different 
solvents, additives (triethylamine, acetic acid) and stationary phases (silica gel and 
alumina). In all cases Dpp-OH was detected at the base line but other spots showed 
tailing. On the other hand, 4.15 was incompatible with the aqueous conditions 
demanded by reverse-phase HPLC and unsatisfactory signals were obtained. 
In conclusion, TLC and HPLC were not adequate techniques to monitor the formation 
of the phosphinic-carboxylic mixed anhydride 4.15. Compound 4.15 was characterised 
by FT-IR and NMR. Besides that, the direct reaction of solid 4.15 with amines yielded 
4-fluorobenzamides (vide infra), which was also evidence of the mixed phosphinic 
anhydride nature of 4.15. 
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4.3.2.1.2. Synthesis of N-butyl-4-fluorobenzamide (compound 4.16 using the 
diphenylphosphinic anhydride method 
The substrate 4.15 was suspended in anhydrous dichloromethane at room temperature 
(Scheme 4.26). The suspension became a colourless solution after the addition of 
butylamine, and 5 minutes later, the reaction mixture was washed with water and with 
saturated sodium hydrogencarbonate. TLC analysis of the crude material only showed 
the spot corresponding to N-butyl-4-fluorobenzamide (compound A. 16) and the 
diphenylphosphinate by-product at the base line. The amide 4.16 was isolated in 
excellent yield (92 %) after flash chromatography purification. 
Ph 
Ph 
4.15 
0 
Butylamine N 
H 
CH2CI2 t. 
4.16 
Scheme 4.26 The reaction of the intermediate 4.15 with butylamine provided amide 
4.16 in high yield 
Compound 4.16 was also obtained from 4-fluorobenzoic acid in a one-pot procedure 
(Scheme 4.27). Dpp-Cl was added to a dichloromethane solution containing 4- 
fluorobenzoic acid and triethylamine. Butylamine was added after 15 minutes and the 
reaction mixture was then worked up. The amide 4.16 was finally obtained in 65-70 % 
yields. 
00 
i) Dpp-Cl / Et3N 
OH ii) Butylamine N 
CH 
H 
2CI2 t. 
FF 
4.16 
Scheme 4.27. One-pot synthesis of N-butyl-4-fluorobenzamide ftom 4-fluorobenzoic 
acid 
The amide 4.16 could be prepared from 4-fluorophenylmagnesium 
bromide in a one- 
pot protocol similar to the one devised for the carbon-1 I radiochemistry 
(Scheme 
4.28). The Grignard reagent was slowly added into a flask containing dry ice pellets. 
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Once the solid carbon dioxide disappeared, Dpp-Cl was added dropwise. The 
intermediate 4.15 was then reacted in situ with butylamine to provide 4.16 in moderate 
yields (20-25 %). 
MgBr 
F'ý' 
0 
i) C02(s) 
11 
ii) Dpp-CI 
Cýý 
N 
iii) Butylamine H 
4.16 
Scheme 4.28. One-pot synthesis of N-butyl-4-fluorobenzamide ftom 
fluorophenylmagnesium bromide. 
4- 
Dpp-Cl reacts with primary amines to give phosphoramides. 209,215,216 Therefore, the 
following experiment was designed to evaluate the selectivity of Dpp-Cl for amines and 
carboxylates. 4-Fluorobenzoic acid (I mmol), butylamine (I mmol) and triethylamine 
(2 mmol) were dissolved in dichloromethane. Dpp-Cl (I mmol) was the last reagent 
added and the reaction was monitored by reverse-phase HPLC (Scheme 4.29). 
C02H 
F 
0 
_.,, 
Ph 
"'ý'P h 
NH2 Et3N 
Dpp-Cl 
Phosphoramide 4.17 
(Minor product) 
N0 
F 
Amide 4.16 
(Main product) 
Scheme 4.29. Dpp-Cl reacted with the carboxylate to yield the amide 4.16, but it also 
reacted with butylamine to give the diphenylphosphoramide by-product 4.17. 
Dpp-Cl reacted with both the carboxylate and the amine (Figure 4.16). However, the 
ratio of amide 4.16 to phosphoramide 4.17 was 3 to 1, showing that Dpp-Cl reacted 
preferably with the carboxylate anion. The compound 4.17 was not detected when 
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butylamine was added after Dpp-Cl (preactivation conditions). This fact demonstrated 
the re gio specificity of the amine attack on the mixed anhydride 4.16. 
c 
"N 
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4.16 
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Ph, 
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ý', 
, ph"ý N 
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4.17 
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'ph 
Ph 
ID 12 14 le 20 
Mnutes 
Figure 4.16 Products obtained when Dpp-Cl was added to a solution containing 4- 
fluorobenzoic acid, butylamine and triethylamine. Column: Phenomenex Luna C18(2) 
(250 mm x 4.6 mm x5 micron). Mobile phase: 50 % water-50 % acetonitrile. 
Wavelength = 245 nm. Flow =I mllmin. 
A series of experiments were designed to simulate the conditions that could be used in 
the radiochemistry procedure. The Grignard reagent would be in great excess over the 
[ 11 C] carboxylate in carbon- II chemistry. Therefore, a stock THF solution containing 64 
[tmol of 4-fluorophenylmagnesium bromide and 20 ýtmol of 4-fluorobenzoic acid was 
used as the starting material. The carboxylate was obtained from the acid-base reaction 
between the Grignard reagent and the carboxylic acid (44 ýtmol of Grignard reagent vs 
20 ýtmol of 4-fluorophenylcarboxymagnesium bromide) (Scheme 4.30). Dpp-Cl (250 
ýtmol) was added to this solution and the reaction mixture was analysed by reverse- 
phase HPLC (Figure 4.17). The excess of Grignard reagent reacted with Dpp-Cl to form 
the triarylphosphine oxide 4.18 . 
217 A peak arising from the hydrolysed Dpp-Cl excess 
(Dpp-OH) was also detected. 
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Two new signals were detected after the addition of butylamine (500 ýtmol) to the 
reaction mixture: the phosphoramide 4.17 peak and the amide 4.16 peak. 
C02H MgBr C02MgBr MgBr 
+ + + 
F F FF 
Excess Excess 
Dpp-Cl 
Ir 
Ph 
Ph 
4.15 
Scheme 4.30. Acid-base reaction between 
0 
11.,, Ph 
Ph 
4.18 
4-fluorobenzoic acid and 4- 
fluorophenylmagnesium bromide. Dpp-Cl reacted with the carboxylate anion and the 
Grignard reagent to give the mixed anhydride 4.15 and a phosphine oxide. 
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Figure 4.17. Reaction mixture before and after adding butylamine 
Ili Ij 11 
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In one of the experiments, butylamine was added to the Grignard reagent/carboxylate 
stock solution. Dpp-Cl was added after the amine and the reaction was followed by 
HPLC. In this case, Dpp-Cl could potentially react with the carboxylate, butylamine 
and the Grignard reagent. However, the triarylphosphine oxide signal was not observed 
and the only two products detected were the amide 4.16 and the by-product 4.17. 
Hence, the relative reactivity sequence observed for Dpp-Cl was: carboxylate > 
butylamine > 4-fluorophenylmagnesium bromide. 
4.3.2.1.3. Synthesis of N-benzyl-4-fluorobenzamide (compound 4.19 using the 
diphenylphosphinic anhydride method 
N-Benzyl-4-fluorobenzamide (A.. 12) was synthesised from 4-fluorobenzoic acid using 
the same one-pot protocol described for the synthesis of substrate 4.16 (Scheme 4.3 1). 
The amide 4.19, was purified as a crystalline white solid in good yield (67 %). 
c 
i) Dpp-Cl / Et3N 
ii) Benzylamine 
CH2CI2 / r. t. 
0 
11 
cl-I 
F 
4.19 
Scheme 4.31. One-pot synthesis of N-benzyl-4-fluorobenzamide ftom 4-fluorobenzoic 
acid 
4.3.2.1.4. Synthesis of N-[2-(4-phenylpiperazin-1-yl)ethyl]-4-fluorobenzamide 
(compound 4.11 using the diphenylphosphinic anhydride method LIL) 
The formation of benzamide 4.11 through the mixed phosphinic anhydride method 
required the synthesis of amine 4.20 (Scheme 4.32). The direct reaction between I- 
phenylpiperazine and 2-bromoethylamine yielded a complex mixture of products. 
Therefore, it was decided to protect the amino moiety of 2-bromoethylamine with the 
tert-butoxycarbonyl group (Boc protecting group) prior to the reaction with I- 
phenylpiperazine. The carbarnate 4.21 was prepared in adequate yield (70 %) 
from 2- 
bromoethylamine and di-tert-butyl dicarbonate. 
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Scheme 4.32. Synthesis of N-[2-(4-phenylpiperazin-1-yl)ethyl]-4-fluorobenzamide 
L4.1 1) by the Dpp-Cl method 
I -Phenylpiperazine was then reacted with substrate 4.21 in refluxing acetonitrile under 
basic conditions. The reaction was extremely clean and only the desired product 4.22 
was obtained (97 % yield). The following step of the synthesis was the removal of the 
Boc group with trifluoroacetic acid. 132,218,2 19 The trifluoroacetic salt of amine 4.20 was 
then converted into the free base and purified by flash chromatography (81 % yield). 
The amide 4.11 was finally prepared using the Dpp-Cl protocol developed for the 
amide 4.16 and was obtained in good yield (60 %). 
224 
Chyj2ter 4 Labellinz of Flesinoxan 
4.3.2.2. Radiochemistry on model compounds 
4.3.2.2.1. System used for the radiosynthesis of 4-fluoro[carbonyl-"Clbenzamides 
The radiosyntheses of all the [carbonyl-"C]amides were carried out on the semi- 
automated module outlined in Figure 4.18. The cryogenic trapping and dispensing of 
["C]carbon dioxide were remotely controlled. The ["C]carbon dioxide trap was 
connected with polypropylene tubing to a system consisting of three slider valves with 
three ports each. Each valve had two positions that enabled the connection between the 
central port and each of the side ports (Position A and Position B). Switching between 
these two positions was pneumatically controlled. Valve 2 and Valve 3 were connected 
by a reaction loop made of polypropylene or stainless steel and 4- 
fluorophenylmagnesiurn bromide was injected through one of the Valve 2 side ports. 
The excess of Grignard reagent that was not adsorbed on the inner surface of the 
reaction loop was purged by a nitrogen stream and was collected in a waste vial. After 
this step, the waste vial was exchanged for a soda lime trap. ["C]Carbon dioxide was 
passed through the reaction loop, where it reacted with the Grignard reagent. Unreacted 
["C]carbon dioxide was directed to the soda lime trap. 
The chemicals required for the formation of the ["Clcarboxylic-phosphinic mixed 
anhydride (Dpp-Cl and triethylamine) were manually injected through Valve 1. 
Additions of reagents were carried out from glass syringes with Teflon plungers. The 
material contained in the reaction loop was washed out into a septum-capped Wheaton 
vial that was connected to Valve 3. During this step, the Wheaton vial was vented with 
a needle. The primary amine was then directly injected into the reaction vial, and after 
the addition of all reagents, the needle was removed. 
The lines were washed successively with IM HCI, water and acetone after the 
radioactivity decayed and the tubing was finally dried using nitrogen purging. 
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4.3.2.2.2. Radiosynthesis of 4-fluoro[carboxy-"Clbenzoic acid (compound 4.23 
Firstly, the optimal conditions for the reaction between 4-fluorophenylmagnesium 
bromide and[ I ICIC02were examined. This reaction was performed using a loop made 
of polypropylene or stainless steel. 170,171,220-223 A THF solution of 4- 
fluoropheny1magnesium bromide was injected through the loop, coating the inner 
surface of the tubing with the Grignard reagent. The loop was then purged with nitrogen 
and[ 
I ICIC02was 
pushed through the loop. 4-Fluorophenylmagnesium bromide reacted 
immediately with[IlCIC02 tOgive the labelled carboxylate (Scheme 4.33). 
MgBr 
11 00 1 C1C02 // Water/Acetic acid // 1- 
--»- F -0- C »- F -<D- C 
OMgBr 0H 
4.23 
Scheme 4.33. Radiosynthesis of 4-fluoro[carboxy-"C]benzoic acid 
The portion of the [11CIC02 that did not react with the Grignard reagent was retained in 
the soda lime trap. The radioactivity lost in the [ 11 CIC02 trap was 15-20 % when the 
stainless steel loop was used in the "C-carboxylation step, compared to 30-40 % loss 
with the polypropylene loop. Therefore, only the metal loop was used in subsequent 
radiosyntheses. 
A mixture of water/acetic acid was used to flush out the contents of the loop and to 
hydrolyse the ["C]carboxymagnesium bromide. The reaction was then analysed by 
reverse-phase HPLC (Figure 4.19). 4-Fluoro[carboxy-"C]benzoic acid (4-23) was the 
only radioactive product observed and was obtained in 62 % isolated radiochemical 
yield (decay-corrected from the initial [11CIC02)- 
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Figure 4.19. Radio-HPLC chromatogram of 4-fluoro[carboxy-1, C]benzoic acid L4.2ý) C) 
spiked with non-radioactive standard Column: Phenomenex Luna C18(2) (250 mm x 
4.6 mm x5 micron). Mobile phase: 50 % water containing 0.1 % acetic acid-50 % 
acetonitrile. Wavelength = 254 nm. Flow =I ml/min. 
4.3.2.2.3. Radiosynthesis of N-butyl-4-fluoro[carbonyl-"C]benzamide (compound 
1.. 2 4D 
Anhydrous dichloromethane was the reaction solvent in the cold synthesis of amides 
4.11,4.16 and 4.19. Therefore, it was the initial solvent used in the radiosynthesis of 
D (Scheme 4.34). the model compound N-butyl-4-fluoro [carbonyl- C]benzamide (4.24 
0' 11 OMgBr 0 0ý , 
Ph 
MgBr "Ic f, -Ph 
1 11 CIC02 Dpp-Cl 
0 
Butylamine 
Dow F 
H 
F 
4.24 
via Scheme 4.34. Radiosynthesis of N-butyl-4-fluoro[carbonyl-"C]benzamide (4-_24 
mixedphosphinic anhydrides. 
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Dpp-Cl and butylamine were diluted in anhydrous dichloromethane in order to facilitate 
the dispensing of reagents. THF solutions of 4-fluorophenylmagnesium bromide were 
used. These stock solutions were prepared in a glove box under nitrogen and were then 
stored in septum-capped vials. Although various reaction parameters were investigated 
(reagent concentration, addition order, reaction time), the labelled amide 4.24 was never 
obtained when dichloromethane was the reaction solvent. 
Reactions involving Grignard reagents are normally carried out in THIF and this solvent 
has also been reported in Dpp-Cl peptide couplings . 
210,214 Thus, inhibitor-free 
anhydrous THF was the next reaction solvent to be explored. 4- 
Fluorophenylmagnesium bromide was injected through the metal reaction loop and 
[I ICIC02was released 2-3 minutes later. Just after the formation of the radioactive 
carboxylate, a solution of Dpp-Cl in THF was passed through the loop and the reaction 
mixture was collected in a Wheaton vial at room temperature. Excess butylamine was 
immediately added to the reaction vial. HPLC analysis of the mixture 5 minutes after 
adding the amine revealed that the amide 4.24 was formed in 47 % analytical 
radiochernical yield (Figure 4.20). A polar peak and a by-product eluting at 6.2-6.3 min 
were the other radioactive signals observed. Two peaks were observed in the UV 
chromatogram: a polar peak at around 2 min and the phosphoramide 4.17. 
Ph- 0 
F0 
Ph-ý -'N 
H 
N+ 
H 
4.16 Ph, 0 
Ph' 
p 
4.24 
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Figure 4.20. The amide 4.24 was the main radiolabelled product when THF was the 
reaction solvent instead of 
CH2C12- 
229 
Chapter 4 Labellinz ofFlesinoxan 
Samples of the reaction mixture were analysed 15,30 and 45 minutes after addition of 
butylamine. All these chromatograrns were almost identical and no decomposition of 
amide 4.24 was observed. 
The reagent addition order was an important factor in the radiosynthesis procedure. A 
solution of butylamine was used to wash the [ 11 C] carboxymagnesium halide out of the 
loop and Dpp-Cl was then added to the Wheaton vial. The analysis of the reaction 
mixture showed that the amide 4.24 was only formed in 22 % yield following this 
addition sequence. The polar peak represented most of the radioactive area (76 %). 
Therefore, the amine should be added to the reaction mixture after Dpp-Cl. 
The effect of the reaction temperature on the yield of 4.24 was also investigated. The 
collection vial was kept at -10 T and the rest of the original protocol was repeated. 
Analysis of the reaction mixture showed that most of the radioactivity (71 %) 
corresponded to ["C]carboxymagnesium bromide (or acid 4.23) (Figure 4.21). The 
amide 4.24 was detected in only 4% and the by-product eluting at 6.5 min represented 
25 % of the radioactive area. The lower temperature decreased the rate of the reaction 
between the ["C]carboxylate and Dpp-Cl. Hence, the radiochernical yield of product 
4.24 was considerably reduced. 
Very different results were obtained when the reaction was carried out at 40 T. The 
[ 11 C] carboxymagnesium bromide peak was negligible in this case. Although amide 4.24 
represented 53 % of the total radioactive area, the formation of an unidentified by- 
product was quite significant (47 %). The formation of this side product was enhanced 
when the reaction temperature was increased. 
60 
50 
40 
E 
30 
0 
20 
lo 
0iIIIII 
-10 0 
10 20 30 40 
Temperature ('C) 
50 
Figure 4.21. Effects of the reaction temperature on the radiochemical yields of amide 
4.24. 
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An experiment was designed to identify the source of the radioactive by-product eluting 
at 6.2-6.5 min. The mixture was analysed at different time points (3 min and 15 min) 
after flushing the [ "C]carboxylate out of the loop with the Dpp-Cl solution (Figure 
4.22). The unidentified by-product was not observed and the retention time of the main 
radioactive peak was 3.5 min, with two other minor peaks eluting between 4.5 and 5 
min. Dpp-OH and a polar compound were the only peaks observed in the UV 
chromatogram. However, the radioactive profile changed drastically after the addition 
of butylamine to the reaction vial. Amide 4.24 represented 40 % of the radioactive area 
and the by-product 60 %. No polar radioactive peaks were detected. An impurity of the 
butylamine could have been the source of this unidentified radioactive product. 
IQ 
X 
'0 
Radioactive 
by-product 
I Before butylandne additi 
4.24 
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Figure 4.22. Radio-HPLC of the reaction mixture before and after adding butylamine. 
The unidentified by-product was only observed after amine addition. 
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The reaction between the labelled mixed anhydride and the butylamine was almost 
instantaneous. However, the reaction time required for the formation of the mixed 
anhydride had to be optimised (Figure 4.23). 
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Figure 4.23. Relationship between the radiochemical vield of 4 24 and the time allowed IIzI --* 
for theformation of the P'C]mixedphosphinic anhydride. 
Butylamine was added to the reaction mixture at various times after flushing out the 
loop contents with Dpp-Cl. A short period of time was required for the reaction 
between Dpp-CI and [ 11 C]carboxymagnesium halide. The highest yields of amide 4.24 
(84-90 %, n= 3) were obtained when butylamine was added to the reaction mixture one 
minute after flushing the ["C]carboxymagnesium bromide with Dpp-Cl (Figure 4.24). 
Increasing the reaction time before the butylamine addition favoured the formation of 
by-products, although amide 4.24 was still obtained in acceptable radiochemical yields 
(40-50%). 
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Figure 4.24. N-butyl-4-fluoro[carbonyl- jbenzamide (A. 24) was obtained in excellent 
C 
yield (90 Yq) when the reaction time requiredfor the P IC]mixedphosphinic anhydride 
formation was optimised. 
In summary, benzamide 4.24 was prepared via a ["C]phosphinic-carboxylic mixed 
anhydride in excellent radiochernical yields and was obtained in less than 15 min (5 
min radiosynthesis + 10 min HPLC purification). However, a series of parameters must 
be controlled in order to synthesise 4.24 reliably: 
-The reaction solvent must be inhibitor-free anhydrous THE 
-Fresh stock solutions of reagents ought to be used only once or twice to avoid 
substantial variations in the radiochemical yields. 
-Vigorous stirring of the reaction mixture was necessary due to the 
different densities of 
the solutions employed in the radiosynthesis. 
-The ideal reaction temperature for the amide formation was 20-40 
OC. 
-The addition of the reagents should follow this sequence: 
filling of the reaction loop 
with 4-fluorophenylmagnesium bromide, [ 11 CIC02 dispensing, loop flushing with Dpp- 
Cl and addition of butylamine to the reaction vial. 
-30-60 seconds should be allowed for the formation of the [1 
'C]mixed anhydride before 
adding the butylamine. 
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4.3.2.2.4. Radiosynthesis of N-benzyl-4-fluoro[carbonyl-"Clbenzamide (compound 
4.25 
The method developed for the radiosynthesis of 4.24 was also successful as a model 
reaction in the preparation of N-benzyl-4-fluoro[carbonyl-"C]benzamide (4.25) 
(Scheme 4.35). 
0 11 OMgBr 0 0, , 
Ph 
MgBr f, -Ph 
1 11 CIC02 i) Dpp-Cl 0 
F 
Benzylamine 
»- F 
N'\o 
H 
4.25 
Scheme 4.35. Radiosynthesis of N-benzyl-4-fluoro[carbonyl-"Clbenzamide (4.25 via 
P'C]carboxylic-phosphinic mixed anhydrides. 
A THF solution of 4-fluorophenylmagnesium bromide was injected through the 
stainless steel loop. [11CIC02 passed through the loop 2 min later, reacting with the 
Grignard reagent and Dpp-Cl in THF was used to flush the ["C]carboxymagnesium 
bromide out of the metal loop. The collection vial was then stirred at room temperature 
for one minute to allow the formation of the [ 11 C]mixed anhydride. Benzylamine was 
finally injected into the reaction vial and the reaction mixture was analysed after 2 
minutes. A major difference observed between the radiosynthesis of 4.24 and 4.25 was 
the formation of a white precipitate as soon as the benzylamine was added to the 
reaction mixture. This white solid was probably the phosphoramide 
[PhCH2NHPO(Ph)2] and was easily dissolved when a few drops of anhydrous DMF 
were added to the reaction vial. The separation of 4.25 and the phosphoramide required 
longer HPLC runs than in the case of compound 4.24. 
Benzamide 4.25 was obtained in 45-57 % radiochernical yields (n = 3) (Figure 4.25) 
and a prominent unidentified radioactive by-product was observed in all the 
experiments. 
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Figure 4.25. Radio-HPLC profile of benzamide 4.25 spiked with non-radioactive CD, 
standard Column: Phenomenex Luna C18(2) (250 mm x 4.6 mm x5 micron). Mobile 
phase: 60 % water-40 % acetonitrile. Wavelength = 225 nm. Flow rate= I mllmin. 
4.3.2.2.5. Radiosynthesis of N-[2-(4-phenylpiperazin-1-yl)ethyll-4-fluoro[carbonyl- 
11 C]benzamide (compound 4.261) 
The method used for amides 4.24 and 4.25 was applied to the preparation of model 
substrate 4.26, with the following modifications: the amount of amine precursor (amine 
4.20 in this case) was reduced from 200 ýtmol to 9.7 ýtmol and a THF solution of 
triethylamine was flushed through the reaction loop to assist in the formation of the 
labelled mixed anhydride (Scheme 4.36). 
MgBr 
i) ["CICO, 
NL 
ii) Dpp-Cl C--, N -1, I 
iii) Et3N / THF H 
iv) Amine 4.20 
F"' 
4.26 
Scheme 4.36 Radiosynthesis of benzamide 4.26 via P'C]carboxylic-phosphinic mixed 
anhydrides. 
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At room temperature, the radiochemical yields of amide 4.26 were only 3-5 % and a 
polar peak was the main radioactive product. This same procedure was repeated at 
different temperatures and the results are summarised on Figure 4.26. It was noted that 
the area of the ["C]carboxylate peak (retention time 2-2.5 min) shrank when the 
reaction temperature was increased and the best radiochernical yields of 4.26 were 
obtained at 55 OC (20 %). Multiple radioactive by-products were detected at higher 
temperatures. 
25 
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Figure 4.26 Analytical radiochemical yields of benzamide 4.26 at various 
temperatures. 
The amount of Dpp-Cl required in the reaction was the next parameter investigated 
(Figure 4.27). The highest radiochernical yield of amide 4.26 (56 %) was obtained with 
50 ýimol of Dpp-Cl (0.25 M, 0.2 ml). The use of only 25 [tmol of Dpp-Cl was 
insufficient to obtain the labelled product 4.26 and on the other hand, the use of 
100- 
150 ýtmol of Dpp-Cl increased considerably the number of radioactive side products 
observed. 
In conclusion, benzamide 4.26 was prepared according to the 
following protocol: 
injection of 4-fluorophenylmagnesium bromide through the metal reaction 
loop, 
reactionOf [11CIC02with the organometallic reagent, injection of 
Dpp-Cl through the 
loop and collection of the loop contents in a reaction vial at 
55 OC, injection of 
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triethylamine through the loop and addition of amine 4.20. This method gave consistent 
analytical radiochernical yields of 4.26 (40-56 %, n- 12, Figure 4.28). 
60 
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Figure 4.2 7. Analytical radiochemical yields of benzamide 4.26 at 55 T using various Cp 
amounts of Dpp-Cl. 
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Figure 4.28. Radio-HPLC profile of benzamide 4.26 spiked with non-radioactive 
standard Column: Phenomenex Luna C18(2) (250 mm x 4.6 mm x5 micron). Mobile 
phase: 55 % (NH4)2HP04 0.05 M-45 % acetonitrile. Wavelength == 245 nm. Flow rate 
=I mllmin. 
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4.3.2.3. Radiosynthesis of [carbonyl-"C]Flesinoxan 
4.3.2.3.1. Synthesis of the amine precursor for the preparation of [carbonyl- 
"C]Flesinoxan by the Dpp-CI method (compound 4.27 
The use of the ["C]mixed phosphinic anhydride strategy to label Flesinoxan required 
the synthesis of the amine 4.27, from the arylpiperazine 4.2 (Scheme 4.37). Although 
the inclusion of the arninoethyl moiety into 4.2 could be achieved by several methods, 
most of them require reaction conditions that would cleave the benzoate protecting 
70,224-228 
group . Therefore, the procedure employed to prepare amine 4.20 was also used 
here. The free amine of 4.2 was dissolved in anhydrous acetonitrile and triethylamine 
was added into the reaction mixture. A solution of 2-(Boc-amino)ethyl bromide in 
acetonitrile was added and the reaction was heated at 60-70 OC. Higher temperatures or 
longer reaction times increased the number of side products, as shown by TLC. The 
crude mixture was worked up and was purified by flash chromatography. This 
purification was not straightforward due to the presence of side products that were 
probably derived from the reaction of 2-(Boc-amino)ethyl bromide with traces of amine 
4.1 and bis-(2-chloroethyl)amine. Therefore, the compound 4.28 was only isolated in 
10 % yield. 
In contrast, much cleaner reaction mixtures were obtained when the free base of 4.2 
was purified by chromatography prior to the alkylation with 2-(Boc-amino)ethyl 
bromide. The compound 4.28 was then obtained in excellent yields (80-86 %). 
The carbamate protecting group in 4.28 was cleaved by the method described for the 
compound 4.22, i. e. substrate 4.28 was dissolved in anhydrous dichloromethane and 
excess of trifluoroacetic acid was slowly added. The trifluoroacetate salt of 4.27 was 
then basified with an aqueous sodium hydroxide solution and the residue was purified 
by flash chromatography. The amine 4.27 was isolated in 80 % yield and was found to 
be of very high purity (> 99 %) by HPLC. 
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Scheme 4.37. Synthesis of the [carbonyl-"C]Flesinoxan amine precursor (compound 
1.. 2 7D. 
4.3.2.3.2. Radiosynthesis of [carbonyl-11CIFIesinoxan 
The method developed for the radiosynthesis of the model compound 4.26 was applied 
to the preparation of the protected benzamide 4.29 (Scheme 4.38). 
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Scheme 4.38. Radiosynthesis of [carbonyl-"C]Flesinoxan via P'C]carboxylic- 
phosphinic mixed anhydrides. 
4-Fluoromagnesium bromide was consecutively treated with [I ICIC02, Dpp-Cl and 
triethylamine. The amine 4.27 was finally added and the reaction mixture was heated at 
55 T for 7-10 min. This protocol gave consistent radiochemical yields of the 
intermediate 4.29 (35-55 %, n= 10, Figure 4.29). 
The addition of catalytic amounts of NaOMe/MeOH to the reaction mixture containing 
4.29 did not provide [carbonyl-1 'C]Flesinoxan. However, 0.4-0.5 ml NaOMe/MeOH (I 
M) yielded the alcohol instantaneously (Figure 4.30). After the addition of sodium 
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methoxide, the reaction mixture consisted of a white slurry. However, this suspension 
was converted into a clear solution by the addition of 0.5 ml of water. 
-0 (? '11 
, OB. aý 
Y- 0 
I; rp-- I, IýP. 2 lo 12 14 
Mnutes 
UV absorbance (225 mn) 
Radioactivity 
-111, .... '', 20 
Figure 4.29. Radio-HPLC chromatogram showing the labelled benzamide 4.29. The 
sample was spiked with non-radioactive standard (compound ýLj). Column: 
Phenomenex Luna C18(2) (250 mm x 4.6 mm x5 micron). Mobile phase: 45 % 
(NH4)2HP04 0.05 M-55 % acetonitrile. Wavelength = 225 nm. Flow rate =I mIlmin. 
U9 Before sodium methoidde 
6a )", 
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Figure 4.30. The addition of NaOCH31 CH30H to the reaction mixture containing the 
labelled precursor 4.29 Provided [carbonyl-"C]Flesinoxan. Column: Phenomenex 
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Luna C18(2) (250 mm x 4.6 mm x5 micron). Mobile phase: 55 YO (NH4)2HP04 0.05 M- 
45 % acetonitrile. Wavelength = 245 nm. Flow rate =I ml/min. 
The radioactive peak of the protected intermediate 4.29 disappeared completely and a 
polar peak that corresponded to [carbonyl-"C]Flesinoxan was detected instead. The 
rest of the radioactive peaks were not affected by the addition of NaOMe/MeOH. 
The chromatographic method had to be optimised to avoid the co-elution of [carbonyl- 
"C]Flesinoxan with non-radioactive impurities (Figure 4.31). The analytical 
radiochemical yields of [carbonyl- 11 C]Flesinoxan were up to 63 % and decay-corrected 
isolated radiochernical yields were 30-35 % (from the initial [11CIC02, n= 15). The 
radiochernical purity of the final product was > 99 % (Figure 4.32) and the total 
radiosynthesis time including HPLC purification was 24 minutes. The specific activity 
of the radioligand was not calculated due to the low levels of radioactivity used in the 
radiosyntheses. 
BioScan Det 168-225nm 
207. dat 207. dat 
Flesinoxan 
[carbonyl - C]Flesinoxan 
'24 24 2ý 3i 1,2 14 16' 1ý 26' 22 
Mnutes 
Figure 4.31. Radio-HPLC chromatogram of [carbonyl-1, C]Flesinoxan showing 
adequate separation from other radioactive and non-radioactive products. The sample 
was spiked with non-radioactive Flesinoxan. Column: Phenomenex Luna C, 18(2) (250 
mm x 4.6 mm x5 micron). Mobile phase: 65 % (NH4)2HP040.05 M-35 % acetonitrile. 
Wavelength = 245 nm. Flow rate =I ml/min. 
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Mntles 
Figure 4.32. Radio-HPLC chromatogram of the isolated [carbonyl-1, C]Flesinoxan. 
The radiochemical purity of the product was 100 %. Column: Phenomenex Luna 
C18(2) (250 mm x 4.6 mm x5 micron). Mobile phase: 65 % (NH4)2HP04 0.05 M-35 % 
acetonitrile. Wavelength = 245 nm. Flow rate =I ml/min. 
4.3.2.3.3. Conclusions and future work 
-A series of model 4-fluoro[carbonyl-"C]benzamides were synthesised from [11CIC02 
in a one-pot procedure that involved the in situ reaction of primary amines with a 
["C]carboxylic-phosphinic mixed anhydride. The formation of the ["C]carboxylic- 
phosphinic mixed anhydride occurred in a loop, minimising the amount of reagents 
required. The amide radiosynthesis was fast, reliable and provided 4-fluoro[carbonyl- 
1 'C]benzamides in high radiochemical yields. 
-This protocol was also successfully applied to the radiosynthesis of the 5-HTIAagonist 
[carbonyl-"C]Flesinoxan. The obtained radiochernical yields were consistent (30-35 
%) and proved that this novel methodology can be used in the routine preparation of the 
radioligand. 
-The automated system depicted on Figure 4.33 will be used for the preparation of 
[carbonyl- 11 C] Flesinoxan and the radioligand will also be evaluated in vitro and in vivo. 
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-Other PET radioligands containing an amide moiety such as WAY- 10063 5 or p-MPPF 
could also benefit from this simple radiosynthesis of [carbonyl-1, C]amides. 
Furthermore, [ 11 C]carboxylic-phosphinic mixed anhydrides may also be applied for the 
preparation of [carbonyl- 11 C] esters. 
-A manuscript describing the radiosynthesis of [carbonyl- C]Flesinoxan and the model 
4-fluoro[carbonyl-"C]benzamides is under preparation and will be submitted for 
publication in a chemistry j ournal. 
4.4. Experimental 
Materials 
The pure (S) enantiomer of benzoic acid (5-amino-2,3-dihydro-benzo[1,4]dioxin-2- 
yl)methyl ester (compound A. 1) was provided by Solvay Pharmaceuticals (Brussels, 
Belgium). 
All other chemicals were obtained from Sigma-Aldrich (Gillingham, UK). All solvents 
were high performance liquid chromatography (HPLC) grade and purchased from 
Fisher Scientific (Loughborough, UK). 
ChemisLry 
Synthesis of R-(+)-benzoic acid 5-(piperazin-1-yl)-(2,3-dihydrobenzo[1,4]dioxin-2- 
yl)methyl ester, hydrochloride salt (compound j.. D2 
The starting material 4.1 (571 mg, 2 mmol) was dissolved in anhydrous chlorobenzene 
(2.5 ml), obtaining a pale brown solution. Then, bis-(2-chloroethyl)amine 
hydrochloride salt (375 mg, 2.1 mmol) was added under a gentle nitrogen flow and the 
reaction was heated up to 135-140 OC. After 72 hours, the mixture was cooled down to 
room temperature, forming a light brown solid which was washed twice with 
chlorobenzene (2 ml) and dried under reduced pressure to give 599 mg of 4.2 (77 % 
yield). The consumption of 4.1 was monitored by TLC (hexane-ethyl acetate, 1: 1, v/v, 
Rf of 4.1 = 0.54; Rf of 4.2 = 0). m. p. 193-195 T. 
IH-NMR (250 MHz, CDC13)6(ppm): 3.39 (bs, 8 H, piperazine), 4.19 (dd, J= 11.4 Hz, 
6.2 Hz, I H. CH20COPh), 4.45 (dd, J= 11.4 Hz, 2.0 Hz, 1 H, CH20COPh), 4.57 (m, 3 
H, OCHCH20), 6.53 (dd, J=7.9 Hz, 1.6 Hz, I H, NCCH), 6.70 (dd, J=7.9 Hz, 1.6 Hz, 
I H, NCCHCHCR), 6.83 (tj J=7.9 Hz, I H, NCCHCH), 7.45 (t, J=7.5 Hz, 2 H, meta- 
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OCOPh), 7.58 (tt, J=7.5 Hz, 1.6 Hz, I H, para-OCOPh), 8.03 (dd, J=7.5 Hz9 1.6 Hz, 
2 H, ortho-OCOPh), 9.89 (bs, 2H, NH2+)- 
13 C-NMR (62.9 MHz, CDC13) 8 (ppm): 43.8 and 47.6 (piperazine), 63.0 and 65.3 
(OCH2CHCH20COPh), 70.7 (OCH2CHO), 111.3,113.2 and 121.4 (NCCHCHCH), 
128.55 129.45 129.8 and 133.5 (OCOC6H5)5 135.9,139.95 143.7,166.2 (OCOPh). 
m1z (EI): 354,312,285,250,226,181,1635 141,113,92,77,635 57. 
IR (vma,, , cm-1): 3000-2700 (salt of secondary arnine), 2010 (N-H ammonium 
combination band), 1724 (C=O aromatic ester), 1600 and 1489 (C=C aromatic), 1268 
and 1107 (C-0 aromatic ester). 
Synthesis of 2-(4-fluorophenyl)-4,5-dihydrooxazole (compound j. f) 
A three-necked round bottom flask was charged with 4-fluorobenzoyl chloride (3.57 
ml, 30 mmol) and anhydrous toluene (10 ml). Then, while purging the flask with 
nitrogen gas, a solution of 2-(chloroethyl)amine hydrochloride salt (3.48 g, 30 mmol) in 
water (1.5 ml) was added. The flask was kept chilled in an ice bath while a NaOH 
solution (3.3 M, 30 ml) was added dropwise. The reaction was heated for two hours at 
90 OC with formation of white crystals. The precipitate was filtered and washed with 
water (4 x8 ml), yielding 4.5 as a white solid (3.22 g, 65 % yield). m. p. 167-169 OC. 
'H-NMR (250 MHz, CDC13) 8 (ppm): 4.12 (t, J=9.4 Hz, 2 H, NCH2), 4.49 (t, J=9.4 
Hz, 2 Hý OCH2), 7.38 (d, J=9.0 Hz, 2 H, ortho to fluorine), 7.95 (d, J=9.0 Hz, 2 H, 
meta to fluorine). 
13C-NMR (62.9 MHz, CDC13) 6 (ppm): 55.7 (NCH2), 67.8 (OCHA 115.7 (d ,2 
JCF 
22.0 Hz), 123.3,128.7 (d, 3 JCF= 8.5 Hz), 162.6 (C=N), 166.7 (d, I JCF= 245.5 Hz). 
m/z (El): 165,146 (-F). 
IR (v,,, a., , cm-1): 
3100-3064 (C-H aromatic hydrogens), 1644 (C=N imine), 1598-1489 
(C=C aromatic ring), 1241 (C-F monofluorinated benzene), 852 (para substitution). 
Synthesis of 2-(4-nitrophenyl)-4,5-dihydrooxazole (compound A-6) 
A three-necked round bottom flask was charged with 4-nitrobenzoyl chloride (5-57 g, 
30 mmol) dissolved in anhydrous toluene (12 ml). Then, while purging the 
flask with 
nitrogen gas, a solution of 2-(chloroethyl)amine hydrochloride salt (3.48 g, 30 mmol) 
in 
1.5 ml of water was added. The flask was kept chilled in an ice bath while 
30 ml of a 
3.3 M NaOH solution was added dropwise. The reaction was heated for two hours at 
90 
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T with formation of yellow crystals. The solid was filtered and washed with water (4 x 
8 ml), yielding A.. 6 as a yellow solid (3.91 g, 70 % yield). m. p. 192-193 T. 
'H-NMR (250 MHz, CDC13) 5(ppm): 4.12 (t, J=9.4 Hz, 2 H, NCH2), 4.50 (t, J=9.4 
Hz, 2 H, OCH2), 8.11 (d, J=9.0 Hz, 2 H, meta to nitro), 8.25 (d, J=9.0 Hz, 2 H, ortho 
to nitro). 
13 C-NMR (62.9 MHz, CDC13) 8 (ppm): 5 5.3 (NCH2), 68.2 (OCHA 123.5 (ortho to 
nitro), 129.2 (meta to nitro), 133.6 (para to nitro), 149.5 (ipso to nitro), 162.9 (C=N). 
m/z (El): 192,162 (-NO), 146 (-N02)- 
IR (vna, cm-1): 3108,3078 (C-H aromatic), 2977-2875 (C-H aliphatic), 1944 (overtone 
for para substitution), 1651 (C=N imine), 1598,1489 (C=C aromatic ring), 1517 and 
1322 (N=O aromatic nitro), 1259 and 1067 (C-0-C vynil ether). 
Synthesis of N-(2-chloro ethyl)-4-fluo rob enzamide (compound 1.9 
A solution of 4-fluorobenzoyl chloride (2.5 ml, 21 mmol) in anhydrous 
dichloromethane (5 ml) was added dropwise to an aqueous solution (10 ml) containing 
2-(chloroethyl)arnine hydrochloride salt (2.67 g, 23 mmol) and potassium carbonate 
(3.74 g, 27 mmol). The reaction flask was kept in an ice bath during the acid chloride 
addition and was stirred overnight at room temperature. The mixture was then extracted 
with dichloromethane (3 x 10 ml) and the organic layers were dried overMgS04 and 
concentrated under vacuum to give 4.9 as a white crystalline solid (4 g, 94 % yield). No 
further purification was required. m. p. 110- 112 OC. 
I H-NMR (250 MHz, CDC13) 8 (ppm): 3.77 (m, 4 H, CICH2CH2NH), 6.56 (bs, I H, 
NR), 7.15 (m, J=9.0 Hz, 2 H, ortho to fluorine), 7.81 (m, J=9.0 Hz, 2 H, meta to 
fluorine). 
13C-NMR (62.9 MHz, CDC13) 8 (ppm): 41.7 and 44.2 (CICH2CH2NH), 115.6 (d , 
2j 
CF -": 
21.9 Hz), 126.5 (d ,4 
JCF= 3.2 Hz), 129.3 (d ,3 
JCF= 8.6 Hz), 165.2 (CO), 168.4 (d, 
IJCF 
= 
244.5 Hz). 
IR (v,,,,,, , cm- 
1): 33 00 (N-H one band), 1914 (overtone para substitution), 1641 (C=O), 
1603 and 1504 (C=C), 1555 (N-H amide), 1239 (C-F monofluorinated benzene), 852. 
Synthesis of N-(2-chloroethyl)-4-nitrobenzamide (compound 4.10 
2-Chloroethylamine hydrochloride (2.32 g, 20 mmol) was dissolved in distilled water 
(30 ml) and a solution of 4-nitrobenzoyl chloride (4.08 g, 22 mmol) in warm toluene 
(20 ml) was added over it. The emulsion was stirred and cooled with an ice 
bath during 
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the gradual addition of a 5% aqueous NaOH solution (1.84 g, 46 mmol NaOH). After 
two hours, a white product precipitated out of the reaction mixture. The solid was 
filtered and washed with an aqueous sodium carbonate solution (10 % w/w, 25 ml). The 
crude solid was purified with flash chromatography (chloroform-ethyl acetate, 20: 1, 
v/v, Rf = 0.27), giving 4.10 as a yellow solid (3.91 g5 77 % yield). m. p. 123-125 T. 
'H-NMR (250 MHz, CD3CN) 8 (ppm): 3.72 (m, 4 H, CICH2CH2NH), 7.47 (bs, I H, 
NH)5 7.97 (d, J=9.0 Hz, 2 H, meta to nitro), 8.28 (d, J=9.0 Hz, 2 H, ortho to nitro). 
13 C-NMR (62.9 MHz, CD3CN) 8 (ppm): 42.2 and 46.4 (CICH2CH2NH), 123.1 (ortho to 
nitro), 130.6 (meta to nitro), 136.5 (para to nitro), 152.8 Qpso to nitro), 167.9 (CO). 
IR (v,, a, , cm-1): 3296 (N-H one band), 1870 (overtone para substitution), 1638 (C=O), 
1605 and 1490 (C=C aromatic system), 1545 (N-H amide), 1517 and 1353 (N=O 
aromatic nitro), 845 (C-N aromatic nitro). 
Synthesis of R-(+)-benzoic acid 5-14-[2-(4-fluorobenzoylamino)ethyl]piperazin-l- 
yl)2,3-dihydrobenzo[1,4]dioxin-2-yI methyl ester (compound 1.7 
A solution of sodium carbonate (127 mg, 1.2 mmol) in water (3 ml) was added to 4.2 
(310 mg, 0.8 mmol) dissolved in dichloromethane (7 ml). The mixture was stirred for 
30 minutes and was then extracted with dichloromethane (3 x 10 ml). The combined 
organic phases were dried over magnesium sulphate and the solvent was evaporated off. 
The resulting brown oil was dissolved in anhydrous acetonitrile (2 ml). Potassium 
carbonate (250 mg, 1.8 mmol) was added to the solution and the resulting slurry was 
stirred at ambient temperature during the slow addition of N-(2-chloroethyl)-4- 
fluorobenzamide (101 mg, 0.5 mmol) dissolved in anhydrous acetonitrile (5 ml). This 
mixture was refluxed for twelve hours and then cooled down to room temperature. The 
solvent was evaporated under vacuum and the residue was taken up in the minimum 
amount of water. The extraction of the product was carried out using dichloromethane 
(3 x 10 ml). The combined organic phases were dried over magnesium sulphate and 
concentrated in vacuo. The purification of the crude product was achieved with flash 
chromatography (ethyl acetate, Rf = 0.14), giving 4.7 as a beige solid (40 mg, 16 % 
yield). m. p. 205-207 OC. 
I H-NMR (250 MHz, CDC13) 8 (ppm): 2.70 (in, 6 H, (CH2)2NCH2CH2NH), 3.11 (bs, 4 
H, ArN(CH2)2), 3.57 (qý J=5.2 Hz, 2 H, CH2NH), 4.19 (dd, J= 11.4 Hz, 6.2 Hz, I H, 
CH20COPh), 4.45 (dd5 J= 11.4 Hz, 2.0 Hz, I H, CH20COPh), 4.57 (in, 3 H, 
OCHCH20), 6.55 (dd, J=8.2 Hz, 1.5 Hz, I H, NCCR), 6.66 (dd, J=8.2 Hz, 1.5 Hz, I 
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H, NCCHCHCH), 6.80 (bs, I H, NH), 6.82 (t, J=8.2 Hz, I H, NCCHCH), 7.12 (t, J= 
8.5 Hz, 2 H, ortho to fluorine), 7.45 (t, J=8.1 Hz, 2 H, meta-OCOPh), 7.58 (t, J=8.1 
Hz, I H, para-OCOPh), 7.79 (m, J=8.5 Hz, 2 H, meta to fluorine), 8.03 (d, J=8.1 Hz, 
2 H. ortho-OCOPh). 
13 C-NMR (62.9 MHz, CDC13) 6 (ppm): 36.3,50.8ý 53 .0 and 56.3 
(N(CH2CH2)2NCH2CE2), 63.0 and 65.2 (OCH2CHCH20COPh), 70.6 (OCH2CHO), 
110.8,112.2 and 121.2 (NCCHCHCH), 115.6 (d ,2 
JCF= 21.9 Hz), 128.5,129.5,129.7 
and 13 3.4 (OCOC6H5)5 129.2 (d ,3 
JCF =9.5 Hz), 135.9,140.2,141.5 (d ,4 
JCF= 3.2 Hz), 
143.51165.3 (CO amide), 166.2 (OCOPh), 168.4 (d, 
IJCF= 244.7 Hz). 
IR (v,,, a,,, cm-1): 3316 (N-H one band), 1714 (C=O aromatic ester), 1631 (C=O aromatic 
amide), 1598 and 1502 (C=C aromatic system), 1587 (N-H amide), 1264 (C-0 broad 
band aromatic ester and aromatic ether), IIII (C-0 aromatic ester), 1097 (C-0 aromatic 
ether). 
Synthesis of R-(+)-benzoic acid 5-14-[2-(4-nitrobenzoylamino)ethyllpiperazin-l- 
yl)2,3-dihydrobenzo[1,4]dioxin-2-yI methyl ester (compound 4.8 
A solution of sodium carbonate (15 9 mg, 1.5 mmol) in water (5 ml) was added to 4.2 
(563.1 mg, 1.45 mmol) dissolved in dichloromethane (10 ml). The mixture was stirred 
for 30 minutes and was then extracted with dichloromethane (3 x 10 ml). The combined 
organic phases were dried over magnesium sulphate and the solvent was evaporated off, 
yielding a brown oil which was dissolved in anhydrous acetonitrile (3 ml). Potassium 
carbonate (345 mg, 2.5 mmol) was added to the solution and the resulting slurry was 
stirred at ambient temperature during the slow addition of N-(2-chloroethyl)-4- 
nitrobenzamide (251 mg, 1.1 mmol) dissolved in anhydrous acetonitrile (5 ml). This 
mixture was refluxed for fifteen hours and was then cooled down to room temperature. 
The solvent was evaporated under reduced pressure and the residue was taken up in the 
minimum amount of water. The extraction of the product was carried out using ethyl 
acetate (3 x 10 ml). The organic phases were dried over magnesium sulphate and 
concentrated in vacuo. The purification of the crude product was achieved with flash 
chromatography (CHC13-MeOH 10: 1, v/v, Rf = 0.13), giving 4.8 as a yellow solid (124 
mg, 25 % yield). m. p. 212-215 T. 
'H-NMR (250 MHz, CDC13)8 (ppm): 2.70 (bs, 6 H, (CH2)2NCH2CH2NH), 3.10 (bs, 4 
H, ArN(CH2)2), 3.60 (q, J 5.2 Hz, 2 H, CH2NH), 4.19 (dd, J= 11.4 Hz, 6.2 Hz, I H, 
CH20COPh), 4.45 (dd, J 11.4 Hz, 2.0 Hz, I H, CH20COPh), 4.57 (m, 3 H, 
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OCHCH20), 6.55 (dd, J=7.9 Hz, 1.5 Hz, I H, NCCH), 6.66 (dd, J=7.9 Hz, 1.5 Hz, I 
H, NCCHCHCH), 6.82 (t, J=7.9 Hz, I H, NCCHCH), 6.94 (bs, I H, NH), 7.45 (t, J= 
7.5 Hz, 2 H, meta-OCOPh), 7.5 8 (tt5 J=7.5 Hz, 1.6 Hz, I H, para-OCOPh), 7.94 (d5 J 
= 8.6 Hz, 2 H, meta to nitro), 8.03 (dd5 J=7.5 Hz, 1.6 Hz, 2 H, ortho-OCOPh), 8.30 (d, 
J=8.6 Hz, 2 H, ortho to nitro). 
13 C-NMR (62.9 MHz, CDC13) 8 (ppm): 36.5,50.8ý 53.0 and 56.1 
(N(CU2M2)2NM2M2)5 63.1 and 65.3 (OCH2CHCH20COPh), 70.7 (OCH2CHO), 
110.85 112.2 and 121.2 (NCCHCHCH), 123.9 (ortho to nitro), 128.1 (meta to nitro), 
128.5,129.5,129.8 and 133.4 (OCOC6H5)5 135.9,140.2,141.5 (para to nitro), 143.5, 
149.6 (ipso to nitro), 165.3 (CO amide), 166.2 (OCOPh). 
IR (vm., cm-1): 3322 (N-H one band), 1719 (C=O aromatic ester), 1638 (C=O aromatic 
amide), 1596 and 1489 (C=C aromatic system), 1540 (N-H amide), 1517 and 1315 
(N=O aromatic nitro), 1259 (C-0 broad band aromatic ester/ether), 1108 (C-0 aromatic 
ester), 865 (C-N aromatic nitro). 
HRMS [M + H]+: Theoretical mass (C29H31N407) = 547.2188. Measured mass 
547.2198. 
Synthesis of R-(+)-Flesinoxan 
The fluoro precursor 4.7 (23 mg, 43 ýtmol) was dissolved in I ml of a 
methanol/dichloromethane mixture (70-30 %), and a sodium methoxide/methanol 
slurry (I M, 20 ýtl) was added. After heating for four hours at 40 OC, the alcohol 
deprotection. was completed, and Dowex 50Vv'X8-200 acidic resin (15 mg) was added to 
the reaction mixture. The resin was filtered and washed with dichloromethane (3 ml) 
and the mother liquors were concentrated in vacuo to give the crude product. This solid 
was purified by flash chromatography (chloroform-methanol, 10: 1, v/v, Rf : 0.33), 
giving Flesinoxan as a white solid (17 mg, 95 %). m. p. 182-183 OC. 
I H-NMR (250 MHz, CDC13) 6 (ppm): 2.72 (m, 6 H, (CH2)2NCH2CH2NH), 3.12 (bs, 4 
H, ArN(CH2)2), 3.60 (q, J=5.2 Hz, 2 H, CH2NH), 4.52-4.60 (m, 5 H, 
OCH2CHCH20H), 4.91 (bs, I H, OH), 6.56 (dd, J=8.2 Hz, 1.5 Hz, I H, NCCH), 6.66 
(dd, J=8.2 Hz, 1.5 Hz, I H, NCCHCHCH), 6.80 (bs, I H, NH), 6.82 (t, J=8.2 Hz, 1 
H, NCCHCH), 7.12 (t, J=8.5 Hz, 2 H, ortho to fluorine), 7.79 (m, J=8.5 Hz, 2 H, 
meta to fluorine). 
13C-NMR (62.9 MHz, CDC13) 6 (ppm): 36.3,50.8,53.0 and 56.3 
(N(CH2CT12)2NC`H2CH2), 59.9 and 67.8 (OCH2CHCH20H), 75.9 (CHCH20H), 110.8, 
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112.2 and 121.2 (NCCHCHCH), 115.8 (d ,2 
JCF= 21.9 Hz), 129.2 (d, 3 JCF = 9.5 Hz), 
135.9,140.2,141.5 (d ,4 
JCF= 3.2 Hz), 143.5,165.3 (CO), 168.4 (d, I JCF= 244.7 Hz). 
IR (v,,,,,, , cm-1): 3403 (0-H alcohol broad band), 3296 (N-H one band), 1646 (C=O 
amide), 1598 and 1489 (C=C aromatic ring), 1550 (N-H amide), 1448 and 1305 (0-H 
alcohol), 1229 (C-F monofluorinated benzene), 1080 (C-0 primary alcohol). 
HRMS [M + H]+: Theoretical mass (C22H27FN304) = 416.1980. Measured mass 
416.1975. 
Synthesis of R-(+)-nitro-Flesinoxan 
This compound was prepared from 4.8 (21 mg, 38 ýtmol) following the same procedure 
described above for Flesinoxan. Nitro-Flesinoxan was obtained as a yellow solid (15.5 
mg, 92 %) m. p. 197-200 ' C. 
'H-NMR (250 MHz, CDC13) 6 (ppm): 2.70 (m, 6 H, (CH2)2NCH2CH2NH), 3.11 (bs, 4 
H, ArN(CH2)2), 3.57 (q5 J=5.2 Hz, 2 H, CH2NH), 4.57 (m, 5 H, OCH2CHCH20H), 
4.90 (bs, I H, OH), 6.54 (dd, J=8.2 Hz, 1.5 Hz, I H, NCCH), 6.67 (dd, J=8.2 Hz, 1.5 
Hz, I H, NCCHCHCH), 6.82 (t5 J=8.2 Hz, I H. NCCHCR), 6.95 (bs, I H5 NH)5 7.94 
(d5 J=8.6 Hz, 2 H, meta to nitro), 8.31 (d5 J=8.6 Hz, 2 H, ortho to nitro). 
13 C-NMR (62.9 MHz, CDC13) 6 (ppm): 36.5,50.8,53.0 and 56.1 
(N(CH2CH2)2NCH2CH2), 60.1 and 67.5 (OCH2CHCH20H), 75.9 (CHCH20H), 110.8, 
112.2 and 121.2 (NCCHCHCH), 123.9 (ortho to nitro), 128.0 (meta to nitro), 135.8, 
140.25 141.4 (para to nitro), 143.5,149.6 (ipso to nitro), 165.3 (CO amide). 
IR (v,, a,. , cm-1): 3413 
(0-H alcohol broad band), 3320 (N-H one band), 1635 (C=O 
aromatic amide), 1596 and 1482 (C=C aromatic ring), 1570 (N-H amide), 1512 and 
1355 (N=O aromatic nitro), 1469 and 1325 (0-H alcohol), 1262 (C-0 aromatic ether), 
859 (C-N aromatic nitro). 
HRMS [M + H]+: Theoretical mass (C22H27N406) = 443.1925. Measured mass = 
443.1928. 
Synthesis of 4-fluoro-N-[2-(4-phenylpiperazin-1-yl)ethyl]benzamide . 
11) 
I-Phenylpiperazine (458 ýtl, 3 mmol) was dissolved in anhydrous acetonitrile (0.5 ml). 
Triethylamine (404 ýtl, 2.9 mmol) was added, and after 10 minutes stirring, a solution of 
N-(2-chloroethyl)-4-fluorobenzamide (302 mg, 1.5 mmol) in anhydrous acetonitrile 
(3 
ml) was added dropwise. Then, the reaction was refluxed overnight and 
the solvent was 
evaporated off. Water (10 ml) was added to the residue, which was 
then extracted with 
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dichloromethane (3 x 15 ml). The combined organic phases were washed with sodium 
carbonate (10 % w/w, 20 ml) and brine. Finally, after drying over magnesium sulphate 
and evaporation of the solvent, a white crystalline solid was obtained. This crude 
product was purified with flash chromatography (chloroform-methanol, 17: 1, v/v, Rf = 
0.55), giving product 4.11 as a white solid (211 mg, 43 %). m. p. 141-143 'C. 
'H-NMR (500 MHz, CDC13) 6 (ppm): 2.73 (m, 6 H, (CH2)2NCH2CH2NH), 3.25 (t, i 
4.9 Hz, 4 H, ArN(CH2)2), 3.62 (q, J=5.3 Hz, 2 H, CH2NH), 6.85 (bs, I H, NH), 6.89- 
6.97 (m, 3 H, C6H5), 7.13 (m, 2 H, ortho to fluorine), 7.28 (m, 2 H, meta-C6HO, 7.81 
(m, 2 H, meta to fluorine). 
13C-NMR (150 MHz, CDC13) 8 (ppm): 36.3,49.2,52.9 and 56.4 
23 (N(CH2CH2)2NCH2CH2), 115.6 (d, JCF = 22.6 Hz), 116.1,120.0,129.1,129.3 (d , 
JCF 
9.6 Hz), 130.8,141.1,164.6 (d, I JCF= 250.5 Hz), 166.3 (CO). 
IR (vm,,, , cm-1): 3300 (N-H one band), 1914 (overtone para substitution), 1641 (C=O 
aromatic amide), 1607 and 1504 (C=C aromatic system), 1554 (N-H amide), 1239 (C-F 
monofluorinated benzene), 852 (para substitution). 
Synthesis of 4-nitro-N-[2-(4-phenylpiperazin-1-yl)ethyllbenzamide (AAD 
I-Phenylpiperazine (458 ýLl, 3 mmol) was dissolved in anhydrous acetonitrile (0.5 ml). 
Triethylamine (404 [d, 2.9 mmol) was added, and after 10 minutes stirring, a solution of 
N-(2-chloroethyl)-4-nitrobenzamide (346 mg, 1.5 mmol) in anhydrous acetonitrile (3 
ml) was added dropwise. Then, the reaction was refluxed overnight and the solvent was 
evaporated off. Water (10 ml) was added to the residue, which was then extracted with 
dichloromethane (3 x 15 ml). The organic phases were washed with sodium carbonate 
(10 % w/w, 20 ml) and brine. Finally, after drying over magnesium sulphate and 
evaporating the solvent, a yellow solid was obtained. This crude product was purified 
with flash chromatography (chloroform-methanol, 17: 1, v/v, Rf = 0.5 8), giving product 
4.12, as a yellow solid (168 mg, 32%). m. p. 175-178 
'H-NMR (250 MHz, CDC13) 8 (pprn): 2.70 (m, 6 H, (CH2)2NCH2CH2NH), 3.23 (t, J= 
4.9 Hz, 4 H, ArN(CH2)2), 3.61 (qý J=5.3 Hz, 2 H, CH2NH), 6.88-6.93 (m, NH and 
C6H5), 7.28 (m, 2 H, meta-C6HO, 7.93 (d, J=8.8 Hz, 2 H, meta to nitro), 8.30 (d5 J= 
8.8 Hz, 2 H, ortho to nitro). 
13C-NMR (62.9 MHz, CDC13) 6 (ppm): 3 8.8,5 0.1,5 5.4 and 5 7.6 
(N(CH2CH2)2NCH2CH2), 111.5,116.6,123.5 (ortho to nitro), 129.1 (meta to nitro), 
129.6,130.8,143.9 (para to nitro), 152.8 Qpso to nitro), 167.9 (CO). 
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IR (v., , cm-1): 3291 (N-H one band), 1654 (C=O aromatic amide), 1600 and 1482 
(C=C aromatic ring), 1575 (N-H amide), 1515 and 1343 (N=O aromatic nitro), 871 (C- 
N aromatic nitro). 
Synthesis of 4-fluorobenzoic acid diphenylphosphinyl ester (compound 4.15 
4-Fluorobenzoic acid (280.2 mg, 2 mmol) and diisopropylethylamine (74 ý11,4.2 mmol) 
were dissolved in dichloromethane (10 ml). Diphenylphosphinic chloride (400 [d, 2.1 
mmol) was then added and the solution stirred at room temperature for 30 minutes. The 
reaction mixture was immediately extracted with NaHC03 (0.2 M, Ix 20 ml), brine, 
HCI (0.2 M, Ix 20 ml) and brine. The organic phases were dried over magnesium 
sulphate and concentrated in vacuo to give an off-white crystalline solid which was 
washed with ethyl acetate (2 x2 ml) to yield the final product 4.15, (63 8 mg, 94 %). 
m. p. 170-173 OC. 
'H-NMR (250 MHz, d6-DMSO) 8 (ppm): 7.13 (m, 2H ortho to fluorine), 7.40-7.48 (m, 
6 H. PO(C6H5)2), 7.70-7.91 (m, 6 H, PO(C6H5)2 and meta to fluorine). 
13C-NMR (62.9 MHz, CDC13) 8: 117.4 (d ,2 
JCF = 23.2 Hz), 128.8 (d , 
2jCP 
= 13.8 Hz), 
129.0 (d ,3 
JCF = 7.5 Hz), 130.6,130.9,131.6 (d , 
3jCP 
= 6.6 Hz), 13 3.0 (d, 1 Jcp = 114.2 
Hz), 160.6 (CO), 162.4 (d, IJCF = 257.6 Hz). 
IR (v .... x, cm-1): 3061 (C-H aromatic hydrogens), 1720 
(C=O aromatic ester), 1604 and 
1506 (C=C aromatic ring), 1230 (C-F monofluorinated benzene), 1179 (P=O aromatic), 
966 (P-0), 853 (aromatic para substitution). 
One-pot synthesis of N-butyl-4-fluorobenzamide (compound A-16) 
Small dry ice lumps (5 g) were placed in a round-bottomed flask under nitrogen flow. 
4-Fluorophenylmagnesium bromide (I M solution in THF, 4 ml, 4 mmol) was added 
dropwise and the mixture was stirred manually until the carbon dioxide evaporated. 
Diphenylphosphinic chloride (790 ýtl, 4.1 mmol) was dissolved in CH2Cl2 (3 ml) and 
was added dropwise to the solution. After five minutes of reaction at ambient 
temperature, butylamine (445 [il, 4.5 mmol) was injected into the flask and the mixture 
was left stirring for 1-2 hours. The organic phase was washed with 
NaHC03 (0.2 M, Ix 
20 ml), brine, and was concentrated in vacuo. The yellow residue was purified, 
by 
column flash chromatography (silica gel, hexane/ethyl acetate, 
2: 1, v/v, Rf = 0.38) to 
give 4.16 as a white crystalline solid (200 mg, 26 % yield). m. p. 
55-57 OC. 
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'H-NMR (250 MHz, CDC13) 8 (PPM): 0.99 (t, J=7.3 Hz, 3 H, CH3), 1.45 (sex, J=7.3 
Hz, 2 H, CH2CHA 1.64 (quin, J=7.3 Hz, 2 H, CH2CH2CHA 3.48 (q, J=7.3 Hz, 2 H, 
NHCH2), 6.24 (bs, I H, NH), 7.15 (m, 2 H, ortho to fluorine), 7.81 (m, 2 H, meta to 
fluorine). 
13 C-NMR (62.9 MHz, CDC13) 6: 13.7 (CHA 20.1 (CH2CHA 31.7 (CH2CH2CHA39.9 
NHCHA 115.5 (d , 
2j 
CF 22.6 Hz), 129.2 (meta to fluorine), 131.1 (para to fluorine), 
164.6(d, I JCF= 250.5 Hz), 166.5 (CO). 
IR (v,,, a., , cm-1): 3300 (N-H one band), 1641 (C=O aromatic amide), 1582 and 1483 
(C=C aromatic ring), 1550 (N-H amide), 1221 (C-F monofluorinated benzene), 852 
(para substitution). 
Synthesis of N-benzyl-4-fluorobenzamide (compound 4.19 
Diphenylphosphinic chloride (114 ýtl, 0.6 mmol) was added to a solution of 4- 
fluorobenzoic acid (70 mg, 0.5 mmol), triethylamine (154 ýtl, 1.1 mmol) and anhydrous 
dichloromethane (3 ml). After 15 minutes stirring at room temperature, benzylamine 
(I 10 ýtl, I mmol) was added to the reaction mixture. The resulting slurry was washed 
with water (I x 10 ml) and brine (I x 10 ml). The organic phase was dried over 
magnesium sulphate and was concentrated under vacuum. The crude material was 
purified using flash chromatography (silica gel, hexane-ethyl acetate 1: 1, product Rf 
0.47), giving 4.19 as a white flaky solid (76 mg, 67 %). m. p. 143-145 OC. 
'H-NMR (250 MHz, CDC13) 8 (ppm): 4.64 (d, J=5.5 Hz, 2 H, NHCH2), 6.33 (bs, I H, 
NH), 7.10 (m, 2 H, ortho to fluorine), 7.29-7.37 (m, 5 H, C6H5), 7.80 (m, 2 H, meta to 
fluorine). 
13 C-NMR (62.9 MHz, CDC13)5(ppm): 44.2 (NHCHA 115.6 (d ,2 
JCF= 22.6 Hz), 127.7, 
127.9 and 128.8 (QHOý 129.3 (meta to fluorine), 130.6 (para to fluorine), 165.8 (d, 
IJCF= 252.0 Hz), 166.3 (CO). 
IR (vn,,, , cm-1): 3313 (N-H one 
band), 1638 (C=O aromatic amide), 1602 and 1501 
(C=C aromatic ring), 1556 (N-H amide bending), 1230 (C-F monofluorinated benzene). 
Synthesis of (2-tert-butoxycarbonyl)aminoethyI bromide (compound 4.21) 
2-Bromoethylamine hydrobromide salt (2 g, 9.8 mmol) and triethylamine (7 ml, 50 
mmol) were dissolved in methanol (15 ml). Di-tert-butyl dicarbonate 
(4-3 g, 19.6 
mmol) was added and the reaction mixture was heated at 60 
T for two hours and was 
254 
r4 abellin, a of Flesinoxan 
left at room temperature overnight. The solvent was evaporated off and the resulting 
white residue was dissolved in dichloromethane. The organic phase was consecutively 
washed with: IM hydrochloric acid (I x 15 ml), brine (I x 15 ml), saturated sodium 
hydrogencarbonate aqueous solution (I x 15 ml) and brine (I x 15 ml). The organic 
fraction was dried over magnesium sulphate and the solvent was evaporated under 
reduced pressure. The crude product was purified using flash chromatography (silica 
gel, dichloromethane, product Rf = 0.54, ninhydrin as developing reagent). The 
protected amine 4.21 was obtained as a colourless oil (1.53 g, 70 % yield). 
'H-NMR (250 MHz, CDC13) 8 (PPM): 1.46 (s, 9 H, C(CH3)A 3.44 (t, J=5.8 Hz, 2 H, 
CH2NH), 3.55 (t, J=5.8 Hz, 2 H, BrCH2), 4.95 (bs, I H, NH). 
13 C-NMR (62.9 MHz, CDC13) 8 (ppm): 28.2 (C-(CH3)3), 32.4 (BrCH2), 42.1(CH2NH, 
80.1 (C-(CH3)A 155.7 (CO). 
IR (vm,, 
-, , cm-1): 
3352 (N-H one band), 1697 (C=O carbarnate), 1515 (N-H bending), 
1393 and 1368 (C-H bending, tert-butyl group), 1171 (C-0 bending). 
Synthesis of [2-(4-phenylpiperazin-1-yl)ethyllcarbamic acid tert-butyl ester (4.227. 
I-Phenylpiperazine (321 ýtl, 2.1 mmol) and triethylamine (850 ýd, 6 mmol) were 
dissolved in anhydrous acetonitrile (I ml). The reaction vessel was purged with argon 
and a solution of compound 4.21 (672 mg, 3 mmol) in anhydrous acetonitrile (2 ml) 
was added dropwise. The mixture was heated at 65 OC for four hours and was left 
stirring at room temperature for one hour, obtaining a yellow slurry. The solvent was 
evaporated off under vacuum and the brown residue was taken on water (10 nil). The 
crude product was extracted with dichloromethane (3 x 15 ml) and the organic phases 
were washed with aqueous sodium carbonate (10 % w/w, 10 ml) and brine. The organic 
phase was dried over magnesium sulphate, was filtered and the solvent was evaporated 
off. The residue was purified by flash chromatography (silica gel, dichloromethane- 
methanol 10: 1; starting material Rf = 0.21, product Rf = 0.50), obtaining 4.22 as a 
colourless oil (296 mg, 97 % yield). 
'H-NMR (250 MHz, CDC13) 5 (PPM): 1.47 (s, 9 H, C(CH3)3), 2.56 (t, 2 H), 2.64 (t, 4 H, 
NCH2CH2NPh), 3.23 (t, 4 H, NCH2CH2NPh), 3.30 (in, 2 H), 5.06 (bs, I H, NH), 6.87 
(t, I H, para-C6HO, 6.93 (d, 2 H, ortho-C6HO, 7.27 (m, 2 H, meta-C6HO. 
13C-NMR (62.9 MHz, CDC13) 6 (ppm): 27.8 (C-(CH3)3)5 36.11 49.1) 52.8 
(NCH2CH-2NPh), 55.4 (NCH2CT12NPh), 79.8 (C-(CH3)3)5 116.2,119.2,120.0 and 15 1.0 
(QHOý 157.6 (carbonyl). 
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IR (v,,, a,, , cm-1): 3352 (N-H one band), 1698 (C=O carbarnate), 1518 (N-H bending), 
1390 and 1367 (C-H bending, tert-butyl group), 1277,1257,1169. 
Synthesis of 2-(4-phenylpiperazin-1-yl)ethylamine (compound 4.20 
The protected material 4.22 (413 mg, 1.35 mmol) was dissolved in anhydrous 
dichloromethane (2 ml). Trifluoroacetic acid (1.5 ml, 19.5 mmol) was added dropwise 
and the solution was stirred at room temperature for three hours. The solvent and the 
acid excess were evaporated off under reduced pressure. The residue was converted into 
the free amine by addition of aqueous potassium hydroxide (10 % w/w, pH = 12). The 
product was extracted with dichloromethane (3 x 10 ml) and the organic phases were 
washed with brine and were dried over magnesium sulphate. The solvent was 
evaporated off under vacuum and the crude product was purified using flash 
chromatography (silica gel, dichloromethane-methanol-triethylamine 10: 1: 0.1; 
protected material Rf = 0.69, final product Rf = 0.27), obtaining 4.20, as a yellow oil 
(277 mg, 81 % yield). 
'H-NMR (250 MHz, CDC13) 8 (PPM): 1.97 (bs, 2 H, NH2), 2.5 0 (t, 2 H), 2.64 (t, 4 H, 
NCH2CH2NPh), 2.85 (t, 2 H), 3.23 (t, 4 H, NCH2CH2NPh), 6.87 (t, I H. para-C6H5), 
6.93 (m, 2 H, orthO-C6H5), 7.27 (m, 2 H, meta-C6H5)- 
13 C-NMR (62.9 MHz, CDC13) 6 (ppm): 38.5,49.2,52.8 (NCH2CH2NPh), 55.4 
(NCH2CH2NPh), 116.2,119.2,120.0 and 151 O(C6H5)- 
IR (v,,, a., , cm-1): 
3359 and 3297 (NH2, two bands), 1599 and 1499 (C=C aromatic 
system), 1235,1034. 
GC-MS (m/z): 205,175,132,1045 70. 
Synthesis of R-(+)-flesi-Boc (compound 4.28 
Aqueous sodium carbonate (5 % w/w, 5 ml) was added to 4.2 (156 mg, 
0.4 mmol) 
dissolved in dichloromethane (5 ml) under vigorous stirring. The organic phase was 
isolated and the solvent was evaporated under reduced pressure. The crude 
free amine 
was purified by flash chromatography (silica gel, dichloromethane-methanol- 
triethylamine 88: 10: 2, product Rf = 0.38) obtaining a brown oil (135 mg). This 
free 
base was dissolved in anhydrous acetonitrile (I ml) and triethylamine 
(0.14 ml, I 
mmol). A solution of compound 4.21 (157 mg, 0.7 mmol) in anhydrous acetonitrile 
(I 
ml) was added dropwise and the reaction mixture was heated at 
70 T for three hours. 
The solvent was evaporated off and the residue was taken on water 
(5 ml). The product 
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was extracted with dichloromethane (3 x5 ml) and the organic phases were washed 
with aqueous sodium carbonate (10 % w/w, 2x5 ml), brine (2 x5 ml) and were dried 
over magnesium sulphate. The crude material was purified by chromatography after 
evaporation of the solvent (silica gel, hexane-ethyl acetate 20: 80, product Rf = 0.28), 
obtaining the title compound as a colourless oil (172 mg, 86 % yield). 
'H-NMR (250 MHz, CDC13) 6 (PPM): 1.45 (s, 9 H, C(CH3)A 2.52 (t, J=5.8 Hz, 2 H, 
NCH2CH2NH), 2.63 (bs, 4 H, N(CH2CH2)2NAr), 3.07 (bs, 4 H, N(CH2CH2)2NAr), 3.26 
(bs, 2 H, CH2NH), 4.15 (m, I H, CH20COPh), 4.44-4.60 (m, 4 H, CH20COPh and 
OCHCH20), 5.01 (bs, I H, NH), 6.54 (dd, J=7.9 Hz, 1.5 Hz, 1 H, NCCR), 6.64 (dd, J 
= 7.9 Hz, 1.5 Hz, I H. NCCHCHCH), 6.80 (t, J=7.9 Hz, I H, NCCHCH), 7.44 (t, J= 
7.5 Hz, 2 H, meta-OCOPh), 7.57 (tt, J=7.5 Hz, 1.6 Hz, I H, para-OCOPh), 8.03 (dd, J 
= 7.5 Hz, 1.6 Hz, 2 H, ortho-OCOPh). 
IR (v,,,,,,, , cm-1): 3406 (N-H one band), 1721 
(C=O aromatic ester), 1597 and 1489 
(C=C aromatic system), 1390 and 1367 (C-H bending, tert-butyl group), 1269 (C- 
C(=O)-O stretching, ester of aromatic acid) 
HRMS [M + H]+: Theoretical mass (C27H36N306) = 498.2526. Measured mass 
498.2430. 
Synthesis of R-(+)-flesi-NH2 (compound 1.27 
Trifluoroacetic acid (0.1 ml, 1.3 mmol) was slowly added to compound 4.28 (75 mg, 
0.15 mmol) in anhydrous dichloromethane (1.5 ml). The reaction mixture was heated at 
30 T for three hours and was left at room temperature overnight. An aqueous sodium 
hydroxide solution (10 % w/w) was carefully added to the reaction vessel until pH 
12 
was reached. The organic phase was washed with brine (5 ml) and was 
dried over 
magnesium sulphate. After evaporation of the solvent, the residue was purified 
by flash 
chromatography (silica gel, dichloromethane-methanol-triethylamine 
10: 1: 0.1, product 
Rf = 0.49), yielding 4.27 as a light brown oil (46.2 mg, 78 %). Amine 
4.27 was obtained 
in >99 % purity as observed by HPLC: 
Analytical system: Phenomenex C18(2) column (250 min x 4.6 mm x5 micron), 
40 % 
(NH4)2HP04 0.05 M-60 % acetonitrile, wavelength = 225 and 245 nm, 
flow rate =I 
ml/min. 4.27 retention time = 3.0 min. 
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Radiochemistrv 
Fluorine-18 
Production of no-carrier-added K+-Kryptofix 2.2.2- [18 F]fluoride: 
The no-carrier-added [18 Ffluoride ion was produced by the 18 O(p, n) 18 F reaction by 
irradiation of an isotopically enriched 180-water target with a beam of protons (19 
MeV, 30 ýA/h) in a Scanditronix MC 40 cyclotron. The aqueous [18 Ffluoride solution 
(74-100 MBq) was transferred to a 2.5 ml conical vial (Wheaton vial) containing dry 
acetonitrile (I ml), Kryptofix 2.2.2 (10 mg, 26.6 ýtmol) and aqueous potassium 
carbonate (I mg, 7.2 ýtmol in 50 ýtl water). The water was removed azeotropically 
during three cycles of addition-evaporation of acetonitrile (I ml each cycle, 110 'C) 
under a gentle nitrogen flow. 
In one case, the aminopolyether Kryptofix was substituted by an aqueous solution of 
cesium carbonate (1.5 mg, 6.2 ýtmol). In another experiment, potassium oxalate (I mg, 
5.5 [imol) was used instead of potassium carbonate. 
Nucleophilic 18 F-fluorinations: Radiosynthesis of compounds 4.13 and 4.14 
A solution of compound 4.12 (3 mg, 8.5 ýtmol) or the Flesinoxan precursor 4.8 (3 ing, 
7.3 ýtmol) in a suitable anhydrous solvent (300-500 ýtl) was added to the vessel 
containing the dry [18 F]Ruoride. The Wheaton vial was then heated (80-150 OC) in an 
oil bath or microwave cavity for 5-30 minutes (Table 4.3). After the reaction, the vial 
was cooled down and diluted with 300-500 [tl of distilled water. The whole solution 
was injected into the radio-HPLC system: 
Semi-preparative Phenomenex Luna I Oýt C 18(2) column (250 x 10 mm), 100 A, mobile 
phase: water buffered with sodium acetate (0.05 M NaOAc adjusted to pH =5 with 
acetic acid) -acetonitrile, wavelength = 245 nm, flow rate =3 ml/min. 
Gradient system: 
0-10 minutes: from 25 % acetonitrile to 45 % acetonitrile. 
The isolated radiochernical yields of 4.13 and 4.14 were 3-4 % and 
0.5-0.8 % 
respectively (decay-corrected from the initial [18F]fluoride radioactivity). 
258 
r4 
Carbon-H 
bellima of Flesinox 
Radiosynthesis of 4-fluoro[carboxy-"Clbenzoic acid (compound 4.23 D 
A coil (Rheodyne 7026 stainless steel sample injector loop, 500 ýtl, 0.03 inch ID) was 
flushed with nitrogen for at least 30 minutes. A freshly prepared solution of 4- 
fluoropheny1magnesium bromide (0.1 M in tetrahydrofuran, 100 ýtl) was flushed 
through the metal tube to leave a thin film of reagent on the inner surface. One minute 
later, ["C]carbon dioxide was dispensed and passed through the loop in a stream of 
nitrogen (4.0 ml/min) for two minutes. The injection of water/0.1 % acetic acid (2 ml) 
through the loop washed out and hydrolysed the ["C]carboxylate salt. The product was 
finally purified by radio-HPLC: 
Semi-preparative Phenomenex Luna I Oýt C 18(2) column (250 x 10 mm), 100 A, mobile 
phase: 50 % water containing 0.1 % acetic acid-50 % acetonitrile, wavelength = 254 
nm, flow rate =3 ml/min. 
The isolated radiochernical yield of 4.23 was 62 % (decay-corrected from the initial 
[11CIC02)- 
Radiosynthesis of N-butyl-4-fluoro[carbonyl-"C]benzamide (compound 4.24 
A 500 Vd coil of stainless steel was flushed with nitrogen for at least 30 minutes. A 
freshly prepared solution of 4-fluorophenylmagnesium bromide (0.25 M in THF, 0.8 
ml) was flushed through the metal tube to leave a thin film of reagent on the inner 
surface. One minute later, ["C]carbon dioxide was dispensed and passed through the 
500 Vd loop in a stream of nitrogen (4.0 ml/min) for two minutes. The injection of a 
diphenylphosphinic chloride solution (0.16 M in THF, 0.8 ml) flushed out the contents 
of the loop into a Wheaton vial. The reaction vessel was stirred for one minute and 
butylamine (200 ýtmol in 0.2 ml of THF) was injected. Samples were withdrawn at 
different time points and were analysed by radio-HPLC: 
Phenomenex Luna C 18 (2) column (25 0 mm x 4.6 mm x5 micron), mobile phase: 55% 
water-45 % acetonitrile, wavelength = 225 nm, flow rate =I ml/min. 
The analytical radiochernical yields of 4.24, were 84-90 %. 
Radiosynthesis of N-benzyl-4-fluoro[carbonyl-"Clbenzamide (compound 4.25 
A 500 ýil coil of stainless steel was flushed with nitrogen for at least 30 minutes. A 
freshly prepared solution of 4-fluorophenylmagnesium bromide (0.25 M in 
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tetrahydrofuran, 800 ýtl) was flushed through the metal tube to leave a thin film of 
reagent on the inner surface. One minute later, ["C]carbon dioxide was dispensed and 
passed through the 500 ýd loop in a stream of nitrogen (4.0 ml/min) for two minutes. 
The injection of a diphenylphosphinic chloride solution (0.16 M in THF, 0.8 ml) 
flushed out the contents of the loop into a Wheaton vial. The reaction vessel was stirred 
for one minute and benzylamine (200 ýLmol in 0.2 ml of THF) was injected. Samples 
were withdrawn at different time points and were analysed by radio-HPLC: 
Phenomenex Luna C 18(2) column (250 mm x 4.6 mm x5 micron), wavelength = 225 
nim, mobile phase: 60 % water-40 % acetonitrile, flow =I ml/min. 
The analytical radiochemical yields of 4.25 were 45-57 
Radiosynthesis of N-[2-(4-phenylpiperazin-1-yl)ethyll-4-fluoro[carbonyl- 
"Clbenzamide (compound 1,20 
A 500 [il coil of stainless steel was flushed with nitrogen for at least 30 minutes. A 
freshly prepared solution of 4-fluorophenylmagnesium bromide (0.2 M in 
tetrahydrofuran, 200 Vtl) was flushed through the metal tube to leave a thin film of 
reagent on the inner surface. One minute later, ["C]carbon dioxide was dispensed and 
passed through the 500 ýtl loop in a stream of nitrogen (4.0 ml/min) for two minutes. 
The loop was flushed with a diphenylphosphinic chloride solution (0.25 M in THF, 200 
ýtl) and the reaction mixture was delivered to an empty Wheaton vial at 55 T. 
Immediately afterwards, a solution of triethylamine (1.25 M in THF, 200 Vd) was also 
injected though the metal loop. After 10-15 seconds, a solution of 2-(4- 
phenylpiperazin-1-yl)ethylamine (2 mg, 9.7 ýtmol) in anhydrous THF (50 ýtl) was 
directly injected into the Wheaton vial. Samples were withdrawn at different time 
points and were analysed by radio-HPLC: 
Phenomenex Luna C 18(2) column (250 mm. x 4.6 mm x5 micron), mobile phase: 55 % 
(NH4)2HP04 0.05 M-45 % acetonitrile, wavelength = 245 nm, flow rate =I ml/min. 
The analytical radiochemical yields of 4.26 were 47-56 %. 
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Radiosynthesis, of benzoic acid R-(+)-5-14-[2-(4-fluoro[carbonyl- 
1 'Cl benzoylamino)ethyll piperazin-1-yl)293-dihydrobenzo [1,41 dioxin-2-yl methyl 
ester (4.22) 
Product 4.29, was prepared following the method described for compound 4.26, using a 
solution of amine 4.27 (3 mg, 7.5 ýtmol) in anhydrous THF (25 gl). Samples were 
withdrawn at different time points and were analysed by radio-HPLC: 
Phenomenex C 18(2) (250 mm x 4.6 mrn x5 micron), mobile phase: 45 % (NH4)2HP04 
0.05 M-55 % acetonitrile, wavelength = 245 m-n, flow rate =1 ml/min. 
The analytical radiochemical yields of 4.291 were 50-55 %. 
Synthesis of R-(+)-N-[2-[4-(2,3-dihydro-2-(hydroxymethyl)-1,4-benzodioxin-5-yl)- 
I -pip erazinyll ethyl] -4-fluo ro [carbonyl- 
11 CIb enzamid e ([carbonyl-11CIFIesinoxan) 
Product 4.29 was prepared as described above and a slurry of sodium methoxide in 
anhydrous methanol (I M, 0.5 ml) was added to the mixture 7 minutes after the 
addition of amine 4.27. The reaction was quenched with water (0.5 ml) after two 
minutes (a clear solution was formed) and was purified by radio-HPLC. 
Analytical system: Phenomenex C18(2) column (250 mm. x 4.6 min x5 micron), 55 % 
(NH4)2HP04 0.05 M-45 % acetonitrile, wavelength = 245 mn, flow rate =I ml/min. 
Semi-preparative system: Phenomenex Luna 10ýt C18(2) column (250 x 10 mm), 100 
A. Mobile phase: (NH4)2HP04 0.05 M-acetonitrile, wavelength = 245 nm, flow rate =3 
ml/min. 
Gradient method: 
0-9 minutes: 45 % acetonitrile 
9-14 minutes: from 45 % to 85 % acetonitrile 
14-18 minutes: 85 % acetonitrile 
18-20 minutes: back to 45 % acetonitrile 
The isolated radiochemical yield of [carbonyl-"C]Flesinoxan was 29-32 
% (decay- 
corrected from the initial [11CIC02). The radiochemical purity of 
[carbonyl- 
"C]Flesinoxan was > 99 %. The total radiosynthesis time including HPLC purification 
was 24 minutes. 
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